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The Integrator Complex: A Multi-Tool For Metazoan Transcription
Abstract
Transcriptional regulation is fundamental for the function and proliferation of eukaryotic cells. Since the
discovery of RNA Polymerase II (RNAPII), our understanding of the mechanisms of transcription has
transformed what we know about basic cell biology and its impact on disease. Precise timing and
coordination of gene expression is vital for the proper development of eukaryotes, and dysregulation of
transcription is a hallmark of tumorigenesis. To translate our knowledge of cellular processes into
innovations for cancer and developmental disease, a comprehensive understanding of transcription is
essential. The Integrator Complex is a transcriptional co-regulator complex found only in metazoa.
Integrator has been shown to regulate multiple facets of transcription, from processing UsnRNAs to
regulating distinct steps of RNAPII at protein-coding genes. However, the functions of most Integrator
subunits remain unknown. For this thesis, my goal was to investigate the contribution of subunit modules
towards the complex’s multifaceted roles in transcriptional regulation. In the first chapter, I identify a
novel submodule of the Integrator complex with protein phosphatase 2A (PP2A). I demonstrate that the
subunit INTS6 recruits PP2A to sites of active transcription where it dephosphorylates numerous
substrates, including the C-terminal domain (CTD) of RNAPII, counteracting the pro-elongation activity of
the kinase CDK9. I show that loss of INTS6 confers resistance to CDK9 inhibition in normal and tumor cell
lines, leading to amplified transcriptional responses. These data identify a submodule of the Integrator
complex responsible for recruiting PP2A to RNAPII, leading to fine-tuned gene expression through a
kinase-phosphatase checkpoint. In the second chapter, I show that INTS13 functions as an independent
submodule of Integrator and regulates enhancer activation in monocyte-macrophage differentiation. I
reveal that INTS13 associates with NAB2 and the transcription factor EGR1 to activate poised enhancers,
eliciting chromatin looping and gene activation. Independent depletion of INTS13, NAB2, or EGR1 impairs
monocytic differentiation in cell lines and primary human progenitors. These data demonstrate an
additional submodule of Integrator that regulates transcription through enhancers for proper
differentiation. Altogether, this thesis demonstrates that the Integrator complex utilizes distinct
submodules to carry out its regulatory functions, which are integral for fine-tuned transcriptional
responses in metazoans.
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Abstract
THE INTEGRATOR COMPLEX: A MULTI-TOOL FOR METAZOAN TRANSCRIPTION
Sarah A. Welsh
Alessandro Gardini
Transcriptional regulation is fundamental for the function and proliferation of eukaryotic cells.
Since the discovery of RNA Polymerase II (RNAPII), our understanding of the mechanisms of
transcription has transformed what we know about basic cell biology and its impact on disease.
Precise timing and coordination of gene expression is vital for the proper development of eukaryotes, and dysregulation of transcription is a hallmark of tumorigenesis. To translate our knowledge
of cellular processes into innovations for cancer and developmental disease, a comprehensive understanding of transcription is essential. The Integrator Complex is a transcriptional co-regulator
complex found only in metazoa. Integrator has been shown to regulate multiple facets of transcription, from processing UsnRNAs to regulating distinct steps of RNAPII at protein-coding genes.
However, the functions of most Integrator subunits remain unknown. For this thesis, my goal was
to investigate the contribution of subunit modules towards the complex’s multifaceted roles in transcriptional regulation. In the first chapter, I identify a novel submodule of the Integrator complex
with protein phosphatase 2A (PP2A). I demonstrate that the subunit INTS6 recruits PP2A to sites
of active transcription where it dephosphorylates numerous substrates, including the C-terminal domain (CTD) of RNAPII, counteracting the pro-elongation activity of the kinase CDK9. I show
that loss of INTS6 confers resistance to CDK9 inhibition in normal and tumor cell lines, leading
to amplified transcriptional responses. These data identify a submodule of the Integrator complex
responsible for recruiting PP2A to RNAPII, leading to fine-tuned gene expression through a kinasephosphatase checkpoint. In the second chapter, I show that INTS13 functions as an independent
submodule of Integrator and regulates enhancer activation in monocyte-macrophage differentiation.
I reveal that INTS13 associates with NAB2 and the transcription factor EGR1 to activate poised enhancers, eliciting chromatin looping and gene activation. Independent depletion of INTS13, NAB2,
or EGR1 impairs monocytic differentiation in cell lines and primary human progenitors. These data
demonstrate an additional submodule of Integrator that regulates transcription through enhancers
for proper differentiation. Altogether, this thesis demonstrates that the Integrator complex utilizes
distinct submodules to carry out its regulatory functions, which are integral for fine-tuned transcriptional responses in metazoans.
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Chapter 1
Introduction
1.1

Transcriptional Regulation

Transcriptional regulation is fundamental to the function and proliferation of eukaryotic cells. Of
the full genome present in the nucleus of every cell, only a subset of genes is expressed at a given
time. The precise timing and selective expression of genes determines each cell’s behavior and
developmental fate. Tight regulation of transcription is particularly necessary for multicellular eukaryotes, or metazoans, as discrete cell types are required for the development and function of the
entire organism. At the cellular level, highly conserved molecular machinery is responsible for
transcribing DNA into RNA, a process that is controlled through specialized regulatory networks.
In eukaryotes, the holoenzyme RNA Polymerase II (RNAPII) is the key player in the transcription
of protein-coding genes. With the help of a host of protein complexes, transcription by RNAPII
follows a series of steps: initiation, elongation, and termination, each with their own (and overlapping) regulatory mechanisms and checkpoints (Figure 1.1). Transcription is initiated as RNAPII
binds upstream of the gene body with the help of general transcription factors. RNAPII is able to
travel just past the transcriptional start site (TSS) before it stops, or pauses. At this checkpoint,
the kinase CDK9 is responsible for phosphorylating a number of factors which, altogether, release
RNAPII from the pause site whereupon it resumes transcription, elongating the nascent transcript.
When RNAPII has transcribed past the transcriptional end site (TES), transcription is terminated;
the new RNA is cleaved and processed, eventually making its way into the cytoplasm where it will
be translated into a functional protein. Our present understanding of eukaryotic transcription is
largely based upon studies in the single-celled eukaryote S.cerevisiae (yeast). In contrast to yeast,
multicellular eukaryotes differentiate into numerous distinct cell types, suggesting that they may
rely upon more complex transcriptional regulation mechanisms. Intriguingly, the past 15 years
have seen the discovery and description of a transcriptional co-regulator, the Integrator complex,
that is not found in yeast, but rather is confined to later eukaryotes.
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F IGURE 1.1

RNAPII transcription cycle

Simplified schematic of the steps and checkpoints in the RNAPII transcription cycle. Traffic lights represent the signal received by RNAPII at each labeled step. Initiation factors represent general transcription
factors, such as TFIID, and the Mediator complex. The grey circles trailing behind RNAPII represent one
heptad repeat (YSPTSPS) of the C-terminal domain (CTD) of RNAPII, with red-orange circles indicating
phosphorylation of that residue. At the pause site, CDK9 (pTEFb), SPT5 (DSIF), and NELF (Negative
elongation factor) are present with RNAPII, the CTD is phosphorylated at Serine 5 (Ser5). During pauserelease, CDK9 phosphorylates SPT5, NELF, and the C-terminal domain (CTD) of RNAPII at Serine 2 (Ser2).
Phosphorylated NELF dissociates from the holoenzyme, and RNAPII is released into elongation. Termination factors represent cleavage and polyadenylation specificity factor complex (CPSF), and the exonuclease
XRN2, among others.

2

1.2

The Integrator Complex

The Integrator complex was first identified in 2005 as a multi-subunit protein complex in mammalian cells that interacts with RNAPII [1]. Unlike most other known transcriptional co-regulator
complexes, Integrator is only found in metazoans, suggesting recent evolution. Despite its young
evolutionary age, however, Integrator is an essential protein complex for cell survival. A recent
study compared the CRISPR-Cas9 screens performed at the Broad and Sanger Institutes to identify the most robust list of genes that cancer cell lines were dependent upon for survival. Out of
16,733 genes surveyed in both screens, 6% were identified as common dependencies, which included ten of the fourteen Integrator subunits [2].While significant research has been accomplished
in the past 50 years since the discovery of RNAPII [3], most of the mechanistic work has been
performed in yeast and therefore has not tested the contribution of the Integrator complex to this
regulation. Given its essentiality in human cells, it is reasonable to suspect that Integrator plays
a fundamental role in metazoan transcription, and particularly in the complex functions that help
specify the diverse cell types found in these complex organisms. A better understanding of how
the Integrator complex (Figure 1.2) regulates RNAPII and transcription could prove to be invaluable for our understanding not only of fundamental cellular biology, but of disease states resulting
from transcriptional dysregulation, such as cancer.
The first evidence of Integrator’s role in regulating RNAPII transcription came from knockdown
studies of the core subunit INTS1 and the catalytic subunit INTS11. Knockdown of these subunits in mammalian cells led to an accumulation of misprocessed uridylate-rich, small nuclear
RNA genes (UsnRNAs), suggesting this complex is involved in cleaving these transcripts after
transcription by RNAPII [1]. More evidence for its function came from the homology of two subunits, INTS9 and INTS11, to previously characterized enzymes of the cleavage and polyadenylation specificity factor (CPSF) complex [1]. CPSF100 and CPSF73 form a catalytic heterodimer
with endonucleolytic activity for cleavage of RNAPII transcripts. Further structural and functional
studies confirmed that INTS9 and INTS11 form a heterodimer with endonuclease activity toward
mature UsnRNA transcripts [4]. Surprisingly, no homologous proteins were identified for any of
the other 12 subunits of the Integrator complex, leaving the function of these subunits unknown.
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F IGURE 1.2

Schematic of Integrator complex subunits

Predicted protein domains of all 14 Integrator subunits are illustrated and the lengths of the human orthologs
are indicated (in amino acids,aa). Abbreviations: ARM = armadillo-like repeats; COIL=coiled- coil domain;
DUF = domain of unknown function; ISDCC = INTS6/SAGE1/DDX26B/CT45 C-terminus; PHD = plant
homeodomain finger; TPR = tetratricopeptide repeats; b-lactamase/b-CASP = endonuclease domain (* indicates the presence of an inactive domain); VWA = von Willebrand type A like domain. Identified interacting
domains with other proteins are underlined. Figure reused with permission from the following publication:
D. Baillat and E. J. Wagner. Integrator: Surprisingly diverse functions in gene expression. Trends in Biochemical Sciences, 40(5):257–64, 2015. [5]

Further studies revealed that knockdown of Integrator subunits led to defects in RNAPII transcription of protein-coding genes [6]. Integrator subunits are recruited to these gene bodies with
RNAPII in a transcription-dependent manner [6]. Transient knockdown of Integrator subunits
INTS1 and INTS11 led to a decreased transcriptional response to stimuli, as shown by reduced accumulation of RNAPII along the gene body and reduced levels of RNA transcripts. In fact, this de4

creased transcriptional response suggested that the loss of Integrator was interfering with RNAPII
pause-release. Pause-release of RNAPII is a tightly regulated step that transitions RNAPII from
initiation into productive elongation. It is hypothesized that RNAPII pausing evolved in multicellular organisms to allow for rapid activation of transcription in response to a variety of environmental cues. After initiation, RNAPII transcribes approximately 50 base pairs (bp) past the transcriptional start site (TSS) where it assumes a paused conformation. This pausing likely acts to
prime these genes if a rapid transcriptional response is necessary, in which case RNAPII and the
required machinery are already poised to respond. This pause-release checkpoint is very tightly
regulated in mammals, involving a number of protein complexes that have appeared in the evolutionary record after yeast, including the Integrator Complex.
Not only is Integrator involved in regulating RNAPII at the gene body, but it has also been found
to be essential for distal regulation of transcription. Enhancers are regions in the genome that are
found up- or downstream of a gene (or set of genes) and are able to regulate the degree to which
those gene(s) are transcribed. These enhancer sites recruit specific co-activators that interact with
complementary co-activators at the promoter region of the gene, creating a transcriptionally active bubble in which RNAPII and the necessary RNA processing factors concentrate. The requirement of enhancer-promoter contact for sustained transcriptional activity adds an additional layer
of control for a cell to carefully titrate its response to stimuli. Interestingly, Integrator subunits are
recruited not only to genes but to enhancers as well, in a transcription-dependent manner [7]. Similar to its role in processing UsnRNAs, the endonuclease activity of the subunit INTS11 was found
to be required for proper termination of enhancer RNAs (eRNA) produced at stimulated genes [7].
These findings laid the foundation for our understanding of the Integrator Complex, and for my
work investigating the role of individual subunits in the mechanism of RNAPII regulation.
While UsnRNA processing is the most established function of Integrator, many of the Integrator
subunits are unnecessary for that role (Figure 1.3). This led us to hypothesize that these additional
subunits play other distinct roles in transcriptional regulation.
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Mis-processing of UsnRNAs after knockdown of Integrator Complex subunits

Quantification of mis-processed U1 and U2 transcripts in Hela cells upon shRNA-mediated knockdown of
Integrator subunits. Schematic represents UsnRNA coding region, with the arrow indicating the INTS11
cleavage site upstream of the 3’box region. Primers were used that target transcripts downstream of the
INTS11 cleavage site, therefore the quantity represents any transcripts that have not been cleaved by INTS11.
Error bars show standard error, 3 replicates

1.3

Goals

In this thesis, I present a set of experiments aimed at unraveling the multi-faceted roles of the Integrator complex in transcriptional regulation. Together, these experiments support the hypothesis
that Integrator carries out these roles as a modular complex, utilizing unique submodules assembled onto a common backbone to perform its many functions.
In the first chapter, I present my thesis work investigating the role of the Integrator subunit INTS6
in recruiting the phosphatase PP2A to sites of active transcription. I found that the subunit INTS6
is required for the association of this phosphatase with the Integrator complex (Int-PP2A) and
subsequent recruitment to chromatin. Furthermore, Int-PP2A is required for proper regulation of
RNAPII pause release by counteracting the pro-elongation factor CDK9. These results show that
6

INTS6 and PP2A together act as a submodule of the complex, adding phosphatase activity to the
full repertoire of Integrator complex functions.
In the second chapter, I present additional experiments that demonstrate the role of a different submodule, containing INTS13, in regulating enhancers during cell fate commitment. This project
revealed an additional function for Integrator in enhancer-promoter looping and proper execution
of transcriptional programs necessary for organismal development.
In the final chapter, I summarize these results and present my conclusions in the context of exciting advances from the rest of the field. I address the lingering questions and propose further
experiments to study in greater detail the mechanisms of mammalian transcription. Importantly, I
also address how these results may contribute to the treatment of numerous disorders that exhibit
transcriptional dysregulation.
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Chapter 2
PP2A-Integrator complex fine-tunes transcription by opposing CDK9

This chapter is currently under review for publication (original submission June 23, 2020; resubmission November 27, 2020). An earlier version of this chapter is published as a preprint [8]:
Stephin J. Vervoort*, Sarah A. Welsh*, Jennifer R. Devlin+, Elisa Barbieri+, Deborah A. Knight+,
Sarah Offley, Stefan Bjelosevic, Matteo Costacurta, Izabela Todorovski, Conor J. Kearney, Jarrod J. Sandow, Zheng Fan, Benjamin Blyth, Victoria McLeod, Joep H. A. Vissers, Karolina Pavic,
Ben P. Martin, Gareth Gregory, Elena Demosthenous, Magnus Zethoven, Isabella Y. Kong, Edwin D. Hawkins, Simon J. Hogg, Madison J. Kelly, Andrea Newbold, Kaylene J. Simpson, Otto
Kauko, Kieran F. Harvey, Michael Ohlmeyer, Jukka Westermarck, Nathanael Gray, Alessandro
Gardini#, Ricky W. Johnstone#. PP2A-Integrator complex fine-tunes transcription by opposing
CDK9. bioRxiv. 2020 Jul 12. doi:(10.1101/2020.07.12.199372)
*Co-first authors, #Co-senior authors, +Authors contributed equally

2.1

Abstract

Gene expression by RNA Polymerase II (RNAPII) is tightly controlled by Cyclin-dependent kinases
(CDKs) at discrete checkpoints during the transcription cycle. The RNAPII pausing checkpoint,
engaged after transcription initiation, is controlled by CDK9 to regulate transcription in metazoans.
We discovered that CDK9-mediated RNAPII pause-release is functionally opposed by a protein
phosphatase 2A (PP2A) complex. PP2A dynamically competes for key CDK9 substrates, DSIF
and RNAPII-CTD, and is recruited to transcription pausing sites by the Integrator complex subunit
INTS6. INTS6 depletion confers resistance to CDK9 inhibition in a variety of normal and tumor
cell lines. Loss of INTS6 abolishes the Integrator-PP2A association leading to unrestrained CDK9
activity, which amplifies transcriptional responses. Pharmacological PP2A activation synergizes
with CDK9 inhibition to kill MLL-rearranged leukemias and solid tumors and provide therapeutic
benefit in vivo. These data demonstrate that finely-tuned gene expression relies on the balance of
kinase and phosphatase activity at the pausing checkpoint.
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2.2

Introduction

Spatiotemporal control of gene expression is essential for appropriate cellular and organismal development, and is required to direct functional responses to a range of intrinsic and extrinsic cellular cues [3]. This essential process is tightly regulated and highly dynamic, directed by the activity of RNA polymerase II (RNAPII) [3, 9] and the concerted action of cyclin-dependent kinases
(CDKs) and their cognate cyclins in a process termed the transcription cycle [10]. Following transcription initiation, RNAPII is arrested shortly after transcribing the first 60-100 base pairs of most
genes and acquires a ‘paused’ conformation, which is stabilized by the DRB sensitivity inducing factor (DSIF) and the negative elongation factor (NELF) [9, 11, 12]. Paused RNAPII is still
engaged in transcription, yet unable to further elongate the nascent transcript, owing to reduced
mobility and impaired binding of NTPs. Dynamic phosphorylation of RNAPII, NELF, and DSIF
facilitates the transition of the paused polymerase into active elongation [9, 11, 13].
The release of RNAPII from its paused state enables productive transcriptional elongation and
requires the kinase activity of the positive transcription elongation factor (pTEFb), comprised of
CDK9 and cyclin T [9, 11]. Through the activity of CDK9, pTEFb phosphorylates DSIF, NELF,
and the RNAPII C-terminal domain (CTD) at serine 2 (Ser2) [9, 11]. While phosphorylation of
NELF prompts its release from the transcription machinery, phospho-DSIF remains associated
with the elongating polymerase but undergoes allosteric changes. RNAPII CTD phosphorylation
at Ser2 (phospho-Ser2) is spread across 52 repeats of the conserved amino acid heptad (YSPTSPS), providing a recruitment platform for multi-protein complexes that regulate co-transcriptional
processes including capping, splicing, termination, and histone methylation [14]. The activity of
pTEFb at the transcriptional pause site is mediated by its recruitment through a variety of protein
interactions, including transcription factors such as c-MYC [15], the bromodomain-containing
protein BRD4 that binds to acetylated histone lysine molecules [16, 17], and the Super Elongation
Complex (SEC) that is recruited to proximal promoters by proteins such as the MLL-AF9 oncogenic fusion protein [18, 19].
Small molecule inhibitors of CDK9 kinase activity, such as flavopiridol, have been effectively used
9

to study the molecular and biochemical events that underpin transcriptional pause-release and to
ascertain greater mechanistic detail of transcription dynamics [20, 21]. Indeed, pharmacological
inhibition of CDK9 blocks productive transcriptional elongation concomitant with accumulation
of hypo-phosphorylated RNAPII at the transcriptional pause site. Given the functional interactions of pTEFb with oncogenic transcription factors such as c-MYC and MLL-fusion proteins, and
that transcriptional amplification is an underlying molecular characteristic of cancer [22], small
molecule inhibitors of CDK9 have previously been applied in the oncology setting, although a selective inhibitor of CDK9 has yet to be approved as standard treatment for any cancer [23].
Despite extensive literature on the various RNAPII-CTD kinases including the “transcriptional kinases” (CDK7, 8, 9, 11, 12, 13), less is known about the phosphatases that target RNAPII-CTD
and oppose pTEFb kinase activity [24]. Multiple phosphatases including Rtr1, Ssu72, Cdc14b,
Glc7, Fcp1, and Scp1 have been shown to de-phosphorylate RNAPII-CTD in mammals and/or
lower organisms [25]. Recently, CDK9-mediated phosphorylation of yeast Spt5, a component of
DSIF, was shown to be opposed by the PP1 phosphatase isoform Dis2 during the regulated progression from transcriptional elongation to termination, a mechanism that is conserved in mammalian cells [26]. In mammalian cells, CDK9 mediated phosphorylation of SPT5 is additionally
opposed at promoter-proximal regions by the PP4 phosphatase [27]. These data provide evidence
for functional interplay between kinases and phosphatases to dynamically regulate the function of
key transcriptional machinery.
In this study, we used whole genome CRISPR-based screens to identify genes that regulate transcriptional pausing and leukemia cell death induced by inhibition of CDK9 (CDK9i). Knockout of
INTS6, a component of the Integrator protein complex, suppressed CDK9i and allowed transcriptional elongation in human leukemia and solid tumor cells, and in untransformed D.melanogaster
cells. Integrator is a metazoan-specific, 14-subunit complex that associates with the RNAPII-CTD
and cleaves nascent RNA species such as U small nuclear RNAs (snRNAs) and enhancer RNAs
(eRNAs) [28, 7]. Recently, Integrator was reported to regulate RNAPII pausing and elongation
through its RNA-directed catalytic subunits INTS11/INTS9 [6, 29]. Here, we uncovered that
INTS6, INTS8 and the PP2A phosphatase (Int-PP2A) form a distinct functional module of Inte10

grator. While PP2A is a well-known phosphatase complex that can act as a tumor suppressor in a
wide range of human malignancies [30], it has not been studied in association to transcriptional
dynamics. We found that PP2A is recruited at actively transcribed genes through INTS6 to oppose
CDK9 activity and promote pausing by controlling the phosphorylation turnover of key CDK9
substrates, including the RNAPII-CTD and DSIF. These discoveries provided a strong molecular
rationale to combine CDK9i with small molecule activators of PP2A (SMAPs), resulting in enhanced transcriptional pausing and synergistic therapeutic efficacy in MLL-rearranged AML and
solid tumors. Taken together, we reveal a previously undescribed function for Integrator in regulating transcriptional pause release through the recruitment of PP2A to chromatin via INTS6, and
provide new mechanistic insights into the fine tuning of transcription through the opposing enzymatic activities of CDK9 and PP2A.

2.3
2.3.1

Results
Loss of the Integrator subunit INTS6 confers resistance to CDK9 inhibition

Pharmacological inhibition of CDK9 (CDK9i) has been proposed to be an effective therapeutic
strategy in hematopoietic malignancies, particularly MLL-rearranged leukemias. On a molecular level, CDK9 inhibition results in widespread RNAPII pausing, preventing most coding and
noncoding genes from being effectively transcribed. To identify proteins that functionally antagonize CDK9 activity on both the phenotypic and transcriptional level, we performed a series of
genome-wide CRISPR-screens on the MLL-rearranged leukemia cell lines THP-1 and MV4;11
treated with CDK9i using the following readouts: (1) long-term cell survival and (2) nascent RNA
transcription (Figure 2.1A). Positive selection, genome-wide CRISPR screens were initially performed in THP-1 cells transduced with a 120,000 single guide RNA (sgRNA) library (GeckoV2)
under selective pressure from two highly selective, chemically distinct CDK9i (AZ5576, A159)
as well as Dinaciclib [31]. This revealed selective enrichment of single guide RNAs (sgRNAs)
targeting the Integrator complex subunit INTS6 in response to all three CDK9i (Figure 2.1B left
panel). These findings were extended in analogous long-term survival screens using THP-1 and
MV4;11 cells transduced with a distinct 76,000 sgRNA library (Brunello) confirming that deletion
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of INTS6 conferred resistance to CDK9i (Figure 2.1B right panel, Supplemental Figure 2.8A and
Supplementary Tables 1).
To directly assess functional antagonism to CDK9 inhibition on a transcriptional level, a flow
cytometry-based readout of nascent RNA production using click chemistry-based fluorescent 5ethynyl uridine (EU) labelling was utilized (Supplemental Figure 2.8B). As expected, CDK9i
treatment of THP-1 cells resulted in a time- and dose-dependent reduction of EU incorporation
(Supplemental Figure 2.8C), validating the utility of this assay to determine the acute effect of
CDK9i on nascent RNA production. Genome-wide CRISPR-screens in THP-1 cells were performed and assessed for nascent RNA production to select a cell population that retained the capacity to efficiently incorporate EU in the presence of AZ5576 (Supplemental Figure 2.8D). In
concordance with the CDK9i survival screens shown in figures 1A and 1B, INTS6 sgRNAs were
enriched in two independent nascent RNA production screens (Figure 2.1C and D, Supplemental
Figure 2.8E), and INTS6 loss was the only resistance mechanism identified consistently across all
screens (Figure 2.1E; Supplementary Tables 1). Enrichment of sgRNAs targeting Integrator subunit INTS8 was observed in both phenotypic and transcription screens (Figure 2.1E, Supplemental
Figure 2.8E and F), suggesting that it may also play a role in regulating responses to CDK9i. The
INTS12 subunit also showed highly signficant enrichment in the CDK9i survival screen (Supplemental Figure 2.8F) while other Integrator subunits were not significantly enriched.
In competitive proliferation and cell death assays (Figure 2.1F), INTS6 deletion conferred a strong
selective survival advantage to THP-1 and MV4;11 cells treated with AZ5576 for up to 11 days,
whilst not providing a competitive advantage in DMSO treated cells (Figure 2.1G-H, Supplemental Figure 2.8G). The competitive advantage observed following INTS6 deletion was CDK9i dosedependent and INTS6 sgRNA expressing cells exhibited significantly lower cell death compared
to Scrambled sgRNA expressing cells after 24, 48 and 72 hours of treatment (Figure 2.1I, Supplemental Figure 2.8H). INTS6 deletion also provided a survival advantage to a CDK9 proteolysis
targeting chimera (PROTAC, 22-533; Supplemental Figure 2.8I and J), further demonstrating selectivity of the effect and highlighting that resistance does not arise from mechanisms acting on
the CDK9 protein directly. To definitively demonstrate that the INTS6 mediated resistance arises
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from on-target CDK9 inhibition we generated analog-sensitive (AS) mutant CDK9 THP-1 cells in
which the gatekeeper phenylalanine residue was mutated to an alanine (F103A) to allow for selective inhibition of the AS-CDK9 kinase using the bulky ATP analog 1-NA-PP1 [32] (CDK9AS/AS ;
Figure 2.1J and K, Supplemental Figure 2.8K). Consistent with the results using small molecule
CDK9i, INTS6 deletion in THP-1 CDK9AS/AS cells provided a competitive advantage over control cells in the presence of 1-NA-PP1. The CDK9i resistance phenotype mediated by INTS6 loss
was not the result of a general disruption of the Integrator complex as sgRNAs targeting distinct
Integrator subunits, INTS3 and INTS11, were unable to confer resistance to CDK9 inhibition
(Supplemental Figure 2.8L and M). INTS6 loss did not provide a competitive advantage following small molecule inhibition of the other major transcriptional CDKs, CDK7, CDK11, CDK12
and CDK13 (Figure 2.1L and Supplemental Figure 2.8N) and did not provide resistance to the
chemotherapeutic agent cytarabine (Supplemental Figure 2.8N), highlighting the specificity of
the resistance phenotype driven by INTS6 deletion for CDK9 inhibition. Importantly, ectopic expression of INTS6 fully re-sensitized cells with INTS6 deletion to CDK9i (Supplemental Figure
2.8O-Q). As validation for the nascent RNA screens, selective INTS6 deletion allowed for efficient
EU incorporation in the presence of CDK9i, whereas RNA production was almost completely abrogated in CDK9i-treated SCR sgRNA control cells (Supplemental Figure 2.8R). Taken together,
these data suggest that experimental deletion of INTS6 confers a selective resistance to CDK9
inhibition on a phenotypic level, that is not the result of disruption of the Integrator complex, offtarget effects or general antagonism of transcriptional CDKs. To investigate whether INTS6 loss
was also associated with acquired resistance to CDK9 inhibition we cultured MV4;11 cells under the selective pressure of increasing doses of CDK9i for 11 weeks (Supplemental Figure 2.8S).
This prolongued exposure rendered the MV4;11 cells less sensitive to CDK9 inhibition as compared to the DMSO-treated control and was concurrent with the spontaneous reduction in INTS6
protein expression (Supplemental Figure 2.8S) suggesting that the loss INTS6 may also play a role
in the context of acquired resistance to CDK9i.
The importance of INTS6 in regulating biological responses to CDK9i extends beyond MLLrearranged leukemia cells. First, we demonstrated that CRISPR-mediated deletion of INTS6 in
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HeLa cervical cancer and MM1.S multiple myeloma cells provides competitive proliferation advantage over control cells following prolonged exposure to AZ5576 (Figure 2.1M-O). Next, we
demonstrated that two independent non-transformed cell lines (HS-5 bone marrow stromal cells
and BJ-T fibroblasts ) exhibited robust dependency on INTS6 loss to overcome CDK9i (Figure
2.1P and Supplemental Figure 2.8T). Interestingly, BJ-T cells carrying an INTS6 deletion were
outcompeted by SCR control cells in the absence of CDK9i (DMSO treated control), suggesting
that in these normal cells INTS6 loss affects homeostatic functions (Supplemental Figure 2.8T).
Moreover, we examined the evolutionary conservation of functional antagonism between CDK9
and INTS6 by ablating IntS6 in D.melanogaster-derived S2 cells. As observed in several human
cell lines, deletion of IntS6 in S2 cells conferred resistance to CDK9 inhibition (Figure 2.1Q), a
phenotype that was rescued by ectopic expression of full-length IntS6 protein (Supplemental Figure 2.8U and V). Altogether, this body of work reveals that depletion of INTS6 confers resistance
to CDK9i across multiple model systems and organisms both at the phenotypic and transcriptional
levels.
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F IGURE 2.1

Loss of INTS6 confers resistance to CDK9 inhibition
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(A) Schematic of CRISPR-Cas9 genome-wide CDK9i survival and nascent RNA screens. (B) Venn diagrams
for significant enriched sgRNAs (CDK9i versus untreated at Tend) in survival screens in THP-1-Cas9 cells
(left; different CDK9 inhibitors) and using different genome-wide sgRNA libraries (adjusted p-value < 0.1
for > 3 sgRNAs in 1 or more replicate screens) (C) Enriched sgRNAs for replicate nascent RNA screens in
THP-1-Cas9 cells (significance relative to T0). (D) Enrichment of INTS6 targeting sgRNAs in CDK9i-treated
THP-1-Cas9 cells at endpoint relative to T0. (E) Comparison of enriched sgRNAs for genome-wide CDK9i
nascent RNA and survival screens. (F) Overview of sgRNA Competitive proliferation assays. (G) Western
blot of THP-1-Cas9 cells expressing indicated sgRNAs. (H) Competitive proliferation assay for THP-1-Cas9
cells expressing indicated sgRNAs in the presence of CDK9i and DMSO. (I) Annexin-V analysis of THP1-Cas9 cells expressing indicated SCR and INTS6 targeting sgRNAs treated as indicated for 72 hours. (J)
Schematic of analogue-sensitive mutant CDK9 (CDK9AS/AS) generated through the mutation of the gatekeeper phenylalanine (F103) to alanine. (K) Competitive proliferation assay for THP1 CDK9AS/AS cells
expressing CFP-Cas9 and sgSCR or mCherry(CH)-Cas9 and sgINTS6 treated with 1-NA-PP1 analogue as
indicated for 96 hours. (L) Competitive proliferation assay for THP-1-Cas9 cells expressing indicated sgRNAs in the presence of YKL-5-124 (CDK7i), THZ1 (CDK7i/CDK12i), THZ531 (CDK12i + CDK13i) and
OTS-964 (CDK11i). (M) Competitive proliferation assay for HeLa cells expressing CFP-Cas9 and sgSCR
or CH-Cas9 and sgINTS6 treated with CDK9i as indicated for 96 hours. (N) Western blot of HeLa cells expressing sgSCR or sgINTS6 (mixed) treated with CDK9i as indicated for 96 hours. Competitive proliferation
assay for (O) MM1.S and (P) HS5 cells expressing CFP-Cas9 and sgSCR or CH-Cas9 and sgINTS6 treated
with CDK9i as indicated for 96 hours. (Q) Annexin-V analysis of D.melanogaster¬ S2-Cas9 expressing indicated SCR and IntS6 targeting sgRNAs and treated as indicated for 72 hours. Blue dots (Figures C and E)
represent nominal p-value < 0.01. Figures G-M and L are representative of 3 independent experiments and
Figures O and P are representative of 2 independent experiments. Figures H, I, K-L and Q were analyzed by
2-way ANOVA, ** p < 0.01, *** p<0.001, **** p<0.0001.

2.3.2

INTS6 bridges the interaction between Integrator and PP2A

To determine how INTS6 regulates the transcriptional and biological responses to CDK9 inhibition, a series of LC-MS/MS analyses were performed to investigate the extended INTS6/Integrator
interactome. Immunoprecipitation (IP) of INTS6 from THP-1 and MV4;11 whole cell lysates resulted in the co-purification of the other 13 members of the Integrator complex (Figure 2.2A and
Supplemental Figure 2.9A-B). Interestingly, the PPP2R1A/PPP2R1B scaffold subunits and the
PPP2CA catalytic subunit (PP2A-C) of the PP2A phosphatase complex were highly enriched
(Figure 2.2A, Supplemental Figure 2.9A-B). Members of the RNAPII complex, including the
Rpb1/POLR2A catalytic core, also co-purified with INTS6 (Figure 2.2A, Supplemental Figure
2.9A-B). To examine the PP2A-Integrator association in a different human cell line, the endogenous INTS6 and PP2A proteomes were isolated from HeLa nuclear extracts and compared against
each other. Affinity purification with a monoclonal antibody specific for PP2A-C identified Integrator and RNAPII as the most abundant interactors of nuclear PP2A, as measured by iBAQ
16

values (Figure 2.2B). As in MLL-rearranged leukemia cells, endogenous INTS6 co-precipitated
all Integrator complex subunits along with RNAPII, and PPP2R1A and PP2A-C subunits (Figure 2.2B). Similar results were obtained in D.melanogaster S2 cells, attesting to the evolutionary conservation of the Integrator, PP2A, and RNAPII association (Supplemental Figure 2.9C). In
summary, proteomic analysis from three human cell lines revealed a robust interacting network between Integrator, RNAPII and PP2A (Figure 2.2C). Additionally, the catalytic subunit of the PP1
phosphatase was consistently found in every interactome (Figure 2.2A-C). We further validated
the interaction between endogenous PP2A and INTS6 in co-IP assays using a V5 epitope-tag immunoprecipitation in THP-1 cells with a V5-tag at the endogenous INTS6 loci (Figure 2.2D), as
well as using a monoclonal INTS6 antibody in HeLa cells (Figure 2.2E).
PP2A is a highly abundant protein complex found in both the nucleus and cytoplasm with the ability to dephosphorylate a wide range of protein targets [33]. PP2A has been previously demonstrated to associate with chromatin-bound transcriptional regulators such as RB1 [34] and BRD4
[35], and was recently demonstrated to regulate RNAPII activity in D.melanogaster through interaction with INTS8 [36]. While most PP2A is cytoplasmic, sub-cellular fractionation of HeLa
cells indicated that a substantial fraction of the phosphatase complex was found in both the nuclear compartment and the insoluble chromatin fraction, where the Integrator complex was also
detected (Supplemental Figure 2.9D). To assess whether INTS6 was directly implicated in recruiting PP2A to Integrator, affinity purification of chromatin-bound endogenous PP2A-C followed by
LC-MS/MS was performed in HeLa cells expressing shRNA targeting INTS6, or luciferase (LUC)
as a control (Figure 2.2F). As expected, IP of PP2A-C resulted in co-purification of Integrator subunits including INTS6, as well as RNAPII subunits including Rpb1/POLR2A (Figure 2.2F). However, following INTS6 depletion, PP2A-C no longer co-precipitated any component of Integrator
or RNAPII. To validate these results and assess specificity of the INTS6-PP2A association, INTS6
and other Integrator subunits including INST5, INTS8, and INTS12 were depleted by shRNA and
IP/western blot assays were performed (Figure 2.2G and Supplemental Figure 2.9E). Depletion
of INTS6 greatly affected the Integrator/PP2A association in HeLa nuclear extract, while the interaction was unperturbed by depletion of either INTS5 or INTS12 (Figure 2.2G). Interestingly,
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depletion of INTS8 also decreased the Integrator/PP2A association, consistent with the results of
our genetic screens where loss of INTS8 conferred some degree of resistance to CDK9i (Supplemental Figure 2.8F), suggesting that INTS8 may also contribute to the Integrator/PP2A functional
interaction. The importance of INTS6 in mediating the Integrator-PP2A interaction was validated
in THP-1 cells, with sgRNA-mediated deletion of INTS6 resulting in decreased co-IP of PP2A-C
and INTS11 (Figure 2.2H and Supplemental Figure 2.9F). Finally, the effect of INTS6 or INTS8
depletion on the basal catalytic activity and overall assembly of the Integrator complex was assessed. A PCR-based assay to measure levels of uncleaved (misprocessed) UsnRNAs was utilized
to assess catalytic Integrator activity (Figure 2.2I and Supplemental Figure 2.9G). While depletion
of a large structural subunit, such as INTS2, increased misprocessed UsnRNA levels by more than
40-fold, depletion of INTS6 or INTS8 had little or no effect (Figure 2.2I). Moreover, depletion of
INTS6 or INTS8 did not perturb migration of the Integrator complex on a glycerol gradient, unlike INTS2, suggesting that INTS6 and INTS8 are dispensable for the structural integrity of the
complex (Figure 2.2J). Interestingly, while depletion of INTS6 was sufficient to desensitize cells
to CDK9i, it did not disrupt the association of INTS8 with the Integrator complex (Supplemental
Figure 2.9H). Conversely, depletion of INTS8 seemed to abolish INTS6 recruitment to Integrator,
revealing an effect on INTS6 protein stability, as mRNA levels were unchanged (Supplemental
Figure 2.9E, I and J). Collectively, these data suggest that INTS6 is part of an Integrator module
responsible for recruitment of PP2A. This Integrator PP2A-module likely includes INTS8 and is
functionally and structurally distinct from the catalytic INTS11/9/4 module.
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F IGURE 2.2

INTS6 bridges the interaction between Integrator and PP2A
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(A) Log10 iBAQ scores of proteins identified in INTS6 IP mass spectrometry experiments for THP-1 versus
MV4;11 cells (filtered for proteins identified in isotype-control IP experiments). (B) Log10 iBAQ scores of
proteins identified in INTS6 versus PP2A-C IPs in HeLa cell nuclear extract. (C) Protein-protein interaction
network of INTS6, RNAPII, and PP2A interaction partners identified in THP-1, MV4;11, and HeLa INTS6
IP experiments. Co-IP western blot of (D) endogenous V5-tagged PPP2R1A IP in THP-1 cells and (E) endogenous PP2A-C, INTS3, and INTS11 IP in HeLa cells. (F) Log10 iBAQ scores of proteins identified in
PP2A-C IP mass spectrometry experiments in HeLa shLUC versus shINTS6 cells. (G) Co-IP western blot
for PP2A-C in shLUC, shINTS5, shINTS6, shINTS8, and shINTS12-infected HeLa cells. (H) Co-IP western
blot for PP2A-C in THP-1-Cas9 sgSCR and sgINTS6-KO cells. (I) Relative expression levels of misprocessed UsnRNA from shLUC, shINTS6, shINTS8, or shINTS2-infected HeLa cells. Values normalized by
expression of ribosomal RNA 18S, and GUSB is used as control (ctrl) mRNA. (J) Western blot of glycerol
gradient fractions of nuclear extracts from shLUC, shINTS6, shINTS8, or shINTS2-infected HeLa cells. IP
mass spectrometry experiments are representative of 3 (THP-1, HeLa) or 2 (MV4;11) independent experiments. Western blots are representative of 3 independent experiments. qPCR (I) was analyzed by one-way
ANOVA followed by Tukey’s HSD post-hoc test, **** p<0.0001.

2.3.3

INTS6 mediates the recruitment of PP2A to the transcription pause-release
checkpoint

Evidence of a physical interaction between INTS6, RNAPII, and PP2A, as well as the demonstration that loss of INTS6 opposed transcriptional pausing induced by CDK9i, raised the possibility that PP2A might co-localize with Integrator and RNAPII throughout the genome. ChIPseq assays in THP-1 cells were performed using antibodies specific for CDK9, BRD4, RNAPII,
INTS6, INTS11, and PPP2R1A (Figure 2.3A and B, Supplemental Figure 2.10A). As with BRD4,
RNAPII, and CDK9, Integrator subunits INTS6 and INTS11 localized to chromatin at or around
transcription start sites (TSS). Treatment of cells with the CDK9 inhibitor AZ5576 resulted in retention of RNAPII at the TSS proximal region, consistent with transcriptional pausing induced
by CDK9i (Figure 2.3A and B, Supplemental Figure 2.10A). Interestingly, there was a concomitant increase in chromatin-bound CDK9, potentially driven by the release of CDK9 from the inhibitory HEXIM1-containing 7SK snRNP complex acting as a compensatory mechanism. This
TSS-localised CDK9 recruitment was also observed, albeit to a lesser extent, in cells with INTS6
depletion, indicating that the resistance mediated by INTS6 loss does not arise from a further
increase in CDK9 recruitment to chromatin (Supplemental Figure 2.10B). BRD4 and INTS11
also accumulated at the TSS following AZ5576 treatment, consistent with the physical interaction between either BRD4 [17] or Integrator with RNAPII [1]. Notably, INTS6 followed an op20

posite trend and was slightly decreased upon CDK9i (Figure 2.3A and B and Supplemental Figure 2.10A). Consistent with our biochemical data that revealed PP2A in the chromatin fraction of
HeLa cells (Supplemental Figure 2.9D), PPP2R1A occupied nearly all actively transcribed genes,
mirroring the localization of BRD4, RNAPII, CDK9, and the INTS6 and INTS11 subunits of the
Integrator complex, and was also enriched around the TSS (Figure 2.3A and B, Supplemental Figure 2.10A).
To assess the dynamic recruitment of PP2A in response to a coordinated and rapid transcriptional
stimulus, ChIP-seq assays were performed using THP-1 cells treated for 3h with lipopolysaccharide (LPS). Treatment with LPS resulted in the expected increase of RNAPII recruitment along the
entire gene body of LPS-responsive genes (Figure 2.3C and D, Supplemental Figure 2.10C). Strikingly, LPS treatment stimulated rapid recruitment of PPP2R1A at the TSS and across the gene
body of LPS-responsive genes (Figure 2.3C and E, Supplemental Figure 2.10C). To control for
experimental variability, our PPP2R1A ChIP assays were performed alongside a D.melanogaster
S2 cell spike-in ChIP (anti-H2av), and these data obtained across multiple biological replicates
demonstrated significant recruitment of PP2A in response to LPS treatment (Figure 2.3F). To
further assess PP2A recruitment to chromatin in response to a physiological stimulus, Epidermal
Growth Factor (EGF) was used to stimulate transcription of Immediate Early Genes in HeLa cells
[6]. A dramatic recruitment of RNAPII, PPP2R1A, PP2A-C and INTS11 along the entire gene
body and the 3’ end of EGF-responsive genes was observed following 15 min treatment with EGF
(Figure 2.3G-I, Supplemental Figure 2.10D and E).
Interestingly, in both THP-1 and HeLa cells, closer analysis of read alignment around the TSS
revealed that PP2A recruitment gradually increased through the initiation region and peaked immediately 3’ of the pausing site (Supplemental Figure 2.10F and G). To further understand how
the PPP2R1A signal correlated with RNAPII, we performed broad peak analysis on four replicates of RNAPII and PPP2R1A ChIP-seq. We identified a set of genes that contained PPP2R1Apeaks in all four replicates (n=1398) and found that > 98 percent of these PPP2R1A-occupied
genes overlapped with RNAPII-peaks, suggesting that PPP2R1A is exclusively recruited alongside RNAPII (Supplemental Figure 2.10H). Although just a subset of those occupied by RNAPII,
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the PPP2R1A-occupied genes are among the most highly expressed (Supplemental Figure 2.10H),
suggesting a correlation between PP2A recruitment and high transcriptional output. Additionally,
the PPP2R1A-associated loci were enriched for genes encoding transcriptional regulators including RNAPII-associated DNA-binding transcription factors (Supplemental Figure 2.10I).
To further establish the ability of PP2A to bind a broad set of expressed genes, we treated HeLa
cells with a small molecule activator of PP2A (SMAP) for 2 hours. This category of PP2A activators is known to exert its activity by stabilizing heterotrimeric PP2A complexes [37, 38, 39]. Normalized, spiked-in ChIP-seq assays showed robust and significant increase of PPP2R1A binding
across the previously defined PPP2R1A-occupied genes (n=1398) in all replicates (Figure 2.3J and
K), whereas total RNAPII levels remained unchanged (Supplemental Figure 2.10J-L). To further
corroborate PP2A binding at chromatin, we obtained ChIP-seq profiles for the catalytic subunit
(PP2A-C), demonstrating a distribution mirroring PP2R1A across EGF responsive genes (Figure
2.3L) and robust correlation across all RNAPII-transcribed genes (Supplemental Figure 2.10M).
To ultimately determine whether INTS6 is critical for PP2A recruitment at actively transcribed
genes, we performed ChIP-seq assays in HeLa cells expressing shRNAs targeting LUC or INTS6.
Depletion of INTS6 dramatically reduced PPP2R1A binding across its target genes in a reproducible and significant manner, even when accounting for total RNAPII levels (Figure 2.3MO). In accordance with our previous observations that INTS8 abolishes PP2A-Integrator binding
and modulates the assembly of INTS6 into the main complex (Figure 2.2 and Supplemental Figure 2.9), depletion of INTS8 phenocopied that of INTS6 and severely reduced PP2A recruitment
genome-wide (Supplemental Figure 2.10N-P). Importantly, total protein levels of PP2A (assessed
by PPP2R1A and PP2A-C) were unchanged by shRNAs targeting either INTS6 or INTS8 (Figure
2.2G). Taken together, these findings demonstrate that pTEFb, Integrator, and PP2A localize to
chromatin under basal conditions, and that PP2A is actively recruited near pausing sites and across
the gene body of genes selectively activated by different physiological stimuli. Moreover, these
data demonstrate that INTS6 plays an important role in recruiting PP2A to chromatin.
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F IGURE 2.3

INTS6-dependent dynamic recruitment of PP2A at actively transcribed genes
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(A) Average profiles of ChIP-seq signal for CDK9, RNAPII, BRD4, INTS6, INTS11, and PPP2R1A around
the TSS, plus metagene occupancy heatmaps for indicated proteins in THP-1-Cas9 cells expressing SCR
sgRNA and treated as indicated for 2 hours. (B) Representative ChIP-seq signal the FUT4 locus for indicated proteins in THP-1 cells treated as indicated for 2 hours. (C) Representative RNAPII and PPP2R1A
ChIP signal at the BTG2 locus in THP-1 cells untreated or acutely treated with 5.0µg/mL LPS for 3 hours.
Average gene profiles for (D) RNAPII and (E) PPP2R1A ChIP-seq with input at LPS-induced genes (n=35)
in THP-1 cells under the same conditions. (F) Boxplot quantifying PPP2R1A ChIP-seq coverage at LPSinduced genes under indicated conditions in two biological replicates. (G) Representative signal of ChIP-seq
for indicated proteins at the CTGF locus in HeLa cells untreated or acutely treated with EGF (0.1µg/mL)
for 15 minutes. INTS11 ChIP-seq tracks are from a published dataset (Gardini et al., 2014). Average gene
profiles for (H) RNAPII, (I) PPP2R1A ChIP-seq with input at EGF-induced genes (n=50) in HeLa cells under the same conditions. J.Average gene profile for PPP2R1A ChIP-seq at PP2A-occupied genes (n=1398,
as defined in Fig.S3F) in Hela cells treated with SMAP (10µM) or DMSO for 2 hours. (K) Quantification
of PPP2R1A ChIP-seq coverage at PP2A-occupied genes (n=1398) normalized to RNAPII ChIP-seq coverage, under the same conditions in two biological replicates. (L) Average gene profile for PP2A-C ChIP-seq
with input at EGF-induced genes (n=50) in HeLa cells under the indicated conditions. (M) Average gene
profile for PPP2R1A ChIP-seq at PP2A-occupied genes (n=1398) in shLUC and shINTS6-infected HeLa
cells. (N) Quantification of PPP2R1A ChIP-seq coverage at PP2A-occupied genes (n=1398) in shLUC and
shINTS6-infected HeLa cells, normalized to RNAPII ChIP-seq coverage, in two biological replicates. (O)
Representative PPP2R1A ChIP-seq signal at the CITED4 locus in shLUC and shINTS6-infected HeLa. Scale
bar for C represents 5kb. Figures F, K, and N were analysed by unpaired, two-sided students t-test, ** p<0.01,
*** p<0.001, **** p<0.0001.

2.3.4

INTS6/PP2A dynamically controls CDK9 substrate phosphorylation levels

To investigate whether the functional antagonism between CDK9 and PP2A/INTS6 was reflected
at the phosphorylation level, reverse phase protein arrays (RPPA) were performed to accurately
quantify RNAPII CTD phosphorylation, in parallel with total phospho-proteomic analyses (Figure
2.4A). As expected, RPPA analysis of RNAPII CTD phosphorylation demonstrated that CDK9i
treatment resulted in a time-dependent loss of phospho-Ser2, phospho-Ser5, and phospho-Ser7
CTD levels in THP-1 cells transduced with control sgRNA (sgSCR) (Figure 2.4B). In contrast,
THP-1 cells with stable deletion of INTS6 (sgINTS6-KO) were largely refractory to CDK9 inhibition, with no significant loss of phosphorylation observed for any of the phospho-CTD antibodies (Figure 2.4B). Characterization of the total phospho-proteome by mass spectrometry identified a large number of CDK9i responsive phospho-peptides in sgSCR THP-1 cells that were resistant to CDK9i treatment in sgINTS6-KO cells (Figure 2.4C and Supplemental Figure 2.11A
and B). Importantly, this included key CDK9 substrates such as SUPT5H (DSIF, SPT5; Figure
2.4D and Supplemental Figure 2.11C), LEO1, and degenerate heptad repeats in the RNAPII CTD
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(POLR2A; Figure 2.4E and Supplemental Figure 2.11D). Gene-ontology (GO) analysis of phosphorylated proteins sensitive to CDK9i in sgSCR cells and resistant to CDK9i in sgINTS6-KO
cells revealed a strong enrichment for mRNA processing and RNA metabolic processes, suggesting that PP2A/INTS6 oppose CDK9 kinase activity on multiple levels (Supplemental Figure
2.11E).
Western blot validation using antibodies targeting specific phospho-residues of the RNAPII-CTD
and phospho-DSIF (SPT5) confirmed that THP-1 sgINTS6-KO cells were refractory to the CDK9i
mediated loss of phosphorylation observed in sgSCR control cells (Figure 2.4F), with this phenotype recapitulated in non-transformed BJ-T fibroblasts (Supplemental Figure 2.11F). Moreover,
INTS6 deletion largely abrogated the reduction in phosphorylation of DSIF and RNAPII-CTD that
was observed upon inhibition of AS-CDK9 using 1-NA-PP1 in THP-1 CDK9AS/AS cells (Figure 2.4G). Consistent with the phenotypic data (Figure 2.1L), the loss of INTS6 did not affect the
molecular consequences of CDK12/13 inhibition with THZ-531, with similarly reduced RNAPII
CTD phosphorylation observed in both control and INTS6-KO cells (Supplemental Figure 2.11G).
To assess whether the ability of PP2A/INTS6 to oppose CDK9 kinase activity is evolutionarily
conserved, analogous experiments in D.melanogaster S2 cells demonstrated that IntS6 deletion
conferred resistance to CDK9i-mediated loss of RNAPII-CTD phospho-Ser2 levels (Supplemental
Figure 2.11H).
To determine whether PP2A can directly dephosphorylate RNAPII CTD residues that are phosphorylated by pTEFb, in vitro kinase/phosphatase assays were performed using purified recombinant proteins (Figure 2.4H and Supplemental Figure 2.11I). As expected, incubation of a recombinant RNAPII-CTD peptide substrate with an active pTEFb complex comprising CDK9 and Cyclin T1 resulted in RNAPII-CTD peptide hyper-phosphorylation, as evidenced by western blots
showing increased migration and increased signal with antibodies that recognize pan-phospho
RNAPII-CTD and specific phospho-Ser2 antibodies (Figure 2.4H). Addition of a GST-tagged
PP2A catalytic subunit (PP2A-C) greatly reduced CDK9-mediated RNAPII-CTD peptide phosphorylation, which was partially rescued through inhibition of PP2A activity by Okadaic Acid,
but not with simultaneous CDK9 inhibition with AZ5576 (Figure 2.4H). To exclude the possi25

bility that PP2A opposes the catalytic activity of CDK9 and its ability to deposit new phosphormarks on the RNAPII CTD, we measured the CDK9-mediated conversion of ATP to ADP using
a luminescent ADP-Glo assay (Figure 2.4I) as a proxy for CDK9 catalytic activity. These assays revealed that while CDK9 kinase activity in vitro increased in the presence of the RNAPII
CTD peptide substrate and could be significantly inhibited by the addition of a CDK9 inhibitor, it
was unaffected by the concurrent addition of recombinant PP2A (Figure 2.4I). Futhermore, when
CDK9/CyclinT1 kinase activity was inhibited by AZ5576 after pre-incubation with the RNAPII
CTD peptide substrate for 50 minutes in vitro, PP2A was still capable of dephosphorylating the
CTD (Supplemental Figure 2.11J). Finally, to probe the importance of PP2A mediated CDK9 antagonism in an endogenous context, the recently reported specific PP2A inhibitor Phendione [40]
was used along with distinct PP1/PP2A inhibitors Calyculin A and Okadaic Acid. Consistent with
the phenotype observed in sgINTS6-KO THP-1 cells, PP2A inhibition with Phendione rescued the
loss of RNAPII-CTD phospho-Ser2 and SPT5 phosphorylation observed upon CDK9 inhibition
in wild-type THP-1 cells treated with CDK9i (Figure 2.4J) as well as THP-1 CDK9AS/AS cells
treated with the 1-NA-PP1 analogue (Supplemental Figure 2.11K). Rescue of CDK9-dependent
phosphor-marks was also observed upon co-treatment with CDK9i and dual PP1/PP2A inhibitors
Calyculin A and Okadaic acid suggesting a complex interplay between these two phosphatases
and CDK9 (Supplemental Figure 2.11L). These data highlight an evolutionarily conserved kinase/phosphatase antagonism between CDK9 and PP2A/INTS6 complexes that regulates the critical transcription pause-release factors RNAPII and SPT5.
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F IGURE 2.4

Loss of INTS6/PP2A results in decreased turnover of CDK9 substrates
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(A) Overview of CDK9-dependent phosphorylation studies in THP-1-Cas9 sgSCR and sgINTS6-KO cells.
(B) RNAPII CTD reverse phase protein array (RPPA): log fold change in relative fluorescence intensity
for indicated antibodies in CDK9i-treated versus untreated THP-1-Cas9 sgSCR and sgINTS6-KO cells at
indicated time points. (C) Heatmap of Z-scores of phospho-peptides in THP-1-Cas9 sgSCR and sgINTS6KO cells treated as indicated for 2 hours, p-value < 0.05. Identification of differentially phosphorylated (D)
SUPT5H and (E) POL2RA peptides in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2
hours. (F) Western blot of THP-1-Cas9 sgSCR and sgINTS6-KO cells treated with CDK9i as indicated for
2 hours. (G) Western blot of THP-1 CDK9AS/AS cells electroporated with recombinant Cas9 and SCR or
INTS6 targeting sgRNAs and treated with 1-NA-PP1 as indicated for 2 hours. (H) Western blot of in vitro
recombinant kinase / phosphatase assay; recombinant RNAPII CTD peptide was incubated with ATP in the
presence/absence of CDK9/CyclinT1 and/or PP2A as indicated for 30 minutes. (I) Overview of ADPGlo
assay; proportion of ATP converted to ADP by recombinant CDK9/Cyclin T1 incubated with recombinant
RNAPII CTD peptide in the presence/absence of PP2A and/or CDK9i as indicated for 30 minutes. (J) Western
blot of THP-1 cells treated as indicated (15 minutes pre-treatment with the PP2A inhibitor Phendione and
2 hours with CDK9i). Three biological replicates were analysed for RPPA and ten biological replicates
were analysed for phospho-peptide mass spectrometry. Western blots are representative of three independent
experiments. Figure I represent the mean +/- SEM of three independent experiments. For Figure F and G,
TUBULIN (#) is representative of individual immunoblots for phospho-CTD and phospho-SPT5 sites. RPPA
(B) was analysed using Welch unpaired t-test, * p<0.05, ** p<0.01.

2.3.5

Loss of INTS6/PP2A overrides a CDK9i-dependent block of transcription
elongation

To assess the impact of INTS6/PP2A loss on CDK9i-induced suppression of nascent transcription, 4-thiouridine metabolic labelling followed by RNA sequencing (4sU-seq) was performed
in sgINTS6-KO and sgSCR THP-1 cells (Figure 2.5A). Data were normalized through the addition of 4sU-labelled RNA from D.melanogaster S2 cells. Strikingly, 4sU-seq analysis revealed
that the global AZ5576-dependent decrease of transcription seen in sgSCR THP-1 cells was significantly rescued to near-baseline levels across all expressed genes in THP-1 sgINTS6-KO cells,
even after six hours of sustained inhibition of CDK9 kinase activity (Figure 2.5B and Supplemental Figure 2.12A). Similarly, nascent transcription in THP-1 cells was significantly rescued by
INTS6 loss at highly expressed genes (top 1000), which are enriched for chromatin organization
and mRNA metabolic processes, and the most sensitive genes to CDK9 inhibition (top 1000 downregulated genes, p < 0.05), which are enriched for immune effector processes (Figure 2.5C and
D, Supplemental Figure 2.12A; Supplementary Table 2). A significant rescue of nascent transcription in sgINTS6-KO cells compared to sgSCR control was also observed at key loci, including
at the IL6R and MYC genes (Figure 2.5E, Supplemental Figure 2.12B and C). ChIP-seq assays
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further demonstrated that compared to sgSCR control cells, sgINTS6-KO THP-1 cells exhibited
reduced accumulation of total RNAPII at TSS proximal regions as well as increased maintenance
of RNAPII-CTD phospho-Ser2 throughout the gene body and at the transcription end site (TES)
following AZ5576 treament (Figure 2.5F, Supplemental Figure 2.12D-I). Importantly normalization of the RNAPII-CTD phospho-Ser2 signal over total RNAPII confirms the conservation of
phosphorylated RNAPII (CTD phospho-Ser2) at TSS-proximal regions in sgINTS6-KO THP1
cells treated with CDK9i (Supplemental Figure 2.12F). The impact of INTS6 depletion was also
conserved across the most highly expressed genes as well as those genes identified in the 4sUseq analysis to be most sensitive to CDK9 inhibition, with sgINTS6-KO cells exhibiting a lesser
decrease in RNAPII gene body coverage compared to sgSCR cells across both these cohorts (Supplemental Figure 2.12H). Importantly, for genes that are less sensitive to CDK9i-mediated transcriptional inhibition, which are enriched for cellular catabolic processes (Supplementary Table
2), there was no difference in RNAPII gene body signal observed between sgSCR and sgINTS6KO cells (Supplemental Figure 2.12H). Calculation of the pausing index (the ratio of total RNAPII
ChIP-seq reads at TSS vs. gene body regions) for all transcribed genes showed that INTS6 loss
reduced AZ5576-induced pausing in comparison to the effect seen in AZ5576-treated sgSCR
THP-1 cells, suggesting maintenance of RNAPII pause-release and elongation in the absence of
full CDK9 kinase activity (Figure 2.5G). The evolutionary conservation of this phenotype was
validated in D.melanogaster S2 cells, with reduced RNAPII pausing observed in AZ5576-treated
sgIntS6 S2 cells compared to the effect of AZ5576 in sgSCR cells (Supplemental Figure 2.12J).
To determine the effect of INTS6/PP2A loss on acutely activated genes that were suppressed by
CDK9i, INTS6 was depleted from HeLa cells (Supplemental Figure 2.12K) and cells were pretreated with AZ5576 for 2 hours prior to stimulation with EGF for 15 minutes. ChIP-seq demonstrated that total RNAPII and RNAPII phos-Ser2 accumulated genome-wide in INTS6-depleted
HeLa cells treated with AZ5576, with accumulation most clearly observed across the gene bodies
of EGF-responsive genes, in contrast to the reduced ChIP-seq signal observed in control shLUC
cells (Figure 2.5H and I, Supplemental Figure 2.12L-N). The experiment was repeated with the
CDK9 inhibitor flavopiridol, with INTS6-depleted cells showing broad escape of pausing after
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only one hour of treatment, as opposed to the control sample (Supplemental Figure 2.12O-Q).
Consistent with our biochemical and functional genomics evidence that implicated the INTS8
subunit in the PP2A-Integrator association (Figure 2.2 and 3), depletion of INTS8 phenocopied
INTS6 loss and conferred resistance to CDK9i-induced pausing (Supplemental Figure 2.12O-Q).
Consistent with the ChIP-seq data for RNAPII and RNAPII phospho-Ser2 detailed above, fastGRO assays [41] to assess nascent RNA production demonstrated that depletion of INTS6 in HeLa
cells counteracted CDK9i-induced transcriptional pausing at all EGF-stimulated genes (Figure
2.5J and K). A broader analysis of the highest-expressed genes (n=2989) demonstrated that INTS6
depletion decreased the pausing index of nearly all active genes (Figure 2.5L), similar to the effects observed in THP-1 sgINTS6-KO cells treated with AZ5576 (Figure 2.5F and G). To determine if the escape from CDK9i-induced pausing observed following INTS6 depletion was phenocopied by depletion of PP2A, RNAPII phospho-Ser2 ChIP-seq assays were performed using HeLa
cells with shRNA-mediated knockdown of PPP2R1A or control knockdown cells (shLUC; Supplemental Figure 2.12R) that had been treated with vehicle or AZ5576 for two hours prior to stimulation with EGF for 15 min. Depletion of PPP2R1A resulted in sustained EGF-induced RNAPII
phospho-Ser2 coverage across EGF-stimulated genes in the presence of AZ5576, particularly
along the first half of the gene body (Supplemental Figure 2.12S), consistent with the aberrant
accumulation of phosphor-Ser2 in the 5’ of the gene after INTS6-mediated escape from CDK9iinduced pausing. Collectively, data from various experimental systems revealed that loss of INTS6
promotes both basal and EGF-stimulated transcriptional elongation and decreases RNAPII susceptibility to CDK9i-induced pausing. Moreover, loss of PP2A phenocopied the transcriptional
modulatory effects of INTS6 deletion/depletion.
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F IGURE 2.5

PP2A/INTS6 loss overrides CDK9i-induced transcriptional pausing
31

(A) Overview of 4sU labelling and analysis of nascent transcription in THP-1-Cas9 sgSCR and sgINTS6KO cells. Log fold change in 4sU-seq signal (CPM) relative to untreated cells in sgSCR and sgINTS6-KO
THP-1-Cas9 cells for (B) all expressed genes, (C) highly expressed genes and (D) CDK9i-sensitive genes.
(E) Example of 4sU-seq signal at the IL6R locus under indicated conditions. (F) RNAPII phospho-Ser2
ChIP-seq signal at the IL6R locus in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2
hours. (G) Pausing index in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated for 2h with CDK9i. (H)
RNAPII and phospho-Ser2 RNAPII ChIP-seq signal at the DDIT4 locus in shLUC and shINTS6 infected
HeLa cells treated with CDK9i for 2 hours and acutely treated with EGF (0.1µg/mL) for 15 minutes. (I)
Average profile of phospho-Ser2 RNAPII ChIP-seq signal, normalized to total RNAPII, under the same conditions at EGF-response genes (n=50). (J) Representative Fast-GRO signal at NR4A1 and FOSB in shLUC
or shINTS6 infected HeLa cells treated with CDK9i for 2 hours and acutely treated with EGF (0.1µg/mL)
for 15 minutes. (K) Average Fast-GRO signal across EGF response genes (n=50) under indicated conditions.
(L) Pausing index calculated by Fast-GRO for CDK9i-treated shLUC and shINTS6 infected HeLa cells at
highest-expressed genes (n=2989). Pausing index defined as (TSS-region coverage)/(Gene-body coverage),
where TSS-region is defined as 50bp upstream of TSS through 150bp downstream of TSS and gene-body is
defined as 151bp downstream of the TSS through the annotated TES. Scale bar for E and F represents 10kb.
Average profiles show 5kb upstream and downstream of the TSS and TES, respectively. Figures B-D were
analysed by unpaired, two-sided students t-test, **** p<0.0001

2.3.6

The INTS6/PP2A axis fine-tunes acute transcriptional responses

While the 4sU-seq, ChIP-seq, and fastGRO nascent RNA analysis demonstrated decreased responsiveness of THP-1 and HeLa cells to CDK9i-induced pausing following the loss of INTS6
expression (Figure 2.5), we further wished to investigate the importance of INTS6 for controlling
transcriptional responses under physiological conditions. Interestingly, ChIP-seq experiments in
THP-1 cells demonstrated increased RNAPII occupancy at the TSS region and in the gene body
of expressed genes following acute (60 hours) INTS6 depletion (Supplemental Figure 2.13A-C),
suggesting that steady state RNAPII-driven transcription is modulated by INTS6 loss in the absence of CDK9 inhibition. Consistently, fastGRO analyses of INTS6-depleted HeLa cells showed
increased elongating RNAPII along the body of the 3000 highest expressed genes, even in the absence of CDK9i (Supplemental Figure 2.13D). While shRNA-mediated depletion of INTS6 in
HeLa cells only modestly increased RNAPII or phospho-Ser2 RNAPII accumulation near the
TSS of EGF-responsive genes, an increase in detectable RNAPII phospho-Ser2 across the gene
bodies and 3’ ends of EGF-responsive genes was observed in INTS6-depleted HeLa compared
to control cells (Figure 2.6A-B). The increase of RNAPII phospho-Ser2 ChIP signal was specifically observed following INTS6 depletion and was not observed upon depletion of the Integra32

tor subunit INTS12 (Figure 2.6B). Similar RNAPII and RNAPII phospho-Ser2 ChIP-seq results
were obtained using HeLa cells depleted of PPP2R1A and treated with EGF, supporting the notion that INTS6 and PP2A functionally cooperate to regulate activated transcriptional elongation
(Figure 2.6C-D). Further supporting the observed increase of RNAPII pause-release and elongation following perturbation of the INTS6/PP2A axis, measurement of nascent RNA production by
transient-transcriptome sequencing (TT-seq) demonstrated a significant increase of EGF-induced
transcription following depletion of INTS6 (Supplemental Figure 2.13E).
Examination of steady-state RNA levels by 3’ mRNA-seq (Quantseq) using an extended time
course of EGF treatment (Figure 2.6E) demonstrated that depletion of INTS6 amplified transcriptional activation of EGF-responsive genes, up to 180 minutes after stimulation (Figure 2.6F and
G), an effect also observed in the presence of CDK9i (Supplemental Figure 2.13F). Since the
EGF-responsive Immediate Early Genes are periodically activated in waves of approximately
30-40 minutes [42], these data suggest that in this context human cells do not functionally compensate for loss of the INTS6/PP2A axis. The role of INTS6/PP2A in regulating transcriptional
responses to physiological stimuli was further assessed by 3’ mRNA Quantseq in THP-1 cells
with and without stable knockout of INTS6 that were treated over time with LPS (Figure 2.6H).
Canonical LPS gene expression programs were induced in THP-1 cells in response to LPS treatment (Figure 2.6I, Supplemental Figure 2.13G and H), with significantly greater up-regulation
of LPS-response genes measured in sgINTS6-KO cells compared to sgSCR controls at all timepoints (Figure 2.6J and K). Expression of key inflammatory LPS-target genes, such as CXCL1,
IL1B, IL23A, and SERPINE2 increased in a time-dependent manner, peaking at 2 to 4 hours posttreatment, with greater levels of gene expression observed in sgINTS6-KO cells under all conditions (Figure 2.6L). These data provide evidence that PP2A recruitment via INTS6 is required to
fine-tune acute transcriptional responses to important pro-inflammatory or growth stimuli.
Dysregulation of inflammatory, developmental, and growth signalling pathways, such as WNT and
EGF signalling, can fuel cancer initiation and progression. Although activation of oncogenic signaling pathways is mostly driven by upstream mutations in the signalling mediators, loss of the
tight transcriptional control over the gene expression responses induced downstream of these path33

ways may further impact disease aetiology. To this end, we examined the role of INTS6 in publicly available data from The Cancer Genome Atlas (TCGA). Analysis of TCGA datasets revealed
that INTS6 deletion is a common occurrence in a wide variety of cancer types, with decreased
INTS6 copy number reflected by reduced INTS6 mRNA expression (Supplemental Figure 2.13I
and J). In a number of human cancers INTS6 deletion appears to correlate with poor-prognosis
(Supplemental Figure 2.13K). Analysis of gene-signatures associated with INTS6 deletion revealed that INTS6 loss was associated with the induction of E2F cell cycle and MYC signatures
with concurrent downregulation of genes located proximal to the INTS6 genomic locus on the
long arm of chromosome 13 at position 14 (13q14) (Figures SL-M).
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F IGURE 2.6

The INTS6/PP2A axis fine-tunes acute transcriptional responses
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(A) RNAPII and RNAPII phospho-Ser2 ChIP-seq signal at the CTGF locus after EGF treatment (0.1µg/mL;
15 minutes) in shLUC and shINTS6 infected HeLa cells. (B) Average profile of RNAPII phospho-Ser2 ChIPseq signal at EGF-response genes (n=50) in shLUC, shINTS6, and shINTS12 infected HeLa cells after EGF
treatment (0.1µg/mL; 15 minutes), with quantification of the total RNAPII-normalized phospho-Ser2 ChIPseq coverage in the inset boxplot. (C) RNAPII and RNAPII phospho-Ser2 ChIP-seq signal at the CTGF locus
after EGF treatment (0.1µg/mL; 15 minutes) in shLUC and shPPP2R1A infected HeLa cells. (D) Average
profile of RNAPII phospho-Ser2 ChIP-seq signal under the same conditions at EGF-response genes (n=50),
with quantification of the total RNAPII-normalized phospho-Ser2 ChIP-seq coverage in the inset boxplot. (E)
Overview of acute EGF stimulation (0.1µg/mL; 15, 55, and 180 minutes) of shLUC and shINTS6 infected
HeLa cells. (F) Log fold change (CPM) in EGF-treated versus untreated shLUC and shINTS6 infected HeLa
cells at indicated timepoints. (G) Log fold change difference between shLUC and shINTS6 infected HeLa
cells (EGF versus untreated) at indicated timepoints. (H) Overview of acute LPS stimulation (1µg/mL; 1,
2, 4 and 6 hours) of THP-1-Cas9 sgSCR and sgINTS6-KO cells. (I) GSEA profile of THP-1-Cas sgSCR
cells treated with LPS (2 hours versus 0 hours). (J) Log fold change (CPM) in LPS-treated versus untreated
THP-1-Cas9 sgSCR and sgINTS6-KO cells at indicated time-points. (K) Log fold change difference between
THP-1-Cas9 sgINTS6-KO and sgSCR cells (LPS versus untreated) at indicated time-points. (L) LPS-target
gene expression in THP-1-Cas9 sgSCR and sgINTS6-KO cells at indicated time-points. Figures B, D, F, and
J were analysed by unpaired, two-sided students t-test, ** p<0.01, *** p<0.001, **** p<0.0001.

2.3.7

Molecular and therapeutic synergy between CDK9 inhibition and PP2A activation

Targeting of CDK9 can be therapeutically efficacious in pre-clinical models of MLL-rearranged
leukemia [43] and various other hematopoietic malignancies [44] and CDK9i have progressed
to clinical trials for both haematological and solid malignancies [45]. Recently, small molecule
activators of PP2A (SMAPs) have been developed, which act by stabilizing PP2A heterotrimers
[37, 38, 39] and we have shown here that SMAPs potentiate recruitment of PP2A to chromatin at
actively transcribed genes (Figure 2.3J and K). Importantly, SMAPs have been demonstrated to be
therapeutically effective in combination with MEK inhibitors in KRAS-mutant lung cancer models [38]. The mechanistic data detailed above provide a strong rationale to target the CDK9/PP2A
controlled pause-release checkpoint via concurrent CDK9 inhibition and SMAP-mediated PP2A
enhancement to treat a range of cancers. In vitro drug synergy studies were initially performed using CDK9i and the SMAP DBK-1154 in THP-1 and MV4;11 leukaemia cells used for genomewide CRISPR resistance screens (Figure 2.1). This demonstrated that at EC50 concentrations
of CDK9i, DBK-1154 greatly enhanced the induction of cell death in THP-1 and MV4;11 cells,
with no single agent activity observed even at high concentrations of DBK-1154 (Figure 2.7A top
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panel and Supplemental Figure 2.14A-B). Importantly, no synergy was observed between CDK9i
and DBK-1154 in sgINTS6-KO THP-1 cells, even at high-dose CDK9 inhibitor treatment, indicating that the therapeutic synergy depends on the INTS6-mediated recruitment of PP2A to the
pause-release checkpoint (Figure 2.7A bottom panel). To assess the broader implications of these
findings, we performed in vitro drug synergy studies across a panel of genetically-diverse human
multiple myeloma and AML cell lines, including non-MLL-rearranged malignancies (HL-60 and
OCI-AML3) (Supplemental Figure 2.14C), as well as solid epidermoid (A431) and colorectal
(HT-29) cancer cell lines (Supplemental Figure 2.14D and E). In all assessed cell lines, combination treatment with CDK9i and DBK-1154 resulted in increased cell death compared to either
single agent alone, highlighting the broad potential to apply this therapeutic strategy across multiple cancer types (Supplemental Figure 2.14C-E). The synergy between CDK9i and DBK-1154
was also reflected on the transcriptional level with markedly enhanced RNAPII pausing observed
in THP-1 cells concurrently treated with both compounds, compared to single agent CDK9i (Figure 2.7B and C). Consistent with the phenotypic data, DBK-1154 treatment alone had a minimal
impact on RNAPII pausing (Figure 2.7B and C), suggesting that, under steady state conditions,
functional compensation is possible to counteract increased PP2A activity. The enhanced transcriptional impact of combined CDK9 inhibition and PP2A activation was reproduced in HT-29
cells where dual CDK9i and DBK-1154 treatment significantly suppressed global mRNA transcription relative to both single agents (Supplemental Figure 2.14F), with combination treatment
resulting in increased down-regulation of the expression of key genes associated with oncogenesis
in colorectal cancer (Supplemental Figure 2.14G; IRF1, MYC, PLAUR, ID2).
To assess the therapeutic benefits of combined CDK9 inhibition with PP2A agonism in vivo, a series of experiments were performed which composed of a cross-sectional analysis that determined
the effects of therapy on leukemic progression after acute treatment, and a chronic long-term survival experiment that interrogated whether therapy resulted in survival benefit in both disseminated
leukaemic and solid cancer xenografts (Figure 2.7D). NOD-scid IL2Rgnull (NSG) mice bearing
mCherry/Luciferase-tagged MV4-11 leukemias or A431 subcutaneous tumors were treated with
the in vivo-optimised CDK9 inhibitor AZD’4573 [46] and the prototype tricyclic-sulfonamide
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PP2A activator DBK-1154 [47, 48]. Cross-sectional analysis of mouse bone marrow and spleen 96
hours post-one cycle of combination therapy showed marked reduction in the number of mCherrypositive MV4;11 cells relative to single agent and vehicle controls (Figure 2.7E). These observations corresponded with concomitant reduction in overall spleen size 24 hours post therapy (Supplemental Figure 2.14H and I), suggesting that AML blasts rapidly undergo apoptosis upon combination treatment and that induction of normal erythroblastic and myeloblastic maturation occurs
(Supplemental Figure 2.14J). The enhanced effect of the combination treatment was also evident
after extended combination therapy (Supplemental Figure 2.14K). Similarly, monitoring progression of A431 solid tumors demonstrated reduced tumor growth rates in individual mice receiving
combination therapy (Supplemental Figure 2.14L) with a significantly reduced mean tumor volume measured across the combination therapy cohort relative to the vehicle control group (Supplemental Figure 2.14M). Long-term treatment of mice harbouring either disseminated MV4;11
leukaemia or orthotopic A431 tumors with four cycles of combination therapy resulted in a significant survival advantage over vehicle controls, with significantly extended survival compared to
single agent CDK9i and DBK-1154 also observed in the haematological model (Figure 2.7F).
Collectively, these data demonstrate that across a diverse panel of haematological and solid malignancies, combined inhibition of CDK9 and agonism of PP2A results in marked acute anti-cancer
effects both in vitro and in vivo including in the bone marrow, spleen and primary tumour, and
provides significant long-term survival advantage in chronically-treated mice.
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F IGURE 2.7

Therapeutic and molecular synergy between PP2A agonist and CDK9i
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(A) Annexin-V analysis of THP-1-Cas9 sgSCR and sgINTS6-KO cells treated with CDK9i, DBK-1154 or
a combination of both as indicated for 72 hours. Orange lines indicate single agent CDK9i activity and
maximal synergistic activity with DBK-1154. (B) RNAPII pausing index for ChIP-seq analysis of THP-1
cells treated with CDK9i (170nM for 2 hours) with or without 15 minutes pre-treatment with DBK-1154
(10µM). (C) Representative RNAPII ChIP-seq signal at the IL6R locus under the same conditions as B. (D)
Schematic of in vivo experimental protocol: cross-sectional analysis of acute effects on AML progression
and long-term survival in AML and solid cancer models in recipients treated with AZD’4573 + DBK-1154
combination therapy. (E) Quantitation of mCherry-positive AML blasts in bone marrow and spleen at 96
hours post-therapy. (F) Kaplan-Meier survival curves for long-term survival experiments at the conclusion
of 4 rounds of therapy for disseminated MV4-11 (n = 8 mice per group) and subcutaneous A431 (n = 7
mice per group) tumor models. One mouse in the MV4-11 cohort treated with combination therapy was
censored due to acute toxicity and removed from the analysis. One mouse in the A431 cohort treated with
single-agent AZD’4573 was censored due to acute toxicity and removed from the analysis. (G) Schematic of
Integrator/PP2A/CDK9 axis. Figure A is representative of the mean +/- SEM of 3 independent experiments.
Figure E error bars represent the SD of 3 mice per group and Figure F represents 8 (MV4-11) or 7 (A431)
mice per group. Figure A was analyzed by 2-way ANOVA, Figure E was analyzed by Students t-Test and
Figure F was analyzed by Log-rank (Mantel-Cox) test, * p < 0.05, ** p < 0.01, *** p<0.001. Scale bar for
C represents 10kb.

2.4

Discussion

RNAPII-driven transcription is a stepwise process comprising of distinct checkpoints, each controlled by dedicated transcriptional CDKs and their cognate cyclins [49, 50]. In metazoans, the
pause-release checkpoint controlled by pTEFb is believed to be the rate-limiting step in the transcription cycle for most protein coding genes [51]. While the basal transcription machinery, including CDK9, is remarkably conserved through evolution, multicellular organisms boast additional multi-subunit regulatory complexes, such as SEC and Integrator, that modulate activity of
the basal machinery and coordinate co-transcriptional processes in response to developmental, environmental, and immunological cues [50, 7, 1, 19]. In yeast, PP1 has recently been demonstrated
to be a substrate of Cdk9 and acts to functionally antagonize Cdk9 by dephosphorylating Spt5
to control the elongation-termination transition [26], with this function of PP1 being conserved
in humans [27, 52, 53]. CDK9 activity has also been recently demonstrated to be antagonised by
the PP4 phosphatase during early states of transcription in both C. elegans and humans [27, 54].
These studies provide important insights into the molecular mechanism by which phosphatases
oppose CDK9 activity at the level of SPT5. Nonetheless, our understanding of the phosphatasemediated antagonism of CDK9 at the pause-release checkpoint is less well defined and it remains
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to be determined whether and how CDK9 substrates, such as the RNAPII CTD and SPT5, are subject to continual turnover at this often rate-limiting step in the transcription cycle.
The study herein provides comprehensive, genome-wide evidence that CDK9 is functionally antagonized in metazoans by the PP2A phosphatase, which is recruited by the RNAPII-associated
Integrator complex at the pause-release checkpoint. These data indicate that CDK9 phosphosubstrates are dynamically controlled prior to and during productive transcriptional elongation,
providing an additional regulatory layer of transcriptional control (Figure 2.7G). In addition to its
role in transcriptional pause-release, CDK9 has also been demonstrated to control RNAPII termination [55] and RNA processing by phosphorylating substrates such as the exoribonuclease XRN2
[56]. It remains to be investigated whether the functional antagonism between CDK9 and IntPP2A extends beyond the pause-release checkpoint to the final steps of transcription. Although alterations in XRN2 phosphorylation were not detected in our proteomic analysis, the potent CDK9i
resistance phenotype conferred by INTS6 depletion suggests that other essential CDK9 controlled
pathways are intact in these cells. Recruitment of PP2A extends into the gene body and 3’ end of
genes, mirroring RNAPII and suggesting that PP2A controls levels of CTD phosphorylation from
end to end. It is noteworthy that, in addition to PP2A, PP1 may play a critical role in mediating the
dephosphorylation of CDK9 substrates as has been described in yeast and human [26, 27, 52, 53].
In agreement with these findings, we also found that PP1 immunoprecipitated with INTS6, and
loss of RNAPII and DSIF phosphorylation upon CDK9 inhibition was more potently antagonized
when both PP2A and PP1 were inhibited. Interestingly, yeast PP1 plays an important role in regulating PP2A signaling by directly activating the PP2A during mitosis [57]. It is possible that in
addition to its role in directly regulating SPT5 phosphorylation, PP1 also acts upon the Int-PP2A
complex during the RNAPII transcription cycle by modulating the activity of PP2A complexes
and thereby indirectly regulating the turnover of CDK9 substrates [26]. In addition to its role in
the phosphorylation of NELF, DSIF and RNAPII, CDK9 also functionally interacts with the Pol2associated-factor 1 (PAF1) containing complex, for which divergent roles have been described
resulting in either increased or decreased CDK9 recruitment and RNAPII pause-release [58, 59].
CDK9 has been proposed to tightly control the recruitment of PAF1C [59], and PAF1C becomes
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stably associated only to the elongating form of Polymerase [60]. It is interesting to speculate that
potentially the turnover of phospho-substrates at the pause-release checkpoint may be dynamically
controlled by the interplay between PAF1/CDK9 and the Int-PP2A complex.
The role of Int-PP2A in antagonizing CDK9 is broadly detected genome-wide and also seems especially important during acute transcriptional responses to LPS and EGF, as unopposed RNAPII
pause-release by CDK9 amplifies the magnitude of pro-inflammatory signals and the duration of
mitogenic stimuli. It is possible that the Int-PP2A-mediated negative feedback loop may have coevolved with the emergence of the CDK9-mediated pause-release in early metazoans, in order
to fine-tune transcription in multicellular organisms that have to respond to developmental and
environmental cues. Concordantly, the multifunctional Integrator complex first arises in metazoans. The Integrator complex, comprised of 14 subunits, appears to have a multifaceted role in
transcription and RNA processing by coordinating termination of short noncoding RNAs through
the INTS11/INTS9 catalytic core [1, 7, 28, 61]. Additionally, Integrator’s catalytic core may help
coordinate RNAPII pause-release. Specifically, depletion of the INTS11 subunit can prevent SEC
recruitment and productive elongation in human cells [6] possibly by using its endonucleolytic activity to identify and clear out nascent transcripts engaged by non-productive RNAPII elongating
forms [62]. Conversely, the D.melanogaster Ints9 subunit may impair RNAPII release by prematurely cleaving nascent transcripts at selected genes [29, 63]. Data presented herein demonstrated
that loss of INTS6 did not affect the catalytic activity of Integrator, nor did it perturb the overall
complex integrity. Our data are instead consistent with a new functional module of Integrator that
functionally associates with PP2A. While INTS6 has an important functional role in PP2A recruitment, we found that INTS8 is an additional component of the Integrator’s PP2A-module, as its
depletion functionally recapitulates resistance to CDK9i and abrogates PP2A binding, possibly
by preventing the assembly of INTS6. Our findings are concordant with an important recent study
that identified INTS8 as a bridge between Integrator and PP2A in D.melanogaster [36]. Additional Integrator subunits may structurally or functionally support the PP2A module: for example,
the INTS3 subunit was shown to interact with INTS6 via a C terminal domain [64] and has been
previously proposed as a negative regulator of RNAPII pause-release [65]. Future studies might
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further address the mechanistic contribution of INTS3 to RNAPII regulation. The modular nature
of Integrator was recently revealed by a study of the INTS13 subunit, and its ability to regulate enhancer activation independent from the core complex [66]. Our data further suggests that Integrator’s activity is the result of an intricate interplay between the core-complex, peripheral modules,
and auxiliary members such as the PP2A holoenzyme.
Interestingly, INTS6 underwent a gene duplication event in mammals with the highly homologous INTS6-like (INTS6L/DDX26B) protein, proposed to localize to mitochondria, whereas
INTS6 localizes to the nucleus. Accordingly, both mitochondrial and transcriptional roles have
been attributed to the ancestral INTS6 protein in lower organisms [28]. In agreement with the
disparate roles for INTS6 and INTS6L, our screens revealed no enrichment for loss of INTS6L.
There is growing evidence that the loss of INTS6 may play an important role in cancer. Indeed
INTS6 was originally identified and named for being frequently deleted in cancer 1 (DICE1),
with loss or downregulation of INTS6 shown to occur in prostate cancer, hepatocellular carcinoma, and hematopoietic malignancies [67, 68, 69]. The tumor suppressive role of INTS6 may
be attributed to its proposed role in the sensor of the ssRNA (SOSS) complex, which controls the
double stranded DNA damage response [64]. However, we propose that INTS6 loss may also promote oncogenic transcription by facilitating pause-release, as it is observed in transcriptionally
addicted MLL-rearranged leukemias and MYC-driven lymphomas [22, 19]. Indeed, analysis of
TCGA datasets revealed that INTS6 is frequently deleted in human cancers and correlated with
poor-prognosis in a subset of these malignancies. Importantly, INTS6 may be co-deleted with
the Retinoblastoma (Rb) tumour suppressor gene which is proximally located on the 13q14 locus and which also exhibits reduced expression in those tumours which carry an INTS6 deletion.
This raises the possibility that concurrent INTS6 loss may potentially impact the transcriptional
landscape of cancers with Rb deletions. Nonetheless, the role of INTS6 as a tumour-suppressor
remain to be formally demonstrated across a wide range of cancers. Reduction of PP2A activity
through epigenetic silencing and/or somatic mutations also occurs in several tumors, including
AML [70, 71]. Moreover, frequently occurring mutations in the PPP2R1A subunit of the PP2A
complex that have been described in uterine and ovarian cancers may affect its binding to interac43

tion partners such as the Integrator complex [72, 71]. Aberrant PP2A activity in cancer may thus
directly affect the transcription cycle to drive a transcriptionally dysregulated state, in addition to
its impact on oncogenic signaling pathways. Taken together, dysregulation of the Int-PP2A complex may contribute to dysregulated transcriptional states in cancer and affect disease initiation or
progression.
The recognition that perturbation of core-transcriptional components can fundamentally drive
oncogenesis in a variety of cancers has spurred the development of small-molecule inhibitors targeting this process. Indeed, numerous CDK9 inhibitors have demonstrated promising results in
pre-clinical studies [45]. The recent development of PP2A agonists [73] provided the opportunity
to explore the molecular and therapeutic synergy between these compounds and CDK9i in MLLrearranged leukemias, where aberrant recruitment of the SEC fuels tumor initiation and progression [19]. Concurrent PP2A activation and CDK9 inhibition resulted in enforced transcriptional
pausing and synergistic cell death in vitro, and greatly diminished tumor burden and prolonged
survival in vivo. These findings demonstrate the therapeutic benefit of dual CDK9/PP2A targeting
in cancer and provide the basis for future pre-clinical and clinical studies.
These studies detail the discovery of an auxiliary module of the Integrator complex containing
PP2A, INTS6 and INTS8 (Int-PP2A), which is actively recruited to chromatin in response to
cellular cues to functionally antagonize CDK9 in multicellular organisms (Figure 2.7G). Loss
of functional CDK9 antagonism by Int-PP2A alters the phosphorylation dynamics at the pauserelease checkpoint, such that limited CDK9 activity is required for effective pause-release, thus
conferring resistance to CDK9 inhibition. While INTS6 loss is tolerated under steady-state conditions (possibly due to a rebalancing of the phosphorylation turnover by reducing CDK9 activity),
acute depletion of INTS6 or INTS8, globally disrupts RNAPII transcription. Importantly, the absence of Int-PP2A antagonism of CDK9 results in unopposed activation of acute transcriptional
responses to cellular stress, growth signalling or inflammatory cues. We posit that antagonism of
kinase activity at the pause-release checkpoint is critical to fine-tune transcriptional output and
our findings establish a role for Int-PP2A in the dynamic control of RNAPII transcription in both
normal and cancer settings.
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2.8

Methods

2.8.1

Cell Lines

THP-1 (ATCC TIB-202), MV4;11 (ATCC CRL-9591), HT-29 (ATCC HTB-38), MM1.S (ATCC
CRL-2974), JJN-3 (DSMZ ACC 541), OPM2 (DSMZ ACC 50), MOLM-13 (DSMZ ACC 554),
HL-60 (ATCC CCL-240) and OCI-AML3 (DSMZ ACC 582) cells were cultured at 37°C and
5% carbon dioxide (CO2 ) in Roswell Park Memorial Institute medium (RMPI; ThermoFisher
Scientific) supplemented with 10-20% fetal bovine serum (FBS; Peter MacCallum Cancer Centre), 100U/mL penicillin, 100µg/mL streptomycin (ThermoFisher Scientific) and 2mM GlutaMAX (ThermoFisher Scientific). Henrietta Lacks (HeLa - ATCC CCL-2) cells were cultured at
37°C and 5% CO2 in Dulbeccos Modified Eagle’s medium (DMEM: ThermoFisher Scientific)
supplemented with 10% super calf serum (GEMcell) and 2mM L-glutamine (Corning). hTERTimmortalized BJ foreskin fibroblasts (BJ-T; ATCC CRL-2522), HS5 bone marrow stromal cells
(ATCC CRL-11882), A431 cells (ATCC CRL-1555) and human embryonic kidney (HEK) 293T
cells (ATCC CRL-11268; used for generation of lentivirus and retrovirus) were cultured at 37°C
and 5% CO2 in DMEM supplemented with 10% FBS, 100U/mL penicillin; 100µg/mL streptomycin and 2mM GlutaMax. D.melanogaster S2 cells (ATCC CRL-9591) were cultured in Scheinder’s Drosophila medium (ThermoFisher Scientific) supplemented with 10% HI-FBS, 100U/mL
penicillin; 100µg/mL streptomycin and 2mM GlutaMax at room temperature and atmospheric
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CO2 . A431 and HT-29 cells were a gift from the Translational Research Laboratory (TRL) at the
Peter MacCallum Cancer Centre.

2.8.2

Reagents

AZ’5576 (CDK9i) and AZD’4573 were provided by AstraZeneca, and reconstituted in dimethyl
sulfoxide (DMSO) for in vitro use. For in vivo use AZD’4573 as reconstituted in a 10:30:70 ratio of N,N-dimethylacetamide (DMA), PEG-400, and 1% Tween-80 in H2 O. Fresh AZD’4573
stocks were prepared weekly. The small molecule activator of PP2A (SMAP) DBK-1154 was provided by Michael Ohlmeyer (Icahn School of Medicine, Mount Sinai Hospital) and was reconstituted in DMSO (in vitro) or prepared daily in 10% DMA, 10% Kolliphor-HS-15 and 80% H2 O (in
vivo). The CDK9 degrader, 22-533, and THZ1 were provided by Nathaneal Gray and were reconstituted in DMSO. 1-NA-PP1 was purchased from Cayman Chemical (10954) and reconstituted
in DMSO. LPS was purchased from Sigma Aldrich (L2630) and reconstituted in PBS. Phendione
(1,10-Phenanthroline-5,6-dione) was purchased from Sigma Aldrich (496383) and reconstituted
in DMSO. Calyculin A (ab141784) and Okadaic Acid (ab120375) were purchased from Abcam
and reconstituted in DMSO. Cytarabine was obtained from the Peter MacCallum Cancer Centre
pharmacy. EGF was purchased from Gibco (PHG0311) and reconstituted in PBS. Flavopiridol was
purchased from Sigma-Aldrich (F3055) and reconstituted in DMSO.

2.8.3

Click-EU labeling/nascent RNA

Cells treated with transcriptional inhibitors were labelled with 1mM ethynyl-uridine (EU, ThermoFisher Scientific E10345) for 1 hour prior to fixation/permeabilization (0.5% paraformaldehyde, 0.2% Tween20, 0.1% BSA, 0.1% Azide). Cells were washed once with PBS and incubated
at room temperature for 30 minutes with the Click-iT reaction buffer, CuSO4 buffer, Alexa-Fluorazide-647 and Click-iT reaction buffer additive from the Click-iT RNA Imaging kit as per the
manufacturer’s instructions (ThermoFisher Scientific, C10329). Cells were washed twice with
Click-iT rinse buffer, and once each with PBS plus 0.1% Tween 20 and fixation/permeabilization
buffer prior to analysis using the BD Fortessa flow cytometer.
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2.8.4

Genome-wide CRISPR-Cas9 screens

THP-1 and MV4;11 cells were engineered to stably express humanized S.pyogenes Cas9 endonuclease by lentiviral transduction with the FUCas9Cherry vector (Addgene 70182) and subsequent FACS-selection for mCherry-positive cells (THP-1-Cas9, MV4;11-Cas9). For THP-1-Cas9
survival screens, cells were transduced with the GeCKOV2 (125000 sgRNAs) [74] or Brunello
(75000 sgRNAs) [75] genome-wide sgRNA libraries at a MOI of 0.3 and a fold representation
of 500 for each individual sgRNA. For nascent RNA screens THP-1-Cas9 cells were transduced
with the Brunello sgRNA library. Transduced cells were selected with puromycin (1µg/mL) for 7
days, at which time cells were split into relevant treatment conditions (DMSO, CDK9i) and cell
pellets were collected and snap-frozen for T0 reference controls. For survival screens, puromycinselected cells were cultured in AZ5576 (150nM), A159 (50nM, GeCKOV2 only) or Dinaciclib
(10nM, GeCKOV2 only) for 21 days to select for CDK9i-resistant populations and cell pellets
were collected from DMSO- and CDK9i-resistant populations (Tend ). For nascent RNA screens
THP-1-Cas9 cells were transduced with the Brunello sgRNA library and puromycin-selected cells
were cultured for 16 hours with DMSO or AZ5576 (170nM). Cells were labelled for 1 hour with
EU and Click-iT RNA detection was performed as described previously prior to FACS-selection
of EU-positive cells using a BD FACSAria sorter. For MV4;11-Cas9 survival screens, cells were
transduced with the Brunello sgRNA library and puromycin-selected cells were cultured for 21
days with DMSO or 350nM AZ5576. Genomic DNA was isolated from T0 , Tend and EU-positive
cells using the DNeasy Blood and Tissue Kit (Qiagen, 69504). Sequencing libraries were generated by PCR amplification as previously described [76, 77] and 75 base-pair single-end reads
were sequenced using the Illumina NextSeq500. Sequencing files were demultiplexed (Bcl2fastq,
v2.17.1.14), reads were trimmed to 20 base-pair sequences using cutadapt (v2.1) and MAGeCK
(v0.5.9) was used to count reads and perform sgRNA enrichment analysis. The R package ggplot2
(v3.3.0) was employed for data visualization of screens. Venn diagrams were generated using the
online web tool BioVenn [78]; represented genes had an adjusted p-value of < 0.1 for > 3 sgRNAs in at least one replicate screens. Only genes with an adjusted p-value less than for INTS6,
INTS8 or INTS12 were included.
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2.8.5

Stable expression of full-length INTS6 in THP-1 MLL-AML cells

Human full-length INTS6 ORF in pCMV6-entry vector was purchased from Origene (RC208036).
The INTS6 ORF was PCR amplified with 5’ Xho I and 3’ EcoRI restriction site overhangs and the
coding sequence for a C-terminal V5 epitope tag was added in frame to the 3’ end of the INTS6
ORF (Key Resources Table. The INTS6 PCR product and MSCVpuro vector (Addgene 68469)
were digested with XhoI (NEB R0146) and EcoRI-HF (NEB R3101) at 37°C overnight and purified digests were ligated overnight at 16°C using T7 DNA ligase as per manufacturer’s instructions
(NEB M0318). Ligation reactions were transformed into One Shot Stbl3 chemically-competent
E.coli cells (42°C heat-shock, 90 seconds; Invitrogen C737303) and positive clones were selected
by Sanger sequencing. THP-1-Cas9 cells expressing FgH1t-UTG-sgSCR-GFP or FgH1tUTGsgINTS6-GFP with stable knockout of INTS6 were engineered to express empty vector MSCVpuro or MSCV-puro-V5-INTS6 by retroviral transduction.

2.8.6

Generation of mCherry-P2A-V5-PPP2R1A knock-in THP-1 cells

5 × 105 THP-1 cells were resuspended in 20µL nucleofection solution (16.4µL SG nucleofector
solution + 3.6µL supplement 1) from the SG Cell Line 4D-Nucleofector X kit (Lonza, V4XC3032). 300pmol PPP2R1A sgRNA (Synthego, Key Resources Table) was incubated with 100pmol
Alt-R S.p. HiFi Cas9 Nuclease V3 (Integrated DNA Technologies, 1081061) at room temperature for 20 minutes prior to the addition of 566ng mCherry-P2A-V5-PPP2R1A donor template
DNA (Integrated DNA Technologies, Key Resources Table) on ice (6µL total volume). THP-1
cells in SG buffer were mixed with the sgRNA/Cas9/template complex and transferred to a 16well nucleocuvette strip. Nucleofection was performed using the FF100 program of the Amaxa
4D Nucleofector X Unit (Lonza, AAF-1002X) and cells were incubated at 37°C for 10 minutes
post-nucleofection before addition of culture media. Following expansion, mCherry cells were
FACS-selected using a BD FACSAria Fusion sorter.
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2.8.7

Generation of THP-1 CDK9AS/AS cells

sgRNAs targeting CDK9 (300pmol; Key Resources Table) were incubated for 20 minutes at room
temperature with 100pmol Alt-R SpCas9 nuclease (Integrated DNA Technologies, 1074182) prior
to the addition of 100pmol of the CDK9 Phe-103-Ala dsDNA HDR template (Key Resources Table; final volume - 5µL). The ribonucleoprotein complex was added to 5 × 106 THP-1 cells resuspended in 20µL Nucleofector solution (16.4µL SG nucleofector solution + 3.6µL supplement 1)
from the SG Cell Line 4D-Nucleofector Kit (Lonza, V4XC-3032). Cells were transferred to a 16well Nucleocuvette strip and electroporated using the Amaxa 4D-Nucleofector X Unit (program
FF-100, AAF-1002X). Electroporated cells were expanded in THP-1 culture media prior to isolation of single cell clones in 96-well culture plates using the Becton Dickinson Fusion FACS sorter.
CDK9AS/AS mutant clones were screened using qPCR analysis (Key Resources Table) and mutant status was confirmed using Sanger sequencing of the CDK9 locus at the Australian Genome
Research Facility (AGRF).

2.8.8

Generation of acquired resistance MV4;11 cells

Wild-type MV4;11 AML cells were cultured continuously in the presence of AZ5576 (100nM,
increasing to 350nM) or the vehicle control (DMSO) for 11 weeks until resistant clones expanded.
Protein lysates were isolated and assessed by SDS-PAGE and Immunoblotting as described below.

2.8.9

Generation of D.melanogaster S2 Cas9 cells

Control (SCR) and IntS6 targeting sgRNAs (Sigma Aldrich, Key Resources Table) with BspQ1
overhangs were ligated using T7 DNA ligase (NEB M0318; 16°C overnight) into BspQ1 digested
(NEB R0712) pAc-sgRNA-Cas9 vector (Addgene 49330) [79]. D.melanogaster S2 cells were
transfected with pAc-sgSCR-Cas9 or pAc-sgIntS6-Cas9 by Effectene transfection (Qiagen) and
positive clones were selected with puromycin.
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2.8.10

Expression of full-length Ints6-SBP in D.melanogaster S2 cells

The D.melanogaster IntS6 coding sequence (FlyBase.org, Clone DmeI/SD04165. FBcl0286688)
was PCR amplified with 5’ XhoI and 3’ KpnI restriction site overhangs. The IntS6 PCR product
and pMK33-SBP C-terminal vector [80] were digested with XhoI and KpnI-HF (NEB R3142)
at 37°C overnight and purified digests were ligated overnight at 16°C. Ligation reactions were
transformed into DH5-α chemically-competent cells (42°C heat-shock, 45 seconds; Invitrogen
18265017) and ampicillin-resistant clones were screened by sanger sequencing. D.melanogaster
S2 clones expressing SCR sgRNA or with stable knockout of Ints6 (sgIntS6-5, clone D and clone
E) were engineered to express pMK33-IntS6-SBP or pMK33-SBP by Effectene transfection and
positive clones were selected using hygromycin [80] (300µg/mL; ThermoFisher Scientific). Expression of IntS6-SBP was confirmed by western blot (SBP-Tag antibody, Key Resources Table).

2.8.11

Competitive Proliferation and Cell Death Assays

For THP-1/MV4;11 competitive proliferation assays 2 independent INTS6 sgRNAs or a control
Scrambled (SCR) sgRNA (Sigma Aldrich, Key Resources Table) with BsmBI compatible overhangs were ligated into BsmBI (NEB R0739) digested FgH1tUTG-GFP vectors (Addgene 70183).
THP-1-Cas9 and MV4;11-Cas9 cells were engineered to stably express FgH1tUTG-sgINTS6-AGFP, FgH1tUTG-sgINTS6-B-GFP or FgH1t-UTG-sgSCR-GFP vectors by lentiviral transduction.
Cells were incubated with doxycycline (1µg/mL; Sigma Aldrich D9891) for 7 days and depletion
of INTS6 protein was confirmed by SDS-PAGE and western blotting. THP-1/MV4;11-Cas9 cells
expressing FgH1tUTG-sgINTS6-GFP or FgH1t-UTG-sgSCR-GFP were mixed 1:1 with THP1/MV4;11-Cas9 cells expressing FgH1t-UTG-sgSCR-BFP, incubated with doxycycline (1µg/mL)
and cultured in the presence of DMSO, CDK9i or the CDK9-degrader at indicated concentrations. The relative proportions of GFP- and BFP-positive cells was measured following mixing
(T0 ) and at 4, 7, 11, and 14 days post-assay initiation using a BD LSRFortessa flow cytometer.
For HeLa, MM1.S, BJ-T and HS5 competition assays, HeLa cells stably expressing either the FUCas9Cherry or FUCas9CFP vector were electroporated with 100pmol Alt-R S.p. HiFi Cas9 Nuclease V3 and 300pmol INTS6-A targeting sgRNA or sgSCR (Synthego, Key Resources Table)
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respectively using the Amaxa 4D Nucleofector X Unit as per manufacturer’s instructions. At five
days post-electroporation mCherry and CFP Cells were mixed 1:1 and incubated with increasing concentrations of AZ5576 for 96 hours. Cell populations were assessed by flow-cytometry
using a BD LSRFortessa and SDS-PAGE/immunoblotting (HeLa). For cell death analysis, THP1-Cas9 cells expressing FgH1tUTG-sgINTS6-A-GFP, FgH1tUTG-sgINTS6-B-GFP or FgH1tUTG-sgSCR-GFP or D.melanogaster S2 cells expressing pAc-sgSCR-Cas9 or pAc-sgInts6-Cas9
were incubated with increasing doses of AZ5576, cytarabine, THZ1 or DBK-1154 for 72 hours.
Cells were stained with Annexin-V APC (BD Biosciences 550475) prior to flow cytometric analysis using a BD LSRFortessa. The R package synergyfinder (v1.8.0) [81] was employed for Zero
Interaction Potency (ZIP) synergy score computing between DBK-1154 and AZ5576. For solid
cancer cell line (A431 and HT-29) combination assays, 5000 cells were seeded in triplicate in a
flat-bottom 96-well plate and incubated for 24 hours prior to treatment with escalating doses of
AZ5576 and/or DBK-1154. At endpoint (72 hours post-drug treatment) cells were incubated with
a 1:2 dilution of the Promega CellTiter-Glo Luminescent cell viability reagent (Promega G7570)
for 10 minutes with gentle agitation. Luminescence was measured using a Biotek Cytation 3 Cell
Imaging Multi-Mode reader and data (expressed as cell death percentage) was normalised to cells
treated with DMSO. For haematological cancer cell lines (MM1.S, OPM2, JJN3, MOLM-13,
HL-60, OCI-AML3) a D300e Digital Dispenser (Tecan Technologies) was used to seed 20000
cells per well in duplicate into flat-bottom 96-well plates and cells were incubated with escalating doses of of AZ5576 and/or DBK-1154. At endpoint (72 hours post-drug treatment) cells were
washed once with PBS and stained with 4’,6-diamidino-2-phenylindole (DAPI, 5µg/mL; Invitrogen D1306).

2.8.12

Infection of HeLa cells with shRNA

Vectors pLKO.1-shINTS6, pLKO.1-shINTS8, pLKO.1-shINTS12, and pLKO.1-shPPP2R1A were
obtained from the Molecular Screening Facility at the Wistar Institute. shINTS2 and shINTS5
were designed with the Broad Institute algorithm and subsequently cloned into pLKO.1 (Addgene
#10879). Sequences of all shRNAs are listed in the Key Resources Table. For infection, lentiviral
particles were produced in HEK293T cells with pLKO.1-shRNA vectors as indicated. HeLa cells
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were incubated overnight in growing media plus virus and polybrene (Sigma-Aldrich, TR-1003).
The following day, the virus-containing media was removed and replaced with growing media, and
cells were selected with puromycin (Invivogen) at 2µg/mL. In all shRNA experiments, cells were
treated and harvested within 72 hours of infection.

2.8.13

SDS-PAGE and Immunoblotting

For whole cell THP-1 lysates, cells were washed once with cold PBS and lysed with laemmli lysis
buffer (60mM Tris-HCl pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS) for 10 minutes at 95°C and
protein concentration was determined using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific 23227). Protein samples were separated by SDS-PAGE using 4-20% Mini-PROTEAN TGX
gels (BioRad, #4561094) in 25mM Tris, 192mM Glycine, 0.1% (w/v) SDS and wet-transferred to
Immobulin-P (Merck Millipore, IPVH00010) or Immobulin-FL membranes (Merck Millipore,
IPFL00010) in 25mM Tris, 192mM Glycine, 5% v/v methanol (4°C, 200mA, 2 hours). Membranes were blocked at room-temperature in Tris-buffered-saline (TBS) supplemented with 0.1%
(v/v) Tween20 (TBST; Sigma Aldrich, P1379) and 5% skim-milk powder (local supermarket)
or Odyssey blocking buffer (LI-COR, 927-50000) prior to incubation at 4°C overnight with primary antibodies (Key Resources Table). Membranes were washed 3 times in TBST and incubated
for 1 hour at room temperature with HRP-conjugated or LI-COR secondary antibodies (Key Resources Table). Membranes were washed 3 times in TBST and incubated with Amersham ECL
PLUS (GE Healthcare, RPN2132) prior to exposure to Super RX film (Fujifilm, 03G01), or images were acquired using the Odyssey CLx machine (LI-COR, 83µm, medium setting). For whole
cell HeLa lysates, cells were harvested and washed three times in 1X PBS and lysed in ChIP lysis buffer (150 mM NaCl, 1% Triton X-100, 0.7% SDS, 500 mM DTT, 10 mM Tris-HCl, 5 mM
EDTA) supplemented with 1 µg/mL aprotinin, 1 µg/mL leupeptin (Sigma) and 1 µg/mL pepstatin
(BMB). Protein samples were loaded into Bolt 4-12% Bis-Tris Plus gels (Invitrogen) and separated through gel electrophoresis (SDS-PAGE) in Bolt MES running buffer (Invitrogen). Separated
proteins were wet-transferred to ImmunBlot PVDF membranes (BioRad) for antibody probing.
Membranes were incubated with 10% BSA in TBST for 30 minutes at room temperature, then incubated for 2 hours at room temperature or overnight at 4°C with the suitable antibodies diluted in
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5% BSA in 1X TBST. After incubation with the primary antibody, the membranes were washed
with TBST, and incubated with a 1:10000 dilution of HRP-linked anti-mouse or anti-rabbit secondary antibody (Cell Signaling) for one hour at room temperature. HRP-linked antibodies were
visualized using Clarity Western ECL substrate (Biorad) and imaged with Fujifilm LAS-3000 Imager (Fujifilm).

2.8.14

Co-Immunoprecipitation

For Co-IP experiments in THP-1 cells this protocol adapted from [82] was used. 10 × 106 cells
were used per IP and all lysis and wash buffers were supplemented with Roche cOmplete protease
inhibitors (Merck, 11873580001) and Pierce phosphatase inhibitors (ThermoFisher Scientific,
A32957). Cells were washed twice with cold PBS and resuspended in 2 pellet volumes of hypotonic lysis buffer (10mM HEPES pH 7.5, 10mM KCl, 1.5mM M gCl2 ) prior to incubation on ice
for 40 minutes. Nuclei were pelleted at 4°C (3900rpm, 15 minutes) and the hypotonic cytoplasmic fraction was removed and discarded. Nuclei were resuspended in 2 original pellet volumes of
nucleoplasmic lysis buffer (20mM HEPES pH 7.9, 1.5mM M gCl2 , 150mM potassium acetate,
10% (v/v) glycerol, 0.05% (v/v) IGEPAL CA-630) and incubated on ice for 20 minutes. Chromatin was pelleted at 4°C (20kg, 20 minutes) and the nucleoplasmic fraction was removed and
stored on ice. Chromatin was incubated with 2 original pellet volumes of low salt chromatin digestion buffer (20mM HEPES pH 7.9, 1.5mM M gCl2 , 10% (v/v) glycerol, 150mM NaCl, 0.1%
(v/v) IGEPAL CA-630, 250 U/mL benzonase (Merck, 70746-4)) on ice for 1 hour prior to centrifugation at 4°C (20kg, 20 minutes). The low salt chromatin fraction was removed and stored on
ice. The remaining undigested chromatin was incubated with 2 original pellet volumes of high salt
chromatin digestion buffer (20mM HEPES pH 7.9, 3mM EDTA, 1.5mM M gCl2 , 10% (v/v) glycerol, 500mM NaCl, 0.1% (v/v) IGEPAL CA-630) on ice for 20 minutes. 6 original pellet volumes
of salt dilution buffer (20mM HEPES pH 7.9, 3mM EDTA, 1.5mM M gCl2 , 10% (v/v) glycerol,
0.1% (v/v) IGEPAL CA-630) was added prior to centrifugation at 4°C (20kg, 20 minutes). The
nucleoplasmic, low salt chromatin and diluted high salt chromatin fractions were pooled and input samples taken. Pooled fractions were tumbled at 4°C for 1 hour with 5µg of antibody (Key
Resources Table) and 25µL Dynabeads Protein A or Protein G (ThermoFisher Scientific, 10001D
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and 10003D respectively). Beads were washed 5 times (20mM Tris-HCl pH 7.5, 150mM NaCl,
1.5mM M gCl2 , 3mM EDTA, 10% (v/v) glycerol, 0.1% (v/v) IGEPAL CA-630) and incubated
for 10 minutes at 95°C in 2X laemmli lysis buffer (120mM Tris-HCl pH 6.8, 4% (w/v) SDS, 1%
β-mercaptoethanol, 0.02% (w/v) bromophenol blue) to elute immunoprecipitated proteins. Eluted
fractions were analyzed by SDS-PAGE and immunoblotting as described previously. For Co-IP
experiments in HeLa, cells were washed twice with ice cold PBS before resuspension in buffer
A (10mM Tris pH 7.9, 1.5mM M gCl2 , 10mM KCl, 0.5mM DTT, 1 mg/ml each of protease inhibitors aprotinin, leupeptin, and pepstatin), and incubated at 4°C for 10 minutes. After spinning
down at 2000rpm for 10 minutes, the pellet was resuspended in buffer A and subject to dounce
homogenization (with B pestle) and spun down again. The supernatant was kept as cytoplasmic
extract. The pellet was resuspended in buffer C (20mM Tris pH 8.0, 1.5mM M gCl2 , 0.42M NaCl,
25% glycerol, 0.2mM EDTA, 0.5mM DTT, protease inhibitors) and dounce homogenized (with
B pestle), followed by incubation at 4°C for 30 minutes. The resulting lysate was spun down at
12,000rpm for 30 minutes. The supernatant was kept as nuclear extract. The chromatin pellet was
resuspended in Nuclease Incubation buffer (150mM HEPES pH 7.9, 1.5mM M gCl2 , 150mM
potassium acetate, 10% glycerol, 0.5mM DTT, and protease inhibitors) with Benzonase nuclease (Sigma-Aldrich), and incubated for 45 minutes at 4°C. The supernatant was kept as chromatin
extract following centrifugation at 12,000rpm for 30 minutes. All extracts were dialyzed overnight
in BC80 (20mM Tris pH 8.0, 80mM KCl, 0.2mM EDTA, 10% glycerol, 1mM β-mercaptoethanol,
0.2mM phenylmethylsulfonyl fluoride (PMSF)), cleared, and stored at -80°C. Prior to IP, 500µg of
nuclear or chromatin extract was diluted in co-IP buffer (20mM Tris pH 7.9, 100mM NaCl, 0.1%
NP-40, protease inhibitors). Each IP was incubated for 2 hours at 4°C with 2µg antibody (Key Resources Table) and 25µL of Dynabeads Protein A or Protein G. Beads were washed three times
with co-IP buffer, followed by a final wash with 0.05% NP-40 in PBS. Elution was performed by
agitation in 0.1M glycine pH 3.0 for one minute, and 1M Tris base pH 11.0 was added to neutralize the pH of the eluate. IP elutions were analyzed by SDS-PAGE and immunoblotting as described previously.
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2.8.15

Immunoprecipitation-Mass Spectrometry (IP-MS)

For THP-1 and MV4;11 IP-MS experiments 50 − 80 × 106 cells were used per IP. Dynabeads
Protein A or Protein G (Invitrogen 10002D and 10003D) were washed 5 times with 5% (w/v)
BSA/PBS and tumbled at 4°C with relevant antibodies (Key Resources Table) for 1 hour. Cells
were washed twice with cold PBS and incubated on 4°C roller for 10 minutes in nuclear extraction buffer (10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.05% (v/v) IGEPAL CA-630, protease
and phosphatase inhibitors) prior to centrifugation at 4°C (2000g, 5 minutes). This step was repeated once before isolated nuclei were incubated in 1mL mass spectrometry buffer (20mM TrisHCl pH 8, 150mM NaCl, 2mM EDTA, 0.5% (v/v) IGEPAL CA-630, protease and phosphatase
inhibitors) on ice for 10 minutes prior to sonication using the Covaris S220 Focused Ultrasonicator (8 minutes per sample). Sonicated lysates were cleared at 4°C (20000g, 10 minutes) prior
to tumbling at 4°C with 50µL antibody-bound Dynabeads Protein A or Protein G for 1 hour. For
IP-MS experiments for SBP or SPB-Ints6 in D.melanogaster S2 cells expressing pAc-sgSCRCas9 and pMK33-SBP or pMK33-IntS6-SBP, 100 × 106 cells were used per IP using 50µL Pierce
Strepavidin Agarose slurry (ThermoFisher Scientific, 20353) under the same conditions. Beads
were washed 5 times (20mM Tris-HCl pH 8, 150mM NaCl, 2mM EDTA, 0.1% (v/v) IGEPAL
CA-630) and 2 times in 100mM ammonium bicarbonate (AMBIC). Beads were resuspended in
50µL 100mM AMBIC and incubated overnight at 37°C with 400ng Trypsin (Promega V5280).
Beads were supplemented with an additional 400ng Trypsin and incubated for a further 4 hours at
37°C. The peptide-containing supernatant was isolated from the beads and acidified through the
addition of 10% formic acid. Peptides were isolated using C18 ultra micro-spin columns (Pierce
#87782) which had been pre-conditioned (100% acetonitrile followed by 2 rounds of 80% acetonitrile) and equilibrated (0.5% formic acid). Columns were washed twice (0.1% formic acid) and
peptides were eluted using 40µL 80% acetronitrile diluted in 0.1% formic acid. Excess acetonitrile
was evaporated using a vacuum centrifuge and samples were analysed at the Bio21 Mass Spectrometry and Proteomics facility (Parkville, VIC 3052, Australia). LC MS/MS was carried out on
a QExactive plus Orbitrap mass spectrometer (Thermo Scientific) with a nanoESI interface in conjunction with an Ultimate 3000 RSLC nanoHPLC (Dionex Ultimate 3000). The LC system was
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equipped with an Acclaim Pepmap nano-trap column (Dinoex-C18, 100 Å, 75 µm x 2 cm) and an
Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100 Å, 75 µm x 50 cm). The tryptic peptides were injected to the enrichment column at an isocratic flow of 5 µL/min of 2% v/v CH3CN
containing 0.1% v/v formic acid for 5 min applied before the enrichment column was switched
in-line with the analytical column. The eluents were 0.1% v/v formic acid (solvent A) and 100%
v/v CH3CN in 0.1% v/v formic acid (solvent B). The flow gradient was (i) 0-6min at 3% B, (ii)
6-40 min, 3-25% B (iii) 40-48 min, 25-45% B (iv) 48-50 min, 40-80% B (v) 50-53 min, 85-85%
B (vi) 53-54 min 85-3% and equilibrated at 3% B for 10 minutes before the next sample injection. The QExactive plus mass spectrometer was operated in the data-dependent mode, whereby
full MS1 spectra were acquired in positive mode, 70 000 resolution, AGC target of 3e6 and maximum IT time of 50ms. Fifteen of the most intense peptide ions with charge states ≥2 and intensity
threshold of 1.7e4 were isolated for MSMS. The isolation window was set at 1.2m/z and precursors fragmented using normalized collision energy of 30, 17 500 resolution, AGC target of 1e5
and maximum IT time of 100ms. Dynamic exclusion was set to be 30sec. Raw files were analyzed
using MaxQuant (version 1.5.8.3). The database search was performed using the Uniprot Homo
sapiens or Drosophila melanogaster databases plus common contaminants with strict trypsin specificity allowing up to 3 missed cleavages. The minimum peptide length was 7 amino acids. Carbamidomethylation of cysteine was a fixed modification while N-acetylation of proteins N-termini
and oxidation of methionine and phosphorylation of Serine/Threonine/Tyrosine were set as variable modifications. The iBAQ quantification option was selected. During the MaxQuant main
search, precursor ion mass error tolerance was set to 4.5 ppm and fragment ions were allowed a
mass deviation of 20 ppm. PSM and protein identifications were filtered using a target-decoy approach at a false discovery rate (FDR) of 1% with the match between runs option enabled. The
RStudio package ggplot2 (v3.3.0) was employed for data visualization: a value of 10 was added
to all raw iBAQ scores to allow log10 transformation. The average value of log10(iBAQ) of each
technical replicate for each condition in THP1 and MV4;11 was calculated and subsequently filtered according the following criteria: log10(isotype) < 2 and log10(IP) > 2. Interaction networks were visualized in Rstudio (v3.5.1) using the packages concaveman (v1.0.0), dplyr (v0.8.1),
ggraph (v2.0.3) and ggforce (v0.3.1). For HeLa cell IP-MS experiments, IPs were performed as
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described previously, but with the following modifications: for each IP, 1-2mg of nuclear or chromatin extract was incubated with 4µg antibody (Key Resources Table) and 50µL Dynabeads Protein A or Protein G. Eluates were prepared for SDS-PAGE and run on a Novex WedgeWell 10%
Tris-Glycine Gel (Invitrogen) with Tris-Glycine-SDS buffer (Bio-Rad), at 110V for 10 minutes.
The gel was stained with Colloidal Blue staining kit (Invitrogen), and further processed at the proteomics facility at the Wistar Institute. Briefly, the gel lanes were excised, digested with trypsin,
and analyzed by LC-MS/MS on a Q-Exactive Plus mass spectrometer. MS/MS spectra generated
from the LC-MS/MS runs were searched with full tryptic specificity against the UniProt human
database (www.uniprot.org; 10/01/2018) using the MaxQuant 1.6.2.3 program. False discovery
rates for protein and peptide identifications were set at 1%. The RStudio package ggplot2 (v3.3.0)
was used for data visualization: a value of 10 was added to all raw iBAQ scores to allow log10
transformation.

2.8.16

qRT-PCR

HeLa cells were lysed in Tri-reagent, followed by RNA extraction using Direct-zol RNA MiniPrep
kit (Zymo Research). Reverse transcription of 900ng of template RNA into cDNA was done using random-hexamer primers with the Revertaid first strand cDNA synthesis kit (Thermo Scientific), according to manufacturer instructions. Real-time quantitative PCR reaction was performed
with 50ng cDNA, 0.4mM primer, 10µL iQ SYBR Green Supermix (BioRAD), in a final volume
of 20µL. We used the CFX96 real-time system (BioRAD), and thermal cycling parameters were as
follows: 3 minutes at 95°C, followed by 40 cycles of [10s at 95°C, 20s at 63°C, 30 s at 72°C]. All
samples were run in triplicate. 18S rRNA used to normalize. Primer sequences are reported in Key
Resources Table.

2.8.17

Glycerol gradient ultracentrifugation

Glycerol gradients were prepared fresh with 1X HEMG buffer (50mM HEPES (pH 7.9), 0.2mM
EDTA, 30mM M gCl2 , 200mM KCl, 0.5mM DTT, 1 mg/ml each of protease inhibitors aprotinin,
leupeptin, and pepstatin) and glycerol from 11% to 50% in increments of 3%. Gradients were assembled on ice by carefully layering 320µL of 1X HEMG-glycerol in descending order of glyc58

erol concentration, starting with 50%, into an ultracentrifuge tube (Beckman Coulter 344057).
Prior to centrifugation, 500µg of nuclear extract (brought to 300µL and cleared) was layered on
top. Gradients were ultracentrifuged in a swinging-bucket rotor at 48,000rpm (272,798 rcf) for 16
hours (accel=8, decel=8). After centrifugation, gradient fractions were collected by piercing a hole
in the bottom of the tube and collecting fractions of 320µL each. Protein was precipitated from
each fraction with 1/10th volume trichloroacetic acid (TCA, Sigma-Aldrich), incubated overnight
at -20°C, washed twice with cold acetone (Sigma-Aldrich), and resuspended in 70µL of 1X BOLT
laemmli sample buffer (Invitrogen) for SDS-PAGE analysis.

2.8.18

Reverse Phase Protein Array

THP-1-Cas9 cells expressing FgH1t-UTG-sgSCR-GFP or FgH1tUTG-sgINTS6-A-GFP with
stable knockout of INTS6 were treated with DMSO or AZ5576 for 2 or 6 hours. 3 biological
replicates were assessed for each treatment condition. Treated cells were lysed with CLB1 buffer
(Zeptosens, Bayer) and quantified using a Pierce BCA Protein Assay Kit (ThermoFisher Scientific 23227). Samples were diluted (100%, 63%, 40%, 25%) with 9:1 CSBL1:CBL1 buffer (Zeptosens, Bayer) using a Sciclone Caplier ALH3000 liquid handling root (Perkin Elmer). Diluted
samples were spotted onto ZeptoChips (Zeptosens; 2 technical replicates) using a Nano-plotterNP2 non-contact microarray system (GeSim). Chips were blocked with BB1 buffer (Zeptosens,
1 hour) prior to incubation with primary antibodies (1:500 dilution for 2 hours, Key Resources
Table) and Alexa-Fluor conjugated secondary antibodies (1:1000 dilution for 4 hours, anti-rabbit
Alexa-Fluor-647, ThermoFisher Z25308; anti-mouse Alexa-Fluor-647, ThermoFisher Z25008;
anti-rat Alexa-Fluor-647, ThermoFisher A21247). Alexa-Fluor signal intensity was measured
using a ZeptoREADER and relative fluorescence intensity (RFI) values were calculated using
ZeptoVIEW software (Zeptosens, version 3.1). RFI values for each sample were normalized to
secondary-antibody only controls.

2.8.19

Phospho-peptide mass spectrometry

THP-1-Cas9 cells expressing FgH1t-UTG-sgSCR-GFP or FgH1tUTG-sgINTS6-A-GFP with stable knockout of INTS6 were treated with DMSO or AZ5576 for 2 hours. 4 biological replicates
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were used for each condition. Cells were pelleted in Eppendorf protein LoBind tubes (Sigma
Aldrich Z666505) washed twice with ice cold PBS and snap-frozen. Thawed cell pellets were
incubated at 95°C for 10 minutes in SDS-lysis buffer (5% SDS, 10mM TCEP, 40mM 2-CAA,
10mM Tris-HCl pH 7.5) prior to DNA hydrolysis using 1% TFA and neutralised through the addition of 3M Tris-HCl pH 7.5 to a final concentration of 160mM. Samples were incubated with
PureCUBE carboxy agarose magnetic beads (Cube Biotech 50201) and 70% acetonitrile at room
temperature for 20 minutes prior to 2 washes with 70% ethanol and 1 wash with 100% acetonitrile. Beads were lyophilised to remove residual acetonitrile and were then incubated with lysis buffer (50µL per sample; 10% trifluoroethanol, 100mM ammonium bicarbonate), Trypsin
(Promega V5280) and Lysyl Endopeptidase (Wako 125-05061) at 1:25 ratio of enzyme:substrate.
Beads were incubated for 2 minutes at room temperature in an ultrasonic water bath (Unisonics
Australia) prior to incubation at 37°C for 4 hours with agitation (1200rpm). The lysis supernatant
was isolated, and the beads were washed with 1 volume of ultrapure H2 O. The lysis supernatant
and wash supernatant were pooled and TFA was added to a final concentration of 1%. Samples
were centrifuged (20000g) and the supernatant was isolated. TFA-supplemented acetonitrile was
added to the supernatant for a final concentration of 80% acetonitrile and 0.1% TFA prior to incubation at room temperature with gentle shaking for 30 minutes with PureCUBE Fe(III)-NTA
beads (Cube Biotech 31501-Fe). Beads were washed 3 times with 80% acetonitrile / 0.1% TFA
and transferred to C8 stage tips pre-wetted with 100% acetonitrile. Isolated phospho-peptides were
eluted using 50% acetonitrile / 2.5% ammonium hydroxide pH 10 (2 x 20µL) and collected into
tubes containing 30µL 10% TFA. Samples were lyophilized and peptides were resuspended in
50µL 5% formic acid prior to being transferred to C18 stage tips pre-wetted with 10% isopropyl
alcohol, 60% acetonitrile and 5% formic acid. C18 stage tips were centrifuged (500g, 1 minute)
prior to washing twice with 5% formic acid. Phospho-peptides were eluted in 60% acetonitrile
and 5% formic acid (50µL) and were lyophilised to dryness prior to storage at minus 80°C. For
analysis, phospho-peptides were resuspended in 2% acetonitrile and 1% formic acid and separated
by reverse phase liquid chromatography using an ThermoFisher Scientific Easy-nLC 1200 UHPLC system (1.6µm C18 packed emitter tip column, 250mm x 75µm, Ion Opticks) with a linear
120 minute gradient at 400nL/min flow rate from 98% solvent A (0.1% formic acid / ultrapure
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H2 O) to 37% solvent B (0.1% formic acid / acetonitrile). The UHPLC was coupled online to a
Q-Exactive HF Orbitrap mass spectrometer equipped with a nano-electrospray ionization source
(ThermoFisher Scientific) and a column oven at 50°C (Sonation, Germany). The Q-Exactive HF
was operated in a data-dependent mode, switching automatically between one full-scan and subsequent MS/MS scans of the ten most abundant peaks. The instrument was controlled using Exactive series version 2.9 and Xcalibur 4.1.31.9. Full-scans (m/z 350–1,850) were acquired with a
resolution of 60,000 at 200 m/z. The 10 most intense ions were sequentially isolated with a target
value of 10,000 ions and an isolation width of 1.4 m/z and fragmented using HCD with NCE of
27. Maximum ion accumulation times were set to 100ms for full MS scan and 110ms for MS/MS.
Raw files were analyzed using MaxQuant (version 1.5.8.3). The database search was performed
using the Uniprot Homo sapiens database plus common contaminants with strict trypsin specificity allowing up to 3 missed cleavages. The minimum peptide length was 7 amino acids. Carbamidomethylation of cysteine was a fixed modification while N-acetylation of proteins N-termini,
oxidation of methionine and phosphorylation of Serine/Threonine/Tyrosine were set as variable
modifications. During the MaxQuant main search, precursor ion mass error tolerance was set to
4.5 ppm and fragment ions were allowed a mass deviation of 20 ppm. PSM and protein identifications were filtered using a target-decoy approach at a false discovery rate (FDR) of 1% with
the match between runs option enabled. Further analysis was performed using a custom pipeline
developed in R, which utilizes the MaxQuant output file evidence.txt. A feature was defined as
the combination of peptide sequence, charge and modification. Features not found in at least 80%
of the replicates in one group were removed. To correct for injection volume variability, feature
intensities were normalized by converting to base 2 logarithms and then multiplying each value
by the ratio of maximum median intensity of all replicates over median replicate intensity. Missing values were imputed using a random normal distribution of values with the mean set at mean
of the real distribution of values minus 2.2 s.d., and a s.d. of 0.15 times the s.d. of the distribution of the measured intensities. The probability of differential peptide expression between groups
was calculated using the Limma R package (version 3.34.9). Probability values were corrected for
multiple testing using Benjamini–Hochberg method. The R package pheatmap (v1.0.12) was used
to compute heatmaps of phospho-sites with the indicated significance cutoff. The values in the
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heatmaps represent the median of z-norm values of biological replicates for each condition. Filtering conditions were applied to phospho-sites in addition to significance cutoffs. To be plotted, znorm values of phospho-sites were to meet the following criteria: SCR-CDK9i − SCR-UT < −0.3
and SCR-UT − INTS6-KO-UT < 0.3 and SCR-CDK9i ≤ INTS6-KO-UT and SCR-CDK9i ≤
INTS6-KO-CDK9i. Kmean cluster line plots and phospho-peptides scatter plots were generated
by using the R package ggplot2 (v3.3.0). To be plotted, z-norm values of phospho-sites in kmean
cluster and in single site plots were to meet the following criteria: SCR-CDK9i < SCR-UT and
SCR-CDK9i ≤ INTS6-KO-UT and SCR-CDK9i ≤ INTS6-KO-CDK9i. In the phospho-peptides
scatterplots, each bar represents the median of z-norm values of different biological replicates for
the same condition. Gene ontology (GO) analysis was performed using Metascape (release 3.5)
[83].

2.8.20

Recombinant protein kinase/phosphatase assay

Reactions were performed in kinase reaction buffer (25mM Tris-HCl pH 7.4, 2mM dithiothreitol
(DTT), 10mM M gCl2 ) supplemented with 200mM ATP-M g 2+ (Sigma Aldrich A9187) in 40µL
final reaction volumes. 0.5µg recombinant human RNA polymerase II CTD repeat YSPTSPS peptide (Abcam ab81888) was incubated with 0.4µg recombinant human 6X-His-CDK9/Cyclin T1
(Merck, 140685) and/or 0.4µg recombinant human GST-tagged PP2A-A (Sigma, SRP5336) in
the presence or absence of AZ’5576 or okadaic acid (Abcam ab120375) for 45 minutes at 30°C
(300rpm). Reactions were stopped through the addition of 20µL 2X laemmli lysis buffer (120mM
Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS) and incubation at 95°C for 10 minutes. Reactions were analyzed by SDS-PAGE and immunoblotting as described previously. To measure
ATP conversion, reactions were performed as described above. ADP generation was analyzed for
each reaction (5µL in triplicate in 384 well white-walled plates) using the ADP-Glo Kinase Assay
as per manufacturer’s instructions (Promega, V6930; ADP-Glo reagent for 40 minutes, Kinase Detection Reagent for 40 minutes). The ADP-Glo luminescence signal was measured using a Biotek
Cytation 5 Cell Imaging Multi-Mode reader.
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2.8.21

3’RNA Quant-Seq

THP-1-Cas9 cells expressing FgH1t-UTG-sgSCR-GFP or FgH1tUTG-sgINTS6-A-GFP with stable knockout of INTS6 were treated with PBS or LPS (1µg/mL) for 1, 2, 4 and 6 hours (2 × 106
cells per condition in duplicate). Cells were lysed with 600µL TRIzol (ThermoFisher Scientific
15596026) and total RNA was isolated using the Diret-zol RNA mini-prep kit (Zymo Research
R2051). Sequencing libraries were prepared using the QuantSeq 3’-mRNA Seq Library Prep Kit
for Illumina (Lexogen) from 500ng total RNA and 75 base-pair single-end reads were sequenced
on the Illumina NextSeq 500. Sequencing files were demultiplexed (Bcl2fastq, v2.17.1.14) and
QC was performed on FASTQ files using FASTQC (v0.11.6). Sequencing reads were trimmed
(cutadapt v2.1) and aligned to the Hg19 human reference genome using HISAT2 (v2.1.0). Read
counting across genomic features was performed using FeatureCounts (Subread, v2.0.0 [84]) and
differential gene expression analysis was performed using Voom-Limma in R (v3.42.2) Gene set
enrichment analyses were performed using the Broad Institute GSEA software [85]. HeLa cells
infected with shLUC or shINTS6 were treated with PBS or EGF (0.1µg/mL) for 15, 55, and 180
minutes. Cells were lysed in Tri-reagent and total RNA was isolated using the Direct-zol RNA
mini-prep kit (Zymo). For spike-in, 200ng of RNA from D.melanogaster S2 cells was added to
1µg of total RNA for each timepoint. Sequencing libraries were prepared at the Wistar Genomics
Facility using the QuantSeq 3’-mRNA Seq Library Prep Kit for Illumina (Lexogen) and 75 basepair single-end reads were sequenced on the Illumina NextSeq 500. Reads were aligned to hg19
and dm5 reference genomes using STAR v2.5 [86] in 2-pass mode with the following parameters: –quantMode TranscriptomeSAM –outFilterMultimapNmax 10 –outFilterMismatchNmax
10 –outFilterMismatchNoverLmax 0.3 –alignIntronMin 21 –alignIntronMax 0 –alignMatesGapMax 0 –alignSJoverhangMin 5 –runThreadN 12 –twopassMode Basic –twopass1readsN 60000000
–sjdbOverhang 100. BAM files were filtered based on alignment quality (q = 10) using Samtools
v0.1.19 [87]. FeatureCounts [88] was used to count reads mapping to each gene, and differential
gene expression analysis was performed using Voom-Limma in RStudio (v3.42.2) with normalizationFactors calculated from the D.melanogaster spike-in. Data was visualized using ggplot2
(v3.3.1).
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2.8.22

Chromatin Immunoprecipitation sequencing (ChIP-seq)

For THP-1 parental, THP-1-Cas9 FgH1t-UTG-sgSCR-GFP or FgH1tUTG-sgINTS6-A-GFP,
20 − 50 × 106 THP-1 cells were incubated with DMSO, AZ5576 or DBK-1154 for indicated
time-points. Cells were washed once with cold PBS prior to cross-linking at room temperature
for 10 minutes with one-tenth volume fresh formaldehyde solution (11% formaldehyde, 0.05mM
EGTA, 1mM EDTA, 100mM NaCl, 50mM Hepes-KOH pH7.5). To quench the cross-linking reaction, 1/20th volume of 2.5M glycine was added and cells incubated at room temperature for a
further 5 minutes. Cells were washed with ice-cold PBS and nuclei were isolated by three successive 10-minute incubations on ice with cold nuclear extraction buffer (20mM Tris-HCl pH 8,
10mM NaCl, 0.5% IGEPAL CA-630, 2mM EDTA). Cell nuclei were resuspended in sonication
buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 2mM EDTA, 0.3% SDS, 1% IGEPAL CA-630)
and sonicated for 18 minutes using the Covaris S2 instrument (20% Duty Cycle, 1000 cycles/burst,
10 Intensity). Fragmented chromatin was diluted 1:1 with dilution buffer (20mM Tris-HCl pH 8,
150mM NaCl, 2mM EDTA, 1% TritonX-100). For each immunoprecipitation, diluted chromatin
was incubated overnight at 4°C with Protein A and Protein G Dynabeads (ThermoFisher Scientific
10002D, 10004D; 25µL each) and indicated antibodies (Key Resources Table). Post-incubation,
Dynabeads were washed once each with dilution buffer, ChIP wash buffer 1 (20mM Tris-HCl pH
8, 500mM NaCl, 2mM EDTA, 0.1% SDS, 1% TritonX-100) and ChIP wash buffer 2 (20mM TrisHCl pH 8, 250mM LiCl, 2mM EDTA, 0.5% deoxycholate, 0.5% IGEPAL CA-630) and washed
twice with TE buffer (10mM Tris-HCl pH 7.5, 1mM EDTA). Washed beads were incubated with
shaking at 55°C for 1 hours in reverse crosslinking buffer (200mM NaCl, 100mM NaHCO3, 1%
SDS, 300µg/mL Proteinase-K) followed by incubation of the supernatant overnight at 65°C. DNA
was isolated using the Zymogen ChIP DNA Clean and Concentrator Kit (Zymo Research D5205).
Sequencing libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit (NEB
E7645) and 200 – 500 base-pair size selection was performed using a Pippin Prep system (Sage
Science). 75 base-pair single end reads or 40 base-pair paired end reads were sequenced on the
Illumina NextSeq500. Sequencing files were demultiplexed (Bcl2fastq, v2.17.1.14) and QC was
performed on FASTQ files using FASTQC (v0.11.6). Sequenced reads were aligned to the Hg19
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human or dm3 D.melanogaster reference genomes using Bowtie2 (v2.3.4.1) and generated SAM
files were converted to BAM files using Samtools (v.1.9) using the view function. Samtools was
used to further sort, index and remove potential PCR duplicates (rmdup) from BAM files which
were converted to BigWig files using Deeptools (v3.0.0; bamCoverage, –nomalizeUsing CPM
–smoothLength 150 –binSize 50 -e 200, scaleFactor 1). BigWig files were visualized using the Integrative Genomics Viewer (IGV; Broad Institute). Average read density across defined genomic
intervals was computed using the Deeptools computeMatrix function and the resulting matrices
were used to generate chromatin occupancy heatmaps using the plotHeatmap function. Pausing indices for Hg19 and dm3 were calculated as a ratio TSS read density (+/- 250bp) over gene
body density (+500 base pairs from TSS and -250 base pairs from TES). In more detail, subread
(v2.0.0; featureCounts -O -M -T 16 -F SAF) was used to count reads within TSS and gene body
intervals generated using bedtools (v2.27.1) slop function that included Hg19 or dm3 chromosome sizes (downloaded from UCSC). Read density was calculated as RPKM in Rstudio (v3.6.1)
using limma (v3.40.6) and edgeR (v3.26.8) packages and visualized using ggplot2 (v3.3.1). For
wild-type HeLa, cells were serum-starved (with 0.3% SCS) for 72 hours prior to induction of gene
expression with 0.1µg/mL recombinant EGF (Gibco) or PBS for 15 minutes. For knockdowns,
HeLa cells infected with indicated shRNAs were placed under serum-starvation (0.3% SCS) the
night before harvesting. Cells were treated for 2 hours with 10µM SMAP, 2hours with 300nM
AZ5576, 1 hour with 2µM Flavopiridol, or time-matched DMSO control, and subsequently treated
with PBS or 0.1µg/mL EGF for 15 minutes. ChIP-seq was performed as previously described
(Lai et al., 2015), with some modifications. To allow for accurate normalization between treatment conditions, tandem ChIP-seq was performed with a D.melanogaster- specific histone H2Av
antibody, similar to that described by [89]. For each replicate, 10 − 20 × 106 HeLa cells were
harvested and cross-linked for 5 minutes at room temperature with 1% formaldehyde for 5 minutes at room temperature and washed twice with PBS. The chromatin pellet was resuspended in
ChIP lysis buffer (150mM NaCl, 1% Triton X-100, 0.7% SDS, 500mM DTT, 10mM Tris-HCl,
5mM EDTA), and supplemented at 5% with chromatin from 0.5 − 1.0 × 106 formaldehydecrosslinked D.melanogaster S2 cells. The chromatin was sheared to an average length of 200–400
base pairs using a Covaris S220 Ultrasonicator. The chromatin lysate was diluted with SDS-free
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ChIP lysis buffer. For ChIP-seq, the following were added to the sheared chromatin and incubated
at 4°C overnight: 10µg of human antibody, 0.5µg Drosophila spike-in antibody, and Protein A or
Protein G Dynabeads (Invitrogen). After incubation, beads were washed twice with each of the
following buffers: Mixed Micelle Buffer (150 mM NaCl, 1% Triton X-100, 0.2% SDS, 20 mM
Tris-HCl, 5 mM EDTA, 65% sucrose), Buffer 500 (500 mM NaCl, 1% Triton X-100, 0.1% Nadeoxycholate, 25 mM HEPES, 10 mM Tris-HCl, 1 mM EDTA), LiCl/detergent wash (250 mM
LiCl, 0.5% Na-deoxycholate, 0.5% NP-40, 10 mM Tris-HCl, 1 mM EDTA), followed by a final wash with 1X TE. Finally, beads were resuspended in 1X TE with 1% SDS and incubated at
65°C for 10 min to elute. Elution was repeated twice, and the samples were incubated overnight at
65°C to reverse cross-link, alongside the untreated input (5% of the starting material). After treatment with 0.5 mg/ml proteinase K for 3 hours, DNA was purified with Zymo ChIP DNA Clean
Concentrator kit (Zymo research) and quantified by QUBIT. Barcoded libraries were made with
NEB Ultra II DNA Library Prep Kit for Illumina, and sequenced on Illumina NextSeq 500, producing 75 base pair single-end reads or 40 base pair paired-end reads. Sequences were aligned
to the human reference hg19 and D.melanogaster dm5 genome using Burrows Wheeler Alignment tool (BWA), with the MEM algorithm [90]. Using Samtools, aligned reads were filtered
based on mapping quality (MAPQ>10) and PCR duplicates removed (rmdup). Data was visualized on the UCSC Genome Browser (http://genome.ucsc.edu/) with Bigwig files generated with
deeptools (v2.4.2): bamCoverage –binSize 10 –normalizeTo1x 3137161264 –extendReads 150
–ignoreForNormalization chrX. For D.melanogaster spike-in normalization, the number of hg19
filtered reads was divided by the lowest number of dm5 filtered reads for each set of experiments,
resulting in a downsampling factor for each sample. Normalized BAM files were generated using
samtools view –s with the downsampling factor, and normalized Bigwigs were generated from the
normalized BAM files using bamCoverage –binSize 10 –extendReads 150. Peaks were called using MACS2 (2.1.2) with the broad peak option [91]: -f BAM –broad –broad-cutoff 0.1 for singleend libraries, or -f BAMPE –broad –broad-cutoff 0.1 for paired-end libraries. Genomic intervals
were generated using valr (v0.6.1) [92], an R-based implementation of BEDtools [93]. To identify genes that overlap peaks, valr’s bed intersect was used with hg19 UCSC known genes, and
filtered for RNAPII-processed transcripts (n=20618). Only genes with peaks identified in mul66

tiple replicates were included for further analysis. Average read density across defined genomic
intervals was computed using seqMINER 1.3.3 package [94] with the following parameters: left
and right extensions = 5.0 kb; internal bins = 160; flanking region bins = 20. Read density matrices were exported to generate average profiles. Where indicated, total RNAPII-normalization was
performed as follows: for average profiles, read density of RNAPII phospho-Ser2 was normalized
by TSS read-density of total RNAPII in the matched condition, and for boxplot quantifications of
RNAPII phospho-Ser2 and PPP2R1A, ChIP-seq coverage was normalized by per-gene coverage
of RNAPII in the matched condition. Coverage of ChIP-seq datasets across genomic intervals was
calculated using valr’s bed coverage. Highest expressed genesets were identified by genes with
largest TT-seq coverage values in two replicates of HeLa shLUC control. Pausing index was calculated as a ratio of coverage at the TSS (−150bp through +50bp) and coverage of the gene body
(+50 bp from TSS through the TES). Heatmaps were generated from the normalized bigwig files
using deeptools computeMatrix (scale-regions –missingDataAsZero -m 20000 -bs 50 -a 5000 -b
5000) with or without k-means clustering and visualized with plotHeatmap. All other data were
visualized in RStudio with ggplot2 (v3.3.1) and ggpubr (v0.4.0).

2.8.23

4sU Nascent RNA sequencing

20 × 106 THP-1-Cas9 cells expressing FgH1t-UTG-sgSCR-GFP or FgH1tUTG-sgINTS6-A-GFP
with stable knockout of INTS6 were treated with DMSO (6 hours) or AZ5576 for 2 or 6 hours.
Cells were labelled with 500µM 4-thiouridine (4sU; Sigma Aldrich T4509) for the final 30 minutes of the treatment time and were lysed in TRIzol. D.melanogaster S2 cells (20 × 106 ) were
also labelled with 4sU as above. Lysates were mixed with 1/5th volume of chloroform and the
aqueous phase was collected after centrifugation at 4°C (13000g, 15 minutes). Total RNA was
precipitated in isopropanol (room temperature for 10 minutes, 4°C for 10 minutes at 13000g) and
washed once with 70 percent ethanol (4°C for 15 minutes at 13000g). RNA was resuspended in
ultrapure nuclease-free H2 O and denatured at 65°C for 10 minutes. 80µg human RNA (with 5%
S2 RNA spike-in) was incubated for 1.5 hours with constant rotation at room temperature with
10mM Tris pH7.4, 1mM EDTA, 200µg/mL dimethylformamide (Sigma Aldrich, 227056) and
300µg EZ-Link HPDP Biotin (ThermoFisher Scientific 21341). The ‘biotin-labeling reaction’ was
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supplemented with 1 volume chloroform and vortexed well prior to centrifugation at 4°C (20000g,
5 minutes). The aqueous phase was isolated and chloroform isolation was repeated twice, prior to
the addition of 5M NaCl to a final concentration of 0.5M and 1 volume of isopropanol. Precipitated RNA was centrifuged at 4°C (20000g, 20 minutes), washed with 75% ethanol (4°C, 20000g,
20 minutes) and resuspended in nuclease-free H2 O (1µg/1µg RNA input) prior to incubation
at 65°C for 10 minutes. Biotinylated RNA was incubated with constant rotation for 15 minutes
at room temperature with µMACs streptavidin beads and was isolated using µMACs columns
(µMACs Strepavidin Kit, Miltenyi Biotec 130-074-101) that had been previously equilibrated
with wash buffer (100mM Tris-HCl pH 7.4, 10mM EDTA, 1M NaCl, 0.1% Tween-20). Columns
were washed with wash buffer pre-warmed to 65°C (5 x 0.9mL washes) and room temperature
wash buffer (5 x 0.9mL washes) and RNA was eluted using DTT (100mM, 2 x 100µL) and collected into 700µL RLT buffer from the RNeasy MinElute Cleanup Kit (Qiagen 74204). RNA was
isolated using the RNeasy MinElute kit as per manufacturer’s instructions and was quantified using the Agilent Tapestation High Sensitivity RNA kit (Agilent 067-5576). RNA sequencing libraries were prepared using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina
and 75 base-pair single-end reads were sequenced using the Illumina NEXTseq 500. Sequencing
files were demultiplexed (Bcl2fastq, v2.17.1.14) and QC was performed on FASTQ files using
FASTQC (v0.11.6). Sequenced reads were aligned to a combined Hg19/dm3 reference genome
using Bowtie (v2.3.4.1) and BAM files were generated and processed as described for ChIP-seq.
Normalization to the D.melanogaster S2 RNA spike-in was performed similarly to that described
previously [95], with reads mapping to Hg19 human and dm3 D.melanogaster genomes calculated
using FeatureCounts (Subread v2.0.0) and a scaleFactor determined by calculating the proportion
of reads mapping to the dm3 genome relative to the combined Hg19/dm3 genome. BigWig files
were generated using Deeptools (v3.0.0) bamCoverage function using the appropriate scale Factor
(–normalizeUsing CPM –smoothLength 150 –binSize 50 –e 200 scaleFactor #). Scaled BigWig
files were visualized in IGV and the bigwigCompare function (Deeptools). Data was visualized in
RStudio using ggplot2 (v3.3.1), ggrepel (v0.8.2) and ggfortify (v0.4.10) packages.
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2.8.24

TT-seq

HeLa cells infected with indicated shRNAs were placed under serum-starvation (0.3% SCS) the
night before harvesting. Cells were treated with EGF (0.1µg/mL) and concurrently labelled with
500µM 4-thiouridine (4sU; Sigma Aldrich T4509) for 15 minutes. Cells were lysed in QIAzol
lysis reagent (QIAgen, #79306), mixed with 1/5th volume of chloroform, and the aqueous phase
collected after centrifugation at 4°C (13000g, 15 minutes). Total RNA was precipitated in isopropanol (room temperature for 10 minutes), centrifuged at 4°C for 10 minutes at 13000g, and
washed twice with 75 percent ethanol. Pellet was air-dried and then re-suspended in ultrapure
nuclease-free H2 O on ice for 10 minutes, then 60°C for 5 minutes. 300µg human RNA (with 5%
S2 4sU-labeled RNA spike-in) was fragmented with the Bioruptor Plus for one cycle of 30s/30s
ON/OFF at high settings. Fragmentation was checked by TapeStation. 150µg of fragmented RNA
was incubated at 65°C for 10 minutes, then on ice for 5 minutes before adding biotin-labeling
reagents (100mM Tris pH 7.5, 10mM EDTA, 200µL dimethylformamide (DMF), 200µg EZ-link
HPDP Biotin (ThermoFisher Scientific 21341)) and incubating in the dark at 24°C and 800rpm
for 2 hours. Chloroform was added to the reaction and mixed well. After centrifugation, the upper aqueous phase was collected and the RNA was precipitated by the addition of 1/10th volume
of 5M NaCl and 1 volume of isopropanol, centrifuged at 4°C (20000g, 30 minutes), and washed
with ice cold 75% ethanol. RNA was resuspended in ultrapure nuclease-free H2 O, incubated on
ice for 10 minutes, then 65°C for 5 minutes. Biotin-labeled RNA was enriched using Streptavidin
beads (Invitrogen). Beads were equilibrated with wash buffer (100mM Tris pH 7.5, 10mM EDTA,
1M NaCl, 0.1% (v/v) Tween-20) before incubation with biotinylated RNA at 4°C and 800rpm for
15 minutes. Beads were washed 3x with 65°C wash buffer and 3x with room temperature wash
buffer. RNA was eluted twice by resuspending the beads in 100mM DTT buffer, and incubating
for 5 minutes. RNA was purified using the RNA Clean and Purification kit (Zymo research) with
DNAse step following manufacturer’s instructions. Sequencing libraries were prepared with the
NEBNext Ultra II Directional RNA Library Prep Kit for Illumina and 75bp single-end or 40bp
paired-end reads were sequenced using the Illumina NEXTseq 500. Reads were aligned to hg19
and dm5 reference genomes using STAR v2.5 (Dobin et al., 2013) in 2-pass mode with the same
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parameters described above for HeLa 3’-Quantseq. BAM files were filtered based on alignment
quality (q = 10) using Samtools v0.1.19 [87]. FeatureCounts [88] was used to count reads mapping to each gene. Normalization to the D.melanogaster S2 RNA spike-in, and subsequent normalized BAM and BigWig file generation was performed as described above for HeLa ChIP-seq.
Average read density across defined genomic intervals was computed on the normalized BAM files
using seqMINER 1.3.3 package [94] with the following parameters: left and right extensions =
5.0 kb; internal bins = 160; flanking region bins = 20. Read density matrices, featureCounts, were
exported for plotting in RStudio with ggplot2 (v3.3.1).

2.8.25

FastGRO

FastGRO was performed as described [41]. HeLa cells infected with shLUC or shINTS6 were
treated with DMSO or 300nM CDK9i AZ5576 for 2 hours, then subsequently treated for 15 minutes with 0.1µg/mL EGF. Per condition, 20 × 106 cells were harvested and washed twice with icecold PBS before adding swelling buffer (10 mM Tris-HCL pH 7.5, 2mM M gCl2 , 3 mM CaCl2 ,
2U/ml Superase-in (Invitrogen)). Cells were swollen for 5 min on ice, washed with swelling buffer
with 10% glycerol, and then lysed in lysis buffer (10 mM Tris-HCL pH 7.5, 2mM M gCl2 , 3mM
CaCl2 , 10% glycerol, 1mL Igepal (NP-40), 2 U/ml Superase-in) to isolate nuclei. Nuclei were
washed twice with lysis buffer and resuspended in freezing buffer (40% glycerol, 5mM M gCl2 ,
0.1mM 0.5M EDTA, 50mM Tris-HCL pH 8.3) to a concentration of 2 × 107 nuclei per 100 µL.
Nuclei were frozen on dry ice and stored at -80 °C. For the run-on reaction, nuclei were thawed on
ice, an equal volume of pre-warmed nuclear run-on reaction buffer (10mM Tris-HCl pH 8, 5mM
M gCl2 , 300mM KCl, 1mM DTT, 500µM ATP, 500µM GTP, 500µM 4-thio-UTP, 2µM CTP, 200
U/ml Superase-in, 1% Sarkosyl (N- Laurylsarcosine sodium salt solution) was added. This was incubated for 7 min at 30°C for the nuclear run-on. Nuclear run-on RNA was extracted with TRIzol
LS reagent (Invitrogen) following the manufacturer’s instructions and precipitated with ethanol.
RNA was then resuspended in water and the concentration was determined with Qubit High Sensitivity Assay kit (Invitrogen). Spike-in D.melanogaster RNA was added at 10%, and RNA was
fragmented with a Bioruptor UCD-200 for 1-5 cycles of 30s ON/30s OFF, high settings. Fragmentation efficiency was analyzed by running fragmented and unfragmented RNA on Agilent 2200
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TapeStation using High Sensitivity RNA ScreenTapes following manufacturer’s instructions. Fragmented RNA was incubated in Biotinylation Solution (100 mM Tris pH 7.5, 10 mM EDTA pH
8.0, 40% dimethylformamide, 200 g/mL EZ-link HPDP Biotin (Thermo Scientific)) for 2h in the
dark at 25 °C and 800 rpm. After ethanol precipitation, the biotinylated RNA was resuspended in
water and separated with M280 Streptavidin Dynabeads (Invitrogen). 100 µl/sample of beads were
washed twice with 2 volumes of freshly prepared wash buffer (100 mM Tris pH 7.5, 10mM EDTA
pH 8.0, 1M NaCl, 0.1% (v/v) Tween-20) and resuspended in 1 volume of wash buffer and added
to the biotinylated-RNA. After 15 minutes in rotation at 4°C, beads were washed three times with
wash buffer pre-warmed at 65°C and three times with room temperature wash buffer. 4-S-UTP
containing RNA was eluted in 100mM DTT buffer and purified with RNA Clean and Purification
kit (Zymo Research) with in-column DNAse reaction to eliminate traces of genomic DNA. The
eluted RNA was quantified with Qubit High Sensitivity Assay kit (Invitrogen) and used to produce
barcoded RNA sequencing libraries using the NEBNext Ultra II Directional RNA Library Prep kit
(New England Biolabs). Libraries were sequenced on Illumina NextSeq 500. Reads were aligned
to hg19 and dm5 reference genomes using STAR v2.5 [86] in 2-pass mode with the same parameters described above for HeLa 3’-Quantseq. BAM files were filtered based on alignment quality (q = 10) using Samtools v0.1.19 [87]. The latest annotations were obtained from Ensembl to
build reference indexes for the STAR alignments. FeatureCounts [84, 88] was used to count reads
mapping to each gene. Normalization to the D.melanogaster S2 RNA spike-in, and subsequent
normalized BAM and BigWig file generation, was performed as described above for HeLa ChIPseq. Average read density across defined genomic intervals was computed on the normalized BAM
files using seqMINER 1.3.3 package [94] with the following parameters: left and right extensions
= 5.0 kb; internal bins = 160; flanking region bins = 20. Read density matrices and featureCounts
outputs were exported for plotting in RStudio with ggplot2 (v3.3.1).

2.8.26

TCGA analysis

RNA-seq by Expectation Maximization (RSEM) scaled transcripts per million for TCGA samples
were downloaded from the GDAC Firehose website [96] and copy number status for INTS6 were
downloaded via the cBioPortal website [97]. TCGA samples were stratified into copy number
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groups (change of 2, 1, 0, -1, -2 from diploid) and PFI survival endpoints were fit to Kaplan-Meier
and Cox regression models using the survival R package (version 3.1-8) [98]. Copy number and
gene expression data from the Cancer Cell Line Encyclopedia were downloaded from the DepMap
portal (20Q3 release) [99]. Differential expression between wild-type samples and homo-deleted
samples for each gene using the limma-trend method with the limma R package (version 3.42.2)
[100].

2.8.27 In vivo methods
All in vivo experiments performed in this study were approved by the Peter MacCallum Cancer
Centre (PMCC) Animal Ethics Committee under ethics approval numbers E555 and E592, and all
NOD-scid IL2Rgnull (NSG) mice utilised were bred in-house (PMCC). For disseminated MV4-11
therapy experiments, 4-6-week-old female NSG mice were IV-injected with 5 × 106 MV4;11 cells
expressing the MSCV-Luc2-mCherry vector [101]. For long-term survival experiments, treatment
commenced when peripheral blood was detected to be 1% mCherry positive as determined by flow
cytometry (day 18). Mice were administered 15 mg/kg AZD’4573 twice daily via intraperitoneal
injection (IP; 100 mL) two hours apart, with 40 mg/kg DBK-1154 (100 mL) administered via oral
gavage two hours prior to, and two hours post, the AZD’4573 injections. This regimen was implemented in a 2-days on, 5-days off manner and repeated for four consecutive cycles of therapy.
For Cross-sectional analysis, therapy commenced 30 days post inoculation, and mice were treated
as per the above regimen. Mice were culled 24 hours and 96 hours post the conclusion of 1 cycle
of therapy. At endpoint in all experiments, blast cells were harvested from femur and tibial/fibial
bone and spleen and assessed for mCherry percentage via flow cytometry using a BD FACSymphony. For A431 long-term survival experiments, 3 × 106 A431 cells in a 1:1 matrigel:PBS solution (In Vitro Technologies, 354230) were subcutaneously transplanted into the right flanks of
7-week old female NGS mice. Treatment commenced at 11 days post-transplant (mean tumor volume: 165.5mm3) using the same dosing regimen as described for MV4-11 transplanted mice. Tumor volume and body weight was monitored 3 times per week and mice were culled when tumor
volume measured 1200mm3 or if mice exhibited a loss of 20 percent of their original body weight.
All treatments were well tolerated with 1 mouse treated with AZD’4753 culled due to > 20 per72

cent body weight loss. Kaplan-Meier survival analyses were performed using the Mantel Cox logrank test and Bonferroni-corrected threshold for multiple pair-wise comparisons. Tumor growth
inhibition (TGI) for each mouse was measured as the change in tumor volume between the day
one and day 15 of treatment. The mean change in tumor volume was calculated for control (∆C)
and treatment (∆Ti) groups and percentage TGI for each treatment group was calculated as 100 x
(1 – (∆Ti / ∆C)), which was analysed using unpaired student t-tests.
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Key Resources Table

REAGENT or RESOURCE
Antibodies
Anti-Actin, mouse monoclonal
Anti-AKT (phospho Ser-473), rabbit polyclonal
Anti-Asunder (INTS13), rabbit polyclonal
Anti-CDK9, rabbit polyclonal
Anti-DICE1 (INTS6), clone H-6, mouse monoclonal
Anti-DSIF
Anti-GAPDH, rabbit monoclonal
Anti-GST, rabbit polyclonal
Anti- Drosophila H2Av, spike-in antibody
Anti-Histone H3, rabbit polyclonal
Anti-INTS1, clone 4.47, mouse monoclonal
Anti-INTS3, rabbit polyclonal
Anti-INTS8, rabbit polyclonal
Anti-INTS11, rabbit polyclonal
Anti-Mouse IgG-AlexaFluor®-647
Anti-Mouse IgG-HRP, horse polyclonal
Anti-Mouse IgG-HRP, rabbit polyclonal
Anti-PP2A, C subunit, clone 1D6, mouse monoclonal
Anti-PPP2R1A, rabbit polyclonal
Anti-Rabbit IgG-AlexaFluor®-647
Anti-Rabbit IgG-HRP, goat polyclonal
Anti-Rabbit IgG-HRP, swine polyclonal
Anti-Rat IgG-AlexaFluor®-647
Anti-Rat IgG-HRP, rabbit polyclonal
Anti-RNA Polymerase II, raised against the N-terminus of
subunit B1, rabbit polyclonal
Anti-RNA Polymerase II, clone CTD 4H8, mouse
monoclonal
Anti-RNA Polymerase II CTD repeat YSPTSPS, clone
8WG16, mouse monoclonal
Anti-RNA Polymerase II subunit B1 (phospho-CTD Ser2), clone 3E10, rat monoclonal
Anti-RNA Polymerase II subunit B1 (phospho-CTD Ser5), clone 3E8, rat monoclonal
Anti-RNA Polymerase II subunit B1 (phospho-CTD Ser7), clone 4E12, rat monoclonal
Anti-RNA Polymerase II subunit B1 (phospho-CTD Thr4), clone 6D7, rat monoclonal
Anti-RNA Polymerase II subunit B1 (phospho-CTD Tyr1), clone 3E12, rat monoclonal
Anti-SBP-Tag, clone SB19-C4, mouse monoclonal
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SOURCE

IDENTIFIER

Sigma-Aldrich
Cell Signaling
Technologies
Bethyl Laboratories
Cell Signaling
Technologies
Santa Cruz
BD Biosciences
Cell Signaling
Technologies
Upstate
Active Motif
abcam
Millipore, Sigma
Proteintech
Sigma
Bethyl Laboratories
Invitrogen,
ThermoFisher
Cell Signaling
Technologies
Agilent, Dako
Millipore, Sigma
Bethyl Laboratories
Invitrogen,
ThermoFisher
Cell Signaling
Technologies
Agilent, Dako
Invitrogen,
ThermoFisher
Agilent, Dako
Alessandro Gardini,
Wistar Institute,
Philadelphia, PA
19104, USA
Millipore, Sigma

Cat#A2228
Cat#9271

Abcam

Cat#ab817

Millipore, Sigma

Cat#04-1571-I

Active Motif

Cat#61085

Millipore, Sigma

Cat#04-1570-I

Active Motif

Cat#61361

Active Motif

Cat#61383

Santa Cruz

Cat#sc-101595

Cat#A303-575A
Cat#2316
Cat#sc-376524
Cat#611106
Cat#2118
Cat#06-332
Cat#61686
Cat#ab1791
Cat#MABS1984
Cat#16620-1-AP
Cat# HPA057299
Cat#A301-274A
Cat#Z25008
Cat#7076
Cat#16102
Cat#05-421
Cat#A300-962A
Cat#Z25308
Cat#7074
Cat#P039901
Cat#A21247
Cat#P0161202
(Barbieri et al., 2018)

Cat#05-623

Anti-SPT5 (phospho Thr-806)

Robert P. Fisher, Icahn
School of Medicine at
Mount Sinai, New York,
NY10029, USA
Merck, Sigma Aldrich
Cell Signalling
Technology
LI-COR
LI-COR
LI-COR
Bethyl Laboratories
BD Biosciences

(Sanso et al., 2016)

Cat#18265017

One ShotTM Stbl3TM chemically competent Escherichia
coli

Invitrogen,
ThermoFisher
Invitrogen,
ThermoFisher

Chemicals, Peptides, and Recombinant Proteins
AZ5576, inhibitor of CDK9

AstraZeneca

(Hashiguchi et al.,
2019)
(Cidado et al., 2020)
(Merisaari et al.,
2020)

Anti-α-Tubulin, clone B-5-1-2, mouse monoclonal
Anti-V5-Tag, clone D3H8Q, rabbit monoclonal
IRDye® 800CW Anti-Mouse IgG, goat polyclonal
IRDye® 680RD Anti-Rabbit IgG, goat polyclonal
IRDye® 680RD Anti-Rat IgG, goat polyclonal
Purified Rabbit IgG
Purified Mouse IgG2b, clone MPC-11
Bacterial and Virus Strains
DH5-α chemically competent Escherichia coli

AZD’4573, inhibitor of CDK9
DBK-1154, agonist of PP2A

22-533, PROTAC of CDK9

THZ1, inhibitor of CDK7 and CDK12

1-NA-PP1, inhibitory ATP analogue
Lipopolysaccharide (LPS) [for 3’RNA seq]
Lipopolysaccharide (LPS) solution [for ChIP-seq]
1,10-Phenanthroline (Phendione), inhibitor of PP2A
Calyculin A, inhibitor of PP2A/PP1
Okadaic Acid, inhibitor of PP2A/PP1
Cytarabine
Epidermal Growth Factor (EGF) Recombinant Human
Protein
Flavopiridol hydrochloride hydrate
4-thiouridine (4sU)
EZ-LinkTM HPDP Biotin
Puromycin dihydrochloride from Streptomyces alboniger
Hygromycin
Doxycycline hyclate
Dimethyl sulfoxide (DMSO)
Dimethylformamide
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AstraZeneca
Michael Ohlmeyer,
Icahn School of
Medicine at Mount
Sinai, New York,
NY10029, USA
Nathaneal Gray, Dana
Farber Cancer
Institute, Boston, MA
02215, USA
Nathaneal Gray, Dana
Farber Cancer
Institute, Boston, MA
02215, USA
Cayman Chemical,
Sapphire Bioscience
Merck, Sigma Aldrich
eBioscience, Invitrogen
Merck, Sigma Aldrich
Abcam
Abcam
Peter MacCallum
Cancer Centre
Pharmacy
Gibco
Sigma-Aldrich
Merck, Sigma Aldrich
ThermoFisher
Merck, Sigma Aldrich
ThermoFisher
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich

Cat#T5168
Cat#13202
Cat#926-32210
Cat#926-68071
Cat#926-68076
Cat#P120-101
Cat#557351

Cat#C737303

NA

(Kwiatkowski et al.,
2014)
Cat#10954
Cat#L2630
Cat#00497693
Cat#496383
Cat#ab141784
Cat#ab120375
NA
Cat#PHG0311
F3055
Cat#T4509
Cat#21341
Cat#P8833
Cat#10687010
Cat#D9891
Cat#D8418
Cat#227056

Formaldehyde Solution (37%)
Paraformaldehyde
Sequa-brene
RNA Polymerase II CTD repeat YSPTSPS, recombinant
protein
6X-His-CDK9/Cyclin T1, recombinant protein complex
GST-PP2A-alpha, recombinant protein
Alt-R® S.p. HiFi Cas9 Nuclease V3, recombinant protein
Roswell Park Memorial Institute medium (RPMI)
Dulbecco’s Modified Eagle’s medium (DMEM)
Scheinder’s Drosophila medium
Penicillin / Streptomycin
GlutaMAXTM
Kolliphor® ELP
Poly(ethylene glycol)-400 (PEG-400)
N,N-Dimethylacetamide (DMA)
Tween® 80
Tween® 20
Sodium dodecyl sulfate (SDS)
XhoI restriction enzyme
EcoRI-HF restriction enzyme
KpnI-HF restriction enzyme
BspQ1
T7 DNA Ligase
CLB1 RPPA lysis buffer
CSBL1 RPPA dilution buffer
BB1 RPPA blocking buffer
Glycerol
Sodium Bicarbonate
Sodium Chloride
Sodium Deoxycholate
Lithium Chloride
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’tetraacetic acid (EGTA)
Potassium Acetate
Potassium Chloride
HEPES
Magnesium Chloride
IGEPAL® CA-630
cOmpleteTM Protease Inhibitors
Phosphatase Inhibitors
Formic Acid
Trypsin
Lysyl Endopeptidase
Acetonitrile
Benzonase
β-mercaptoethanol
Dithiolthreitol (DTT)
Annexin-V APC
TRIzol®
TritonTM X-100
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Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Abcam

Cat#252549
Cat#16005
Cat#S2667-1VL
Cat#ab81888

Merck
Merck, Sigma Aldrich
Integrated DNA
Technologies
Gibco, ThermoFisher
Gibco, ThermoFisher
ThermoFisher
ThermoFisher
ThermoFisher
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
New England Biolabs
New England Biolabs
New England Biolabs
New England Biolabs
New England Biolabs
Zeptosens, Bayer
Zeptosens, Bayer
Zeptosens, Bayer
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich

Cat#140685
Cat#SRP5336
Cat#1081601

Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Roche
Pierce, ThermoFisher
Scientific
Merck, Sigma Aldrich
Promega
Wako
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
BD Biosciences
Ambion, ThermoFisher
Scientific
Merck, Sigma Aldrich

Cat#P1190
Cat#P9333
Cat#H3375
Cat#M8266
I8896
Cat#1183580001
Cat#A32957

Cat#11875093
Cat#11995073
Cat#21720
Cat#10378016
Cat#35050061
Cat#30906
Cat#202398
Cat#185884
Cat#P6474
Cat#P1379
Cat#L3771
Cat#R0146
Cat#R3101
Cat#R3142
Cat#R0712
Cat#M0318
NA
NA
NA
Cat#G9012
Cat#S7277
Cat#S7653
Cat#D6750
Cat#L4408
Cat#E3889

Cat#06473
Cat#V5280
Cat#125-05061
Cat#34851
Cat#70746-5
Cat#M6250
Cat#D0632
Cat#550475
Cat#15596026
Cat#T8787

Proteinase K
Tris(2-carboxyethyl)phosphine (TCEP)
2-Chloroacetamide (CAA)
2,2,2-Trifluoroethanol
Trifluoroacetic acid (TFA)
Ammonium bicarbonate
Trichloroacetic acid (TCA)
Odyssey® Blocking Buffer
Enhanced Chemiluminescence PlusTM Reagent (ECL)
DynabeadsTM Protein A
DynabeadsTM Protein G
Strepavidin Agarose
Effectene Transfection Reagent
4’,6-diamidino-2-phenylindole (DAPI)
Matrigel ®
U.S. Origin SuperCalf Serum
Tris Buffered Saline (TBS)
Phosphate Buffered Saline (PBS)
Ethylenediaminetetraacetic acid (EDTA)
Tris Buffer
Heat inactivated fetal bovine serum (FBS)
Critical Commercial Assays
Direct-zol RNA mini-prep kit
RNeasy MinElute Cleanup kit
Zymogen ChIP DNA Clean and Concentrator Kit
μMACS Streptavidin Kit
Tapestation High Sensitivity RNA kit
BCA Protein Assay Kit
Click-iTTM RNA Alexa-Fluor Imaging Kit
SG Cell Line 4D-NucleofectorTM Kit
NEBNext Multiplex Oligos for Illumina (Index Primers)
NEBNext Ultra II DNA Library Prep Kit
QuantSeq 3’-mRNA Seq Library Prep Kit
NEBNext Ultra II Directional RNA Library Prep Kit
Revertaid first strand cDNA synthesis kit
CellTiter-Glo® Luminescent Cell Viability Assay
ADP-GloTM Kinase Assay
Deposited Data
4sU-seq data
3’-mRNA-seq data
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Zymo Research
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
Merck, Sigma Aldrich
LI-COR
Amersham, GE
Healthcare
Invitrogen,
ThermoFisher
Scientific
Invitrogen,
ThermoFisher
Scientific
Pierce, ThermoFisher
Scientific
Qiagen
Invitrogen,
ThermoFisher
Scientific
In Vitro Technologies
GemCell
Peter MacCallum
Cancer Centre
Peter MacCallum
Cancer Centre
Peter MacCallum
Cancer Centre
Peter MacCallum
Cancer Centre
Peter MacCallum
Cancer Centre

Cat#D30001-2-5
Cat#75259
Cat#22790
Cat#96924
Cat#302031
Cat#09830
Cat#T6399
Cat#927-50000
Cat#RPN2132

Zymo Research
Qiagen
Zymo Research
Miltenyi Biotec
Agilent
Pierce, ThermoFisher
Invitrogen,
ThermoFisher
Lonza
New England Biolabs
New England Biolabs
Lexogen
New England Biolabs
Thermo Scientific
Promega
Promega

Cat#R2051
Cat#74204
Cat#D5205
Cat#130-074-101
Cat#067-5576
Cat#23227
Cat#C10330

This paper
This paper

Cat#10002D
Cat#10003D
Cat#20353
Cat#301425
Cat#1306
Cat#354230
Cat#100-510
NA
NA
NA
NA
NA

Cat#V4XC-3032
Cat#E7335
Cat#E7645
Cat#015
Cat#E7760S
Cat#K1622
Cat#G7570
Cat#V6930

ChIP-seq data
TT-seq data
Fast-GRO data
Experimental Models: Cell Lines
Human: THP-1
Human: MV4;11
Human: HeLa
Human: BJ
Human: MM1.S
Human: HS5
Human: JJN3
Human: A431
Human: HT-29
Human: OPM2
Human: MOLM-13
Human: HL-60
Human: OCI-AML3
Drosophila melanogaster: S2
Human: HEK-293T
Experimental Models: Organisms/Strains
Mice: NOD-scid IL2Rgnull (NSG) mice

This paper
This paper
This paper
ATCC®
ATCC®
ATCC®
ATCC®
ATCC®
ATCC®
DSMZ
ATCC®
ATCC®
DSMZ
DSMZ
ATCC®
DSMZ
ATCC®
ATCC®

Cat#TIB-202
Cat#CRL-9591
Cat#CCL-2
CRL-2522
CRL-2974
CRL-11882
ACC 541
CRL-1555
HTB-38
ACC 50
ACC 554
CCL-240
ACC 582
Cat#CRL-1963
Cat#CRL-11268

Peter MacCallum
Cancer Center

N/A

Oligonucleotides
Scrambled sgRNA (sgSCR) for Human cells

(Doench et al., 2016)

Non-Targeting
Control

GCCTAGTCTCGGTAAGAGTG
sgRNA A targeting Human INTS6

(Sanjana et al., 2014)

HGLibA_23426

GGCTGTTACCTTGATAGCAT
sgRNA B targeting Human INTS6

(Sanjana et al., 2014)

HGLibB_23394

AGAGCCGCCCTATGCTATCA
sgRNA A targeting Human INTS3

(Doench et al., 2016)

ID_48444

CCTAGCATGTCGTCTAACCC
sgRNA B targeting Human INTS3

(Doench et al., 2016)

ID_48445

GGAGATGGACAACCATATGT
sgRNA A targeting Human CPSF3L (INTS11)

(Doench et al., 2016)

ID_41187

AAGATCGCCGTAGACAAGAA
sgRNA B targeting Human CPSF3L (INTS11)

(Doench et al., 2016)

ID_41188

GAAGAAAGTCCACGAGACCG
Scrambled sgRNA (sgSCR) for D.melanogaster S2 cells

This paper

NA

TTCGGGGCGAGGAGCTGTTCACCG
sgRNA targeting D. melanogaster IntS6

This paper

NA

TTCGCCAGCAGCTGGCTGTAGTCT
sgRNA targeting Human PPP2R1A

This paper

NA

GGACGGAGCCAAGAUGGCGG
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sgRNA targeting human CDK9

(Gressel et al., 2017)

NA

CACCGGCTCGCAGAAGTCGAACACC
shRNA targeting INTS2

This paper

NA

CCGGCCCAACATGAATCTGCATATTCTCGAGAATATG
CAGATTCATGTTGGGTTTTT
shRNA targeting INTS5

This paper

NA

CCGGGAAGTTCATCTTCCAATCAGACTCGAGTCTGAT
TGGAAGATGAACTTCTTTTT
shRNA targeting INTS6 in pLKO.1 vector

Sigma-Aldrich

TRCN0000001264

CCGGGCCACGAAGGTTGCATACATTCTCGAGAATGT
ATGCAACCTTCGTGGCTTTTT
shRNA targeting INTS8 in pLKO.1 vector

Sigma-Aldrich

TRCN0000144908

CCGGGAAGAACGAAAGCTACTTGTTCTCGAGAACAA
GTAGCTTTCGTTCTTCTTTTTTG
shRNA targeting INTS12 in pLKO.1 vector

Sigma-Aldrich

TRCN0000021865

CCGGCCGATGTACCAGACAAATGAACTCGAGTTCAT
TTGTCTGGTACATCGGTTTTT
shRNA targeting PPP2R1A in pLKO.1 vector

Sigma-Aldrich

TRCN0000010718

CCGGGACTGTGTGAACGAGGTGATTCTCGAGAATCA
CCTCGTTCACACAGTCTTTTT
18S primers for qRT-PCR

This paper

NA

Forward: ATACATGCCGACGGGCGCTG
Reverse: AGGGGCTGACCGGGTTGGTT
U1 primers for qRT-PCR

This paper

NA

Forward: TCAATATCTGCAAGAGTGGCA
Reverse: CGTTAAAGCCAAGAGCCCCT
GUSB primers for qRT-PCR

This paper

NA

(Gressel et al., 2017)

NA

Forward: CTCATTTGGAATTTTGCCGATT
Reverse: CCGAGTGAAGATCCCCTTTTTA
DNA donor template for CDK9AS/AS mutation
AAAGTGTGTTGGGTGTGGTTTTCTTGACTTTTTCTTCT
TTCTATTCCTGCCTCAGCTTCCCCCTATAACCGCTGC
AAGGGTAGTATATACCTGGTCGCGGACTTCTGCGAG
CATGACCTTGCTGGGCTGTTGAGCAATGTTTTGGTCA
AGTTCACGCTGTCTGAGATCAAGAGGGTGATGCAGA
TGCTGCTTAACGGCCT
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DNA donor template for mCherry-P2A-V5-PPP2R1A
CCAGCGGAACCACGGCCTGGTAACCCAAAACCTGCA
CACCCTCCAGCTCCCCACAGGACGTCACGTATTACC
ACCGACGCACGCGCAGAAGCCTTCCCGGGGACTCA
AGAAAGGGCAGGCTTAGCCTCCTCCCCATGTCGCCC
CTCATTGGCTAGAAACTACTGCTCGTCTCGGTCGTTG
TTAGCAGCGACCAGGGCGGGTACAATCTTGGTCGCT
AGGACACGGCTAACTTCCGCTTTCTTCCCCCTCTCCT
AGGCTCAAACTAGTCAAATCTTGTTCACTCGACCAAT
GGCAAATCGGAAGTGGGCGGGACTTCACAAGTCCG
GACCAAAGAAACGCGAGCTTAGCCCTGGGTAGCGC
GGCCAATGGCCGTGGAGCAGCCCCTGTAAACTGGC
TCGGGCGCCCCCACGCCCGCCCTTCCTTCTTCTCCC
AGCATTGCCCCCCCCACGTTTCAGCACAGCGCTGGC
CGCAGTCTGACAGGAAAGGGACGGAGCCAAGATGG
TGAGCAAGGGCGAGGAGGATAACATGGCCATCATCA
AGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCT
CCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAG
GGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGC
CAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTT
CGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGG
CTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCC
CGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAA
GTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCG
TGGTGACCGTGACCCAGGACTCCTCCCTGCAGGAC
GGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACC
AACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAG
ACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTA
CCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGC
AGAGGCTGAAGCTGAAGGACGGCGGCCACTACGAC
GCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCC
GTGCAGCTGCCCGGCGCCTACAACGTCAACATCAAG
TTGGACATCACCTCCCACAACGAGGACTACACCATC
GTGGAACAGTACGAACGCGCCGAGGGCCGCCACTC
CACCGGCGGCATGGACGAGCTGTACAAGGCCACGA
ACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAG
AAAACCCCGGTCCTGGTAAGCCTATCCCTAACCCTC
TCCTCGGTCTCGATTCTACGGGAGGATCAGGAGGAG
GAGCGGCGGCCGACGGCGACGACTCGCTGTACCCC
ATCGCGGTGCTCATAGACGAACTCCGCAATGAGGAC
GTTCAGGTCCGGAGGCTACGGGGGACTTGGGGAAG
ACGCGGAGGGGTACCTGGGGGCACGGGCGGCCCT
CGCGGAGAAGACTCAGCGTTCGCTGGGAGTGGCGG
AAGGGGGCGACGGCCAATCAGCGTGCGTCTCTTATC
TCCCCGGTTGCCCGGACTCCTTGAGACGGCGCTCC
CGATTGGGTGTCGGCCCAGTGGAGGGCGGGGGCCA
GCGCTAGCCTCGAGGGTCCCGGGCCTGCCCTGTGC
GCGCGGCGGTCCGCGGTCCTGGGAGGTTGTGGCCA
GGGCTGGGGTCTGCGGACTGGGTCTGGGAGAGAGG
AGGACTCCGTGATTGGCGGCGGCCTCTGAATGGCCT
CTTGGGGATGTGGGGCGCGCATGACTTGCTCCAAG
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This paper

NA

Cloning PCR primers for Human INTS6

This paper

NA

This paper

NA

Addgene
Addgene
Addgene
Addgene
Origene
Addgene

(Aubrey et al., 2015)
(Aubrey et al., 2015)
(Doench et al., 2016)
(Sanjana et al., 2014)
Cat#RC208036
(Akama-Garren et al.,
2016)
(Bassett et al., 2014)

Forward:AAAACTCGAGACCATGCCCATCTTACTGTTC
CTGATAG
Reverse:AAAAGAATTCTTACGTAGAATCGAGACCGAG
GAGAGGGTTAGGGATAGGCTTACCTCCTCCTCCTGA
TCCTCCATTGCTATTAATATGGTTGATCTG
Cloning PCR primers for D. melanogaster IntS6
Forward:ATGACAATCATACTCTTCCTGGTG
Reverse:ACTAGTGGTACCACTCTTGGCGACGGC
Recombinant DNA
FUCas9Cherry Cas9 expression vector
FgH1tUTG-GFP sgRNA expression vector
Human CRISPR Knockout Pooled Library (Brunello)
Human CRISPR Knockout Pooled Library (GeCKO v2)
Human full length INTS6 ORF in pCMV6
MSCV Puro expression vector
pAc-sgRNA-Cas9 expression vector
pMK33-SBP expression vector
D. melanogaster IntS6 coding sequence

Addgene
(Yang and Veraksa,
2017)
FlyBase.org

pLKO.1 shRNA expression vector

Addgene

Software and Algorithms
Bcl2fastq2, v2.17.1.14

Clone
DmeI/SD04165
FBcl0286688
Cat#10879

support.illumina.com/
downloads/bcl2fastqconversion-softwarev2-20.html

FASTQC, v0.11.6

bioinformatics.babrah
am.ac.uk/projects/fas
tqc/

HISAT2, v2.1.0
Subread, v2.0.0

(Kim et al., 2015)
(Liao et al., 2013)

Bowtie2, v2.3.4.1

(Langmead and
Salzberg, 2012)

Samtools, v1.9

(Li et al., 2009)

Deeptools, v3.0.0

(Ramirez et al., 2014)

https://deeptools.read
thedocs.io/

MAGeCK, v0.5.9

(Li et al., 2014)

https://sourceforge.n
et/p/mageck/wiki/Ho
me/
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http://subread.source
forge.net/
http://bowtiebio.sourceforge.net/b
owtie2/
http://www.htslib.org/

Cutadapt, v2.1

(Martin, 2011)

BWA
MACS2
STAR, v2.5
FeatureCounts
RSEM
Valr, v0.6.1

(Li, 2013)
(Zhang et al., 2008)
(Dobin et al., 2013)
(Liao et al., 2014)
(Li and Dewey, 2011)
(Riemondy et al., 2017)

seqMINER, v1.3.4
Other
HeLa INTS11 ChIP-seq data
HeLa NELF ChIP-seq data

(Ye et al., 2014)
(Gardini et al., 2014)
(Lai et al., 2015)
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https://cutadapt.readt
hedocs.io/en/stable/

https://rnabioco.githu
b.io/valr/

GEO GSE58255
GEO GSE68401

2.9
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Loss of INTS6 confers resistance to CDK9 inhibition
(A) Comparison of enriched sgRNAs for replicate survival screens in THP-1-Cas9 and MV4;11-Cas9 cells
(CDK9i versus untreated at Tend) plus enrichment of INTS6 sgRNAs in CDK9i-treated versus untreated
cells at Tend. (B) Overview of nascent RNA analysis using ClickIT-EU assay and flow cytometry. (C)
Representative flow cytometry profiles for EU incorporation/Alexa-Fluor647 staining as a measure of nascent
RNA production in THP-1 cells treated with CDK9i (170nM) for the indicated time-points (left) or for 24
hours with the indicated dose of CDK9i (right). (D) Overview of nascent RNA CRISPR-Cas9 genomewide screen in THP-1-Cas9 cells; resistant cells were selected by FACS for the maintenance of high-EU
signal in the presence of CDK9i. (E) Identification of significantly enriched guides in EU-high cells (CDK9i
treated relative to T0). (F) Enrichment of sgRNAs for Integrator complex subunits in THP-1-Cas9 cells for
individual replicate survival screens (significance relative to DMSO-treated cells at Tend) and nascent RNA
screens (significance relative to T0). (G) Competitive proliferation assay for MV4;11-Cas9 cells expressing
indicated INTS6 targeting sgRNAs in the presence of CDK9i and DMSO. (H) Annexin-V analysis of THP1-Cas9 cells expressing indicated SCR and INTS6 targeting sgRNAs treated as indicated for 24 and 48 hours,
and comparison of THP-1-Cas9 cells expressing SCR sgRNA treated with indicated doses of CDK9i at 24, 48
and 72 hours. (I) Western blot of THP-1 cells treated with 22-533 for 6 hours. (J) Competitive proliferation
assay for THP-1-Cas9 cells expressing indicated SCR or INTS6 targeting sgRNAs in the presence of 22533. (K) Overview of THP1 CDK9AS/AS, HeLa, MM1.S and HS5 competitive proliferation assays for
Figure 2.1K, M, O and P: cells expressing sgSCR (CFP-Cas9) and sgINTS6 (CH-Cas9) were mixed 1:1
and incubated for 96 hours with CDK9i or 1-NA-PP1. Competitive proliferation assay for THP-1-Cas9
cells expressing indicated SCR, INTS3 (L) or INTS11 (M) targeting sgRNAs in the presence of CDK9i or
DMSO. (N) Annexin-V analysis of THP-1-Cas9 cells expressing indicated INTS6 targeting sgRNAs treated
as indicated for 72 hours. (O) Western blot of THP-1-Cas9 cells expressing SCR or INTS6-A targeting
sgRNAs plus/minus V5-INTS6 overexpression. (P) Competitive proliferation assay and (Q) Annexin-V cell
death analysis of THP-1-Cas9 cells expressing indicated SCR or INTS6-A targeting sgRNAs plus/minus V5INTS6 overexpression in the presence of A5576 (CDK9i). (R) Representative flow-cytometry profiles and
quantitation of the relative inhibition of nascent RNA production (as measured by EU incorporation/AlexaFluor647 staining) following CDK9i treatment for 24 hours in THP-1-Cas9 cells expressing indicated SCR
or INTS6 targeting sgRNAs. (S) Overview of CDK9i acquired resistance; MV4;11 cells were cultured for 11
weeks in the presence or absence of CDK9i as indicated. At endpoint cells were assessed by western blot and
cell death was measured by Annexin-V staining following treatment with CDK9i as indicated for 72 hours.
(T) Competitive proliferation assay for BJ-T-Cas9 cells expressing indicated INTS6 targeting sgRNAs in the
presence of CDK9i and DMSO. (U) Western blot of D. melanogaster S2-Cas9 sgSCR and sgIntS6-5D cells
plus/minus SBP-IntS6 over-expression. (V) Annexin-V analysis of D. melanogaster S2-Cas9 cells expressing
indicated SCR or IntS6 targeting sgRNAs plus/minus SBP-IntS6 overexpression treated as indicated for 72
hours. Blue dots (Figures A and E) represent nominal p-value < 0.05 or p-value < 0.01 respectively. Figures
G, H-J, L-R and T-V are representative of 3 independent experiments. Figures G, H, J, L, M, P, Q, R and V
were analyzed by 2-way ANOVA, ** p < 0.01, *** p< 0.001, **** p<0.0001.
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F IGURE 2.9

S UPPLEMENT (related to F IGURE 2.2)
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INTS6 bridges the interaction between Integrator and PP2A
Log2 iBAQ scores of proteins identified in INTS6 IP versus mouse IgG isotype control IP mass spectrometry experiments for (A)THP-1 and (B) MV4;11 cells. (C) Volcano plot of differentially enriched proteins in
SBP-IntS6 versus SBP (isotype control) streptavidin-IP mass spectrometry experiments in D. melanogaster
S2 cells. (D) Western blot of HeLa cell cytoplasmic, nuclear, and chromatin fractions. (E) Relative expression levels of INTS6, INTS8, and INTS12 from shLUC, shINTS6, shINTS8, or shINTS12 infected HeLa
cells. Values normalized by expression of ribosomal RNA 18S. RT-PCR results are representative of knockdown validation for all shRNA experiments. (F) Co-IP western blot for INTS11 in THP-1-Cas9 sgSCR and
sgINTS6-KO cells. (G) Relative expression levels of INTS2, INTS6, and INTS8 from shLUC, shINTS6,
shINTS8, or shINTS2 infected Hela cells, as presented in Fig 2I-J. (H) Western blot of glycerol gradient fractions of nuclear extracts from shLUC, shINTS2, or shINTS6-infected HeLa cells. (I) Western blot of nuclear
extracts from HeLa cells infected with shLUC, shINTS5, shINTS6, shINTS8, or shINTS12. The same panel
of PP2A-C INPUT presented in Fig 2G is re-presented here as a loading control. (J) Western blot of glycerol
gradient fractions of nuclear extracts from shLUC or shINTS8 infected HeLa cells.
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F IGURE 2.10

S UPPLEMENT (related to F IGURE 2.3)
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INTS6-dependent dynamic recruitment of PP2A at actively transcribed genes
(A) ChIP-seq signal at the SETD2 locus for indicated proteins in THP-1 cells treated as indicated for 2
hours. (B) Average profiles of ChIP-seq signal for CDK9 around the TSS, THP-1-Cas9 cells expressing
INTS6 targeting sgRNA and treated as indicated for 2 hours. (C) Heatmap with average profiles of RNAPII
and PPP2R1A ChIP-seq, including inputs, from THP1 cells treated with acutely with LPS. The geneset is
from the top two (out of five) clusters from k-means clustering of all four replicates of PPP2R1A ChIP-seq
in THP1, n=2501. (D) Quantification of PPP2R1A ChIP-seq coverage in HeLa cells untreated or acutely
treated with EGF, at EGF genes (n=50) in two replicates. (E) Heatmap with average profiles of RNAPII and
PPP2R1A ChIP-seq at EGF genes (n=50) in HeLa cells treated as indicated. (F) Average profiles of ChIPseq signal for RNAPII and PPP2R1A around TSS profiles at highest-expressed genes (n=100) in untreated
THP1, presented as percent of maximum read density to visualize the location of the peaks. (G) Average
profiles of ChIP-seq signal for RNAPII, PPP2R1A, and NELF around TSS profiles at highest-expressed
genes (n=990) in HeLa cells treated acutely with EGF (0.1µg/mL; 15 minutes). NELF ChIP-seq tracks
are from a previously published dataset [7]. (H) Visualization of MACS2 broad peak calling results for
HeLa RNAPII and PPP2R1A ChIP-seq. After selecting for genes that had peaks called in four replicates for
each antibody, there were 1398 robust PPP2R1A-bound genes, of which 98.7% overlapped with RNAPIIoccupied genes. Inset boxplot represents quantification of gene expression by TT-seq coverage for each gene
set. (I) GO term analysis was performed with ToppGene Suite for PPP2R1A-bound genes in HeLa (n=1398
genes) and in THP1 (n=564 genes) – defined as above. (J) Western blot of HeLa cell lysates after treatment
with DMSO or SMAP (10µM, 2 hours). (K) Average profile of RNAPII ChIP-seq in Hela after treatment
with DMSO or SMAP (10µM, 2 hours) at PPP2R1A-occupied genes (n=1398). (L) RNAPII and PPP2R1A
ChIP-seq signal at the FOS locus after treatment with DMSO or SMAP (10µM, 2 hours). (M) Coverage of
PP2A-C and PPP2R1A ChIP-seq plotted against each other at all RNAPII-transcribed genes (n=20618), with
Pearson correlation. (N) Heatmap with average profiles of PPP2R1A ChIP-seq in HeLa infected with shLUC,
shINTS6, or shINTS8 at 303 PPP2R1A-occupied genes. (O) PPP2R1A ChIP-seq signal at the JUNB locus
in HeLa infected with shLUC, shINTS6, or shINTS8. (P) Quantification of PPP2R1A ChIP-seq coverage
shown in (N). Scale bar for A represents 10kb. Figures D, H, M, and P analysed by unpaired, two-sided
students t-test, *** p<0.001, **** p<0.0001.
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F IGURE 2.11

S UPPLEMENT (related to F IGURE 2.4)
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Loss of INTS6/PP2A results in decreased turnover of CDK9 substrates
(A) Heatmap of Z-scores of phospho-peptides in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2 hours, p-value < 0.25. (B) K-means clustering of differentially phosphorylated peptides identified
by phospho-peptide mass spectrometry in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated
for 2 hours. Additional differentially phosphorylated peptides (C) SUPT5H and (D) POL2RA peptides in
THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2 hours. (E) GO-analysis of proteins with
differentially phosphorylated peptides in CDK9i-treated THP-1-Cas9 sgSCR (compared to DMSO-treated
THP-1-Cas9 sgSCR and CDK9i-treated THP-1-Cas9 sgINTS6-KO cells; p< 0.05 and p < 0.25). (F) Western blot of BJ-T cells electroporated with recombinant Cas9 and SCR or INTS6 targeting sgRNAs and treated
with CDK9i as indicated for 2 hours. (G) Western blot of THP-1-Cas9 sgSCR and sgINTS6-KO cells treated
with THZ531 as indicated for 6 hours. (H) Western blot of D. melanogaster S2-Cas9 cells expressing indicated sgRNAs and treated as indicated for 2 hours. (I) Overview of in vitro recombinant CDK9/Cyclin-T1 and
PP2A kinase/phosphatase assay related to Figure 2.4H. (J) Overview of in vitro recombinant CDK9/CyclinT1 and PP2A kinase / phosphatase assay. RNAPII CTD peptide was incubated with CDK9/CyclinT1 for
50 minutes prior to the addition of CDK9i for 10 minutes. PP2A was added to the reaction for 30 minutes and RNAPII CTD peptide phosphorylation was assessed by western blot. (K) Western blot of THP-1
CDK9AS/AS cells treated as indicated (15 minutes pre-treatment with the PP2A inhibitor Phendione and
2 hours with 1-NA-PP1). (L) Western blot of THP-1 cells treated as indicated (15 minutes pre-treatment
with Calyculin A or Okadaic acid and 2 hours with CDK9i). Ten biological replicates were analysed for
phospho-peptide mass spectrometry. Western blots are representative of 3 independent experiments.
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F IGURE 2.12

S UPPLEMENT (related to F IGURE 2.5)
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PP2A/INTS6 loss overrides CDK9i induced transcriptional pausing
(A) 4sU-seq signal (log2CPM) across all expressed genes and difference in log fold change of 4sU-seq
signal (Figure 2.5B-D) between THP-1-Cas9 sgINTS6-KO and sgSCR cells for all expressed genes, highly
expressed genes and the most and least CDK9i-sensitive genes as indicated. (B) 4sU-seq signal for MYC
and IL6R genes in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated. (C) Example of 4sUseq signal at the MYC locus under indicated conditions. Average profile of (D) RNAPII and (E) RNAPII
phospho-Ser2 ChIP-seq signal in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2 hours.
(F) Log2 ratio of RNAPII phosphor-Ser2 / total RNAPII ChIP-signal at TSS proximal regions (bin 51-75)
of all expressed genes in THP-1-Cas9 sgSCR and sgINTS6-KO cells treated as indicated for 2 hours. (G)
Representative RNAPII ChIP-seq signal at the IL6R locus under the same conditions. (H) Total and log fold
change RNAPII ChIP-seq gene body signal at (i) all expressed, (ii) highly expressed, (iii) highly CDK9i
sensitive and (iv) least CDK9i sensitive genes as defined by 4sU-seq analysis in THP-1-Cas9 sgSCR and
sgINTS6-KO cells treated as indicated for 2 hours. (I) Total and log fold change RNAPII phospho-Ser2 gene
body (left) and TES ChIP-seq signal (right) at all expressed genes for the same conditions as H. (J) RNAPII
pausing ratio in D. melanogaster S2-Cas9 cells expressing indicated sgRNAs and treated as indicated for 2
hours. (K) Western blot of shLUC and shINTS6 infected HeLa cells treated with CDK9i for 2 hours. (L)
Average profile of RNAPII ChIP-seq signal at EGF response genes (n=50) in shLUC and shINTS6 infected
HeLa cells treated with CDK9i for 2 hours and acutely treated with EGF (0.1µg/mL; 15 minutes). (M)
Quantification of Fig. 5I, RNAPII phospho-Ser2 ChIP-seq signal across gene body quartiles. (N) RNAPII
and RNAPII phospho-Ser2 ChIP-seq signal at the NR4A1 locus under the same conditions. Average profile
of (O) RNAPII and (P) RNAPII phospho-Ser2 ChIP-seq signal at EGF-response genes (n=50) in shLUC,
shINTS6 or shINTS8 infected HeLa cells treated with Flavopiridol (2µM) for 1 hour and acutely treated with
EGF (0.1µg/mL; 15 minutes). (Q) RNAPII and RNAPII phospho-Ser2 ChIP-seq signal at the NR4A1 locus
under the same conditions. (R) Western blot of shLUC and shPPP2R1A infected HeLa cells treated with
CDK9i for 2 hours. (S) RNAPII phospho-Ser2 ChIP-seq signal across the first half of the gene body for
EGF-response genes (n=50), in EGF-treated shLUC or shPPP2R1A HeLa cells, and treated as indicated for
2 hours. Scale bar for C represents 5kb. Scale bar for G represents 10kb. Figures F, H and I were analysed
by unpaired, two-sided students t-test, *** p<0.001, **** p<0.0001
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S UPPLEMENT (related to F IGURE 2.6)
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The INTS6/PP2A axis fine-tunes acute transcriptional responses
(A) Overview of acute INTS6 depletion; ChIP-seq for RNAPII was performed on THP-1 cells 60 hours
following electroporation with recombinant Cas9 protein and SCR or INTS6 targeting sgRNAs. (B) Average
ChIP-seq profile and (C) gene body signal for RNAPII in THP-1 cells at 60 hours post-electroporation with
Cas9 and SCR or INTS6 sgRNAs. (D) Average Fast-GRO signal for highly expressed genes (n=2989) in
shLUC and shINTS6 infected HeLa cells treated with EGF (0.1µg/mL; 15 minutes) and DMSO (top) or
CDK9i (bottom) for 2 hours. (E) TT-seq coverage in HeLa shLUC or shINTS6 cells for highest expressed
genes (n=990) after EGF treatment (0.1µg/mL; 15 minutes). (F) Expression of EGF-induced genes (n=50)
in HeLa shLUC or shINTS6 cells treated with CDK9i for 2 hours followed by treatment with 0.1µg/mL
EGF for the indicated time-points. (G) GSEA profile of THP-1-Cas sgSCR cells treated with LPS (2 hours
versus 0 hours). (H) Volcano plot of differentially expressed genes in THP-1-Cas9 sgSCR and sgINTS6-KO
cells treated with LPS for 2 hours (relative to untreated control). (I) Proportion of INTS6 copy number (CN)
gains and losses across indicated cancer types (TCGA). (J) INTS6 expression levels across cancer types
(S4L) subset by copy number change (TCGA). (K) Significance and hazard ratio (HR) ranking of INTS6
loss/mutation across indicated cancer types (TCGA). Gene set enrichment analysis of (L) E2F and (M) MYC
targets as well as (N) chromosome 13q14 in cancer cells exhibiting significant INTS6 loss/mutation. Figure
E was analysed by unpaired, two-sided students t-test, **** p<0.0001
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S UPPLEMENT (related to F IGURE 2.7)
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Therapeutic and molecular synergy between PP2A agonist and CDK9i
(A) Synergy for combined CDK9i and DBK-1154 treatment of THP-1-Cas9 sgSCR cells was determined
using the SynergyFinder computational package and the ZIP synergy index and is denoted as regions of red
in the graphs. (B) Annexin-V analysis of MV4;11 cells treated as indicated for 72 hours. (C) DAPI cell
death analysis of indicated multiple myeloma (top) and AML (bottom) cell lines treated as indicated for
72 hours. Heatmaps of in vitro cell death in (D) A431 and (E) HT-29 cells treated with as indicated with
AZ5576 and/or DBK-1154. Potential synergistic/additive interactions are highlighted by the red box. (F)
Log fold change relative to DMSO control of 3’RNA-seq signal (log2(CPM)) across all expressed genes
for HT-29 cells treated as indicated for 2 hours. (G) 3’RNA-seq signal for IRF1, MYC, PLAUR and ID2
transcripts in HT-29 cells treated as indicated for 2 hours. (H) Spleens and (I) spleen masses from mice
treated as indicated at 24 hours post-therapy. Scale bar in millimetres (mm). (J) May-Grünwald Giemsa
histological staining of bone marrow cytospins from mice treated as indicated 96 hours post therapy. Scale
bar represents 20 µm. (K) Spleen masses of mice with disseminated MV4;11 leukaemia at endpoint for the
long-term survival experiment. (L) Individual tumor and (M) mean tumor volumes of A431-transplanted mice
treated as indicated. The dotted horizontal line indicates the ethical endpoint based on tumor volume (1200
mm3). Figures B and C represents the mean +/- SD of two independent experiments each containing two
technical duplicates. Figures D and E represent the mean of three independent experiments each containing
three technical replicates. Figures F and G represent three biological replicates for each treatment condition.
Figure I (mean +/- SD) and J represents three mice per treatment group while Figures L and M represent
seven mice per group. Figure K represents eight mice per group. Figure C was analyzed by 2-way ANOVA,
and Figures F, I, K and M were analyzed by unpaired student’s t-test, * p < 0.05 ** p < 0.01, *** p< 0.001,
**** p<0.0001.
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Targeted Enhancer Activation by a Subunit of the Integrator Complex
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3.1

Abstract

The control of cell fate is an epigenetic process initiated by transcription factors (TFs) that recognize DNA motifs and recruit activator complexes and transcriptional machineries to chromatin.
Lineage specificity is thought to be provided solely by TF-motif pairing, while the recruited activators are passive. Here we show that INTS13, a subunit of the Integrator complex, operates as
monocytic/macrophagic differentiation factor. Integrator is a general activator of transcription at
coding genes and is required for eRNA maturation. Here we show that INTS13 functions as an independent sub-module and targets enhancers through Early Growth Response (EGR1/2) TFs and
their co-factor NAB2. INTS13 binds poised monocytic enhancers eliciting chromatin looping and
activation. Independent depletion of INTS13, EGR1 or NAB2 impairs monocytic differentiation of
cell lines and primary human progenitors. Our data demonstrate that Integrator is not functionally
homogeneous and has TF-specific regulatory potential, revealing a new enhancer regulatory axis
that controls myeloid differentiation.

3.2

Introduction

Cis-regulatory elements orchestrate spatial and temporal gene expression in metazoans. Enhancers
are essential during tissue development and cell differentiation, such as in the hematopoietic com98

partment [102, 103, 104]. Precisely, recognition of DNA motifs by a select combination of transcription factors (TFs) activates enhancers that were otherwise repressed or in a poised/inactive
conformation [105, 103]. While repressed enhancers lack DNA accessibility and are embedded
in a repressive chromatin conformation, poised enhancers are generally nucleosome-free to facilitate binding of lineage-determining TFs to their respective DNA motifs. Poised enhancers are
devoid of H3K27ac mark (enriched at enhancers that are active or recently dismissed) but carry
sustained levels of H3K4me1 [106, 107]. It is believed that recruitment of TFs first leads to hyperacetylation of nucleosomes surrounding the enhancer core [108]. Next, TFs pair with the Mediator
complex to recruit the RNAPII holoenzyme and initiate bi-directional transcription of enhancerassociated noncoding RNAs (eRNAs) [109]. The Integrator, a large co-activator complex endowed
with RNA endonucleolytic activity, is required to terminate eRNA transcripts, and consequently
allow their accumulation at chromatin. eRNAs are implicated in enhancer activation, perhaps by
enforcing chromosomal looping between enhancers and their target promoters [110, 7]. In addition, eRNAs may function in maintenance of H3K27ac levels [111], and in release of the paused
RNAPII at target promoters [112]. The overall mechanistic process of enhancer activation is not
clear. For instance, the series of events that bring inactive or poised enhancers to full activation is
poorly understood. Here, we present a novel function for a component of the Integrator complex in
activating lineage-specific enhancers.
Integrator is conserved across metazoans, and is composed of 14 subunits (INTS1 to INTS14)
[1, 113]. This protein complex associates with the C-terminal domain of RNAPII and is implicated in the biogenesis of spliceosomal U snRNAs [1]. In fact, the endonucleolytic heterodimer
INTS9/INTS11 cleaves nascent U snRNA transcripts to initiate their maturation [1]. Integrator’s
activity at enhancers is also critical to establish chromosomal looping with target promoters to
drive gene activation [7]. Furthermore, Integrator is loaded at the proximal promoter of proteincoding genes, where it controls the release of paused RNAPII by recruiting the SEC/pTEFb complex and modulating the activity of Negative Elongation Factor (NELF) [6, 65]. While the catalytic function and genomic distribution of the INTS9/INTS11 heterodimer has been established,
the remaining 12 subunits of the complex are largely uncharacterized. Here, we describe that the
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INTS13 subunit has a lineage-specific role in regulating enhancer activity. Our data indicate that
INTS13 regulates enhancer regions bound by the EGR1/2 transcription factors, in association with
the co-factor NAB2, during differentiation of progenitor cells into monocytes and macrophages.
In the myeloid branch of hematopoiesis, monocytes and macrophages (the tissue-resident counterpart of monocytes) are specialized phagocytic cells that rely on transcription factors such as
SPI1, CEBPα, and CEBPβ as master determinants of commitment and differentiation [102, 114,
115]. Some of these TFs, such as SPI1, are also critical in regulating the activity of terminally
differentiated macrophages [116, 105, 117]. While the Early Growth Response (EGR) TFs have
largely been studied during neural development [118, 119, 120], EGR1/2 are also active during
myelopoiesis, promoting monocytic/macrophagic differentiation in a variety of human cell lines
as well as primary myeloid precursors [121, 122, 123, 124]. Our data support a fundamental role
for EGR1/2 in monocytic commitment and defines their activity at critical lineage-determining enhancers, such as the enhancer of CSF1R. Furthermore, we identify NAB2, previously suggested
to be a repressor of EGR1 activity [125], as the fundamental co-activator of monocytic enhancers
in association with EGR1 and the Integrator complex. In summary, we describe a network of enhancers driving differentiation via the Integrator/EGR/NAB2 axis, and provide the first evidence
that Integrator has modular components, conferring lineage-specific activity to this evolutionarily
conserved complex.

3.3
3.3.1

Results
Functional dissection of the INTS11 and INTS13 subunits of Integrator

Integrator targets active protein-coding genes and regulates the release of paused RNAPII from
proximal promoters [6, 65, 126], and modulates the biogenesis of noncoding eRNAs at enhancers
through the endonucleolytic activity of the INTS11 subunit [7]. Unlike Mediator, Integrator is specific to metazoans, suggesting that it may play a role in tissue and cell fate specification. To dissect
the role of Integrator in gene regulation, we examined the poorly characterized INTS13 subunit,
along with the core catalytic subunit INTS11, in the myeloid HL-60 cell line.
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First, we immunoprecipitated INTS13 from the nuclear extract of HL-60 cells and found strong
association with INTS11 and INTS1, indicating that INTS13 is a bona fide component of Integrator in myeloid cells (Figure 3.1A-B). Second, to begin characterizing the role of INTS13
within the Integrator complex, we assayed RNA endonucleolytic activity by qRT-PCR. We depleted INTS13 and INTS11 in HL-60 cells and measured accumulation of primary, unprocessed
U1 snRNA transcript. In the absence of INTS13, the basal catalytic activity of the Integrator complex was not affected (Figure 3.1C, Supplemental Figure 3.8A-B). Additionally, we found that
INTS13 is dispensable for proliferation of HL-60 myeloid progenitor cells, whereas depletion of
INTS11, predictably, suppresses cell growth (Figure 3.1D). These data suggest that INTS13 is not
essential for the fitness of HL-60 cells and may have a very limited function within the Integrator
complex in this cell model.
Next, we assessed whether the Integrator subunits were required for gene activation associated
to monocytic differentiation of HL-60. HL-60 are progenitor-like cells of myeloid origin (established from a patient with promyelocytic leukemia) [127] that can be differentiated into functional
monocytes/macrophages upon stimulation with PMA (phorbol myristate acetate), providing a convenient model of differentiation. We examined the induction of the prototypical monocytic gene
CSF1R, which encodes the membrane receptor for the monocytic cytokine M-CSF and is specifically induced during differentiation, and found that INTS11 is necessary for induction of CSF1R
(Figure 3.1E), similar to its requirement for activation of Immediate Early Genes by the Epidermal
Growth Factor [6, 7]. Surprisingly, we also found INTS13 to be required for induction of CSF1R
(40-70% reduction of expression with shRNAs for INTS13, Figure 3.1E and Supplemental Figure 3.8A for knock-down efficiency) suggesting that this subunit, while dispensable in progenitor
cells, may be necessary for differentiation. We treated HL-60 cells with PMA for 48h and measured expression of the surface marker CD11b by FACS analysis [128]. Depletion of INTS13 with
two different shRNAs resulted in significant decrease of CD11b (Figure 3.1F, Supplemental Figure
3.8A). To ensure that the effect of INTS13 on monocytic differentiation is physiologically relevant
and not dependent on HL-60 cells and PMA stimulation, we purified CD34+ stem and progenitor
cells from cord blood. First, we assessed proliferation of primary cells after depletion of INTS11
101

and INTS13 by measuring their metabolic activity (MTT assay at day 4 post puromycin selection). Similar to HL-60, only INTS11 depletion affected the growth of primary progenitor cells
(Figure 3.1G, Supplemental Figure 3.8B). Next, we leveraged INTS13-depleted CD34+ cells in a
colony forming unit (CFU) assay to assess their potential to form monocytic/macrophagic colonies
in semi-solid medium upon stimulation with M-CSF and GM-CSF for 2 weeks. Our data indicated
that INTS13 is required, in primary human cells, to form monocytic colonies (Figure 3.1H, Supplemental Figure 3.8B-C) and suggest that INTS13 has a specific role in determining the monocytic fate of progenitor cells.
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(A) Immunoprecipitation of INTS13 in HL-60 cells Immunoblots of antibodies against the Integrator subunits
INTS1 and INTS11 show that the complex co-precipitates with INTS13. (B) Model representation of the
Integrator protein complex, including the subunits INTS11 and INTS13. (C) qRT-PCR of U1 snRNA in
untreated HL-60 transduced with two different shRNAs against INTS11 and INTS13 shows that INTS11
depletion abrogates the catalytic activity of the complex while it is maintained upon INTS13 knockdown.
Primers were designed downstream to the core snRNA sequence, after the region recognized and cleaved by
Integrator. shRNAs against luciferase (shLUC) were used as a control, and ribosomal 18S as housekeeping
gene. (D) Five-days growth curve (MTT assay based) of unstimulated HL-60 cells transduced with shRNAs
against INST11 and INTS13. Depletion of INTS13 does not impair proliferation of HL-60, whereas depletion
of INTS11 results in strong growth suppression. Two shRNAs per subunit were employed. (E) qRT-PCR
of the monocytic gene CSF1R in PMA-treated HL-60 following depletion of either INTS11 or INTS13.
Depletion of both INTS13 and INTS11 negatively affects CSF1R activation by PMA. (F) HL-60 cells treated
with PMA differentiate into a macrophagic-like stage and expression of the surface integrin CD11b is a
measure of differentiation. The mean fluorescence intensity (MFI) of CD11b decreases in differentiated cells
after depletion of INTS13 with two different shRNAs (48h post-PMA induction). (G) Metabolic activity
assay (MTT) was performed on CD34+ cells transduced with shRNAs for INTS11 and INTS13, data were
collected at day 1 and day 4 after selection with puromycin, and plotted as fold change (FC; day 4 versus
day 1). The MTT shows that also in primary cells the depletion of INTS13 does not impair proliferation,
whereas depletion of INTS11 results in strong growth suppression. (H) Colony-forming unit (CFU) assay of
cord blood derived CD34+ cells infected with two different shRNAs for INTS13 and induced by M-CSF in
methylcellulose medium. The number of monocytic/macrophagic CFUs is significantly reduced in INTS13depleted cells compared to control (shLUC).

3.3.2

The INTS13 subunit of Integrator is required for activation of the monocytic
transcriptome

We analyzed the transcriptome of HL-60 cells before and after 16h of PMA induction using RNAseq. PMA stimulation resulted in differential expression of 842 genes (DESeq2, FDR < 5%). Notably, the majority (75%) of genes were upregulated (Figure 3.2A) and highly enriched in gene
ontology categories related to immune cell differentiation and cellular movement, the latter being
a feature of differentiated macrophages (Supplemental Figure 3.9A). In sum, a short treatment of
PMA triggered robust induction of genes that confer monocytic/macrophagic identity in HL-60
cells (similar to primary cells after a short treatment with M-CSF in liquid culture, see Supplemental Figure 3.9B-C). Next, we depleted INTS13 in HL-60 cells using lentiviral-transduced shRNAs.
We found 974 genes differentially expressed (2 independent replicates, fold change > +/- 2, FDR
< 5%) with respect to control (shLUC). The genes differentially expressed (DE) were enriched
for hematopoiesis and immune cell development, as revealed by pathway analysis (Figure 3.2C).
Notably, we observed that monocytic/macrophagic genes were not properly activated in the ab103

sence of INTS13 (Figure 3.2B, Supplemental Figure 3.9D-E). Among DE genes were CSF1R
(surface receptor for M-CSF) and ITGAM (part of the monocytic adhesion molecule CD11b)
(Figure 3.2D). Taken together, our data suggest that INTS13 is critical for the timely activation
of monocytic genes, and is essential to coordinate transcriptome changes that define the monocytic/macrophagic lineage.
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(A) 842 genes are differentially expressed between differentiated (PMA) and undifferentiated (CTRL) HL-60
cells (FDR <5%): 653 upregulated, 189 downregulated. The heatmap displays the change in expression for
the 653 upregulated genes. (B) Heatmap and box-plot show that the depletion of INTS13 in PMA treated HL60 significantly decreases expression of genes associated to hematological system and diseases. (C) Ingenuity
Pathway Analysis on 974 genes detected as differentially expressed in INTS13-depleted cells (FDR <5%)
reveals enrichment for hematopoiesis related processes. (D) Screenshots of the monocytic genes CSF1R and
ITGAM, whose expression is strongly decreased upon INTS13 depletion in PMA-stimulated HL-60 cells.

3.3.3

Modular properties of the Integrator complex during myeloid differentiation

To define the activity of the Integrator complex during lineage commitment and differentiation of
monocytes/macrophages, we generated ChIP-seq profiles before and after differentiation induced
by PMA (Figure 3.3A), to determine whether the dynamics of INTS11 and INTS13 binding at
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chromatin could explain their different roles in progenitors and monocytes. Our ChIP-seq analysis
retrieved comparable numbers of binding sites for the two subunits: 11,418 replicated peaks for
INTS11-CTRL; 14,337 for INTS11-PMA; 14,408 for INTS13-CTRL; and 15,966 for INTS13PMA (Supplemental Table S4).
To focus on the changes in Integrator binding upon differentiation, we independently performed
differential binding analysis (CTRL vs PMA) using EdgeR for each of the two subunits [129]
(FDR < 10%, Supplemental Table S1). With this analysis, we detected 5,728 regions that significantly gained INTS13 binding upon differentiation (hereafter INTS13-gained regions; Figure
3.3B), and 2,438 regions with significant increase in INTS11 (hereafter INTS11-gained regions;
Figure 3.3B). Notably, INTS11-gained regions were largely enriched for proximal promoters
(62.2%), mirroring the known RNAPII-associated activity of the complex, and displayed robust
binding of INTS13 as well (Figure 3.3B-C). Conversely, INTS13-gained regions were largely
found distal from the TSS of protein-coding genes (82.5%) and only partially overlapped with
INTS11 (Figure 3.3B, D).
We further investigated whether isolated INTS13-gained regions could simply be the result of differences in pull-down efficiency. First, we profiled INTS11 and INTS13 at all active U snRNA
genes (due to their high rate of transcription, U snRNA loci bear the highest amount of the Integrator complex) and found INTS11 to be more abundant than INTS13, suggesting that the INTS11
antibody performs well in ChIP-seq (Figure 3.3E). Next, we validated our findings by quantitative
ChIP at select loci. While INTS13 and INTS11 were recovered at similar levels at the transcription start site of genes such as FOS and JUN (Figure 3.3F and Supplemental Figure 3.10), only
INTS13 was significantly detected at intergenic loci for which ChIP-seq revealed isolated binding (Figure 3.3F and Supplemental Figure 3.10). INTS1 and INTS6, additional subunits of the full
Integrator complex, were also absent from INTS13-specific sites (Figure 3.3F and Supplemental
Figure 3.10). To investigate the modularity of the Integrator complex in vivo, we subjected nuclear
extract of HL-60 cells to fractionation on a size-exclusion column (Superose 6). Notably, INTS13,
along with other Integrator subunits (INTS1, INTS6, INTS11), elutes at a large molecular weight
(>2MDa), comprising the full Integrator complex and associated RNAPII, as previously described
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[1]. However, we observed a second elution peak of INTS13, centered around fraction 38 ( 200
KDa), which suggests the existence of INTS13 as a sub-module (Figure 3.3G). To ensure that the
smaller INTS13 module is biochemically distinct from the previously described INTS9/INTS11
heterodimer [1, 4] we performed immunoprecipitation of INTS13 from fraction 38 and subjected
the eluate to LC-MS/MS. Besides INTS13, we retrieved peptides of INTS14 and INTS10 and no
peptides of INTS11 (Supplemental Figure 3.10). Together, our data demonstrate that INTS13 may
also exist as a separate module in the nucleoplasm, perhaps associated with additional Integrator
subunits, and may be selectively recruited to genomic sites during monocytic differentiation, even
in the absence of the full Integrator complex.
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(A) Schematic panel describing the experimental pipeline. The catalytic activity of Integrator is impaired
by INTS11 depletion, while it is not affected upon INTS13 depletion. The chromatin occupancy of the two
subunits was profiled in undifferentiated (CTRL) and differentiated (PMA) cells by ChIP-seq with specific
polyclonal antibodies. (B) Schematic panel describing the analytical pipeline. A differential binding analysis
between CTRL and PMA conditions for INTS11 and INTS13 (edgeR, FDR < 10%) detected 2,438 INTS11gained and 5,728 INTS13-gained regions, respectively. The majority of the INTS11-gained regions are proximal to protein coding genes (distance < 1 Kb from nearest TSS), while the large majority of INTS13-gained
regions are distal (distance > 1 Kb from TSS). INTS13 is bound to all of the INTS11-gained regions. Conversely, a fraction of INTS13-gained regions is devoid of INTS11. (C) An intronic region within the CD84
gene on Chr16 and the JUNB locus both display robust recruitment of INTS11 and INTS13 upon PMA induction. (D) An intergenic region on Chr22 shows significant recruitment of INTS13, but not INTS11. (E)
Average profile of INTS11 and INTS13 at all active U snRNAs (Gencode annotation) displays stronger enrichment of INTS11 compared to INTS13, suggesting that the INTS11 antibody performs well in ChIP-seq.
(F) ChIP-qPCR on the TSS of FOS shows comparable enrichment for multiple INTS subunits, while the
qPCR performed on a distal INTS13-gained regions suggests that INTS13 is the sole INTS subunit recruited.
(G) Nuclear extract of HL-60 cells was fractionated on a Superose 6 chromatography column in the presence
of 0.5M KCl. All Integrator subunits eluted with the high molecular weight fractions, corresponding to the
intact complex. Additionally, INTS11 elutes in a known lower molecular weight interaction with the other
catalytic subunit, INTS9. INTS13 is detected eluting with lower molecular weight fractions that differ from
INTS11 and other Integrator subunits, suggesting that INTS13 can associate separately from the full complex
in the nucleoplasm. Molecular weight standards are labeled above. Lanes are as follows: input, even fractions
20-46.

3.3.4

INTS13 binds to monocytic enhancers during differentiation

To understand the lineage-specific role of INTS13, we examined the regions where it was recruited
to chromatin upon differentiation (5,728 INTS13-gained regions, Figure 3.3B). Topological analysis suggested that the large majority of INTS13-gained sites (82.5% = 4,274 sites) were distal
from the TSS of protein-coding genes (Figure 3.3B). We identified the nearest genes for all the
distal regions, based on distance from TSS, and examined gene ontology categories. We found
that, collectively, INTS13-gained distal regions were significantly associated with genes implicated in immune cell development, trafficking, and hematopoiesis (Supplemental File S1). We hypothesized that these distal regions could be enhancers, and we characterized them by performing
H3K27ac, H3K4me1, and total RNAPII ChIP-seq in HL-60 cells, both untreated and upon 16h of
PMA stimulation. We specifically examined the status of acetylation and methylation at INTS13gained distal regions and found that 90% of these regions overlap a peak of H3K4me1, but only
50% also overlap a peak of H3K27ac, supporting two distinct categories of INTS13-bound enhancers (Figure 3.4A). The first category (representing 50% of all enhancers) comprised active
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enhancers with high H3K27ac, RNAPII, and INTS11 (Figure 3.4A-B). In particular, the intronic
enhancer of CSF1R, also known as the FIRE element [130, 131], was active and significantly enriched for INTS13 (Figure 3.4B). Notably, these enhancers boast transcription of eRNAs, underscoring their active status (Supplemental Figure 3.11). The second category of INTS13-bound
enhancers was enriched in H3K4me1, but lacked RNAPII and INTS11, and displayed low or undetectable H3K27ac (Figure 3.4A-B). These data suggested that INTS13 can also be recruited to
enhancers that are poised (Figure 3.4B). Therefore, we speculated that INTS13 might be recruited
to the active monocytic enhancers at earlier time points of PMA induction, when the enhancers
are still in a poised/inactive state. Consistently, time course analysis of PMA induction suggested
that binding of INTS13 precedes activation of the enhancer as measured by increase in acetylation of H3K27 (Figure 3.4C). In particular, the enhancer of CSF1R displays a 25-fold increase
of INTS13 at 4h post-induction, whereas the surge of H3K27ac ( 18 fold) was detected at 6h. On
the other hand, poised enhancers bound by INTS13 at 16h of PMA treatment may be activated at
later time points, as suggested by our ChIP-seq analysis of an extended time-course of H3K27ac
(Figure 3.4D).
In summary, we demonstrated that the INTS13 subunit of Integrator selectively binds monocytic
enhancers during lineage-specific differentiation. INTS13 is recruited to enhancers before acetylation of H3K27 and is likely to play a role in the enhancer activation process.
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INTS13 at active and poised enhancers during monocytic differentiation

(A) 4,274 of the 5,728 INTS13-gained regions are distal elements. The heatmap shows (K-means clustering)
that nearly half of these distal elements are active enhancers (enriched for INTS13, INTS11, RNAPII and the
chromatin marks H3K27ac, H3K4me1), while the other half likely represent poised/inactive enhancers, enriched for INTS13 and the chromatin mark H3K4me1. (B) Average profiles of H3K27ac, H3K4me1 and
INTS13 at active and poised enhancers, with representative examples. (C) ChIP-qPCR of INTS13 and
H3K27ac during a time course of early PMA induction (0h, 2h, 4h, 6h) for the CSF1R enhancer supports a
model in which INTS13 binding precedes the activation of the enhancer. (D) Screenshots for two INTS13gained enhancers classified as poised at 16h of PMA induction. These enhancers show increase of H3K27ac
levels suggesting their activation at a later time point following INTS13 binding.

3.3.5

INTS13 targets Early Growth Response (EGR) responsive sites genome-wide

The Integrator complex is believed to be recruited at chromatin through its well-established interaction with the CTD of RNAPII [1, 132]. Our data suggested, for the first time, that a component
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of Integrator is recruited at chromatin independently of the rest of the complex and in the absence
of RNAPII. Specifically, we have established that INTS13 targets poised enhancer sites, which are
deprived of RNAPII and INTS11. We surmised that a transcription factor may be implicated in the
recruitment of INTS13, whose protein sequence lacks any recognizable DNA/chromatin binding
domain. Therefore, we performed de novo motif analysis on the 4,274 INTS13-gained enhancers
enriched during differentiation (see Figure 3.4A). We identified a matrix for the EGR1/EGR2
transcription factors as the most significant hit of the motif analysis (Figure 3.5A). While other
myeloid TF motifs were also retrieved (i.e. SPI1, ERG/Ets, AP-1), their relative abundance and
their significance lag well behind that of EGR1/2 (see Supplemental File S2). Importantly, the
EGR1/2 motif was centrally enriched, further underscoring its association with INTS13. We tested
the possibility that association with INTS13 and EGR1 sites may be a conserved feature in different model systems. We treated Jurkat lymphoblastic T cells with PMA to mimic T-cell activation,
and assessed the distribution of INTS13. Notably activation of Jurkat cells resulted in de novo
binding of INTS13 to 1,026 EGR1 sites, distinct from the monocytic ones, which appeared to be
enhancers associated with T cell activity (Supplemental Figure 3.12A-F; motif and IPA pathways
analyses in Supplemental Files S3, S4).
The Early Growth Factor 1 and 2 are paralog genes that encode zinc finger transcription factors
widely implicated in cell growth and differentiation. Importantly, EGR1 determines monocytic
and macrophagic differentiation when expressed in primary and stable cell lines, similar to EGR2
[122, 123]. We performed ChIP-seq for EGR1 in HL-60 cells and observed co-localization of
EGR1 and INTS13 genome-wide (Figure 3.5B-C). Motif analysis of EGR1 ChIP-seq retrieved
an EGR1/2 matrix nearly identical to that of INTS13 (Supplemental Figure 3.12G). ChIP-qPCR
assay confirmed that EGR1 and EGR2 as both present at select monocytic enhancers, suggesting
their functional redundancy in our system (Supplemental Figure 3.12H). We reasoned that binding of EGR1/2 may be a prerequisite for INTS13 binding to enhancers. To assess the importance
of EGR1/2 in recruiting Integrator, we performed ChIP-seq of INTS13 after depletion of EGR1
in HL-60 (Figure 3.5D-E, Supplemental Figure 3.125). INTS13 recruitment at enhancers was significantly impaired by EGR1 knock-down (Wilcoxon’s rank sum test, p < 2.2 ×10−16 , Figure
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3.5D-E). While some INTS13 binding persisted, it must be noted that EGR2 is still expressed in
these cells, even if a much lower level compared to EGR1, and that double depletion bears acute
effects on survival and cell cycle [122]. Furthermore, we tested the overlap of INTS13 and EGR1
peaks pre- and post-stimulation of PMA. In undifferentiated cells, EGR1 colocalized with 5%
of INTS13 sites. Conversely, monocytic differentiation boosted the share of overlapping peaks to
40% (Figure 3.5F). Collectively, we demonstrated that EGR1 is a determinant of INTS13 binding at enhancers during monocytic differentiation, while progenitor cells maintain distinct binding
profiles for both. These data suggest that additional factors may be required to draw INTS13 to
EGR1 responsive elements.
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3.3.6

NAB2 is an essential co-factor for enhancer activation mediated by INTS13
and EGR1/2

We surmised that INTS13 binding to EGR1/2 at enhancers may be overall mediated by proteinprotein interactions, therefore we performed proteomic analysis of untreated and differentiating
HL-60 cells in two independent replicates. We used rabbit antibodies to immunoprecipitate endogenous INTS13 and subjected the eluate to LC-MS/MS analysis. As expected, INTS13 coprecipitated the full Integrator complex and subunits of RNAPII (Figure 3.6A and Supplemental
Table S2). Next, we looked for non-Integrator components in our proteomic analysis. We previously described that widespread recruitment of INTS13 to EGR1/2 monocytic enhancers (Figure 3.3 and 3.5) is specific to differentiating monocytes. In fact, INTS13 is largely dispensable
for undifferentiated progenitor cells, but is required for maturation into functional monocytes/
macrophages (Figure 3.2, Supplemental Figure 3.9). We reasoned that additional protein partners
of INTS13 may be specific to differentiating cells, therefore we calculated the ratio of peptides retrieved in differentiating (PMA) over undifferentiated (CTRL) HL-60 cells. Notably, we identified
the NGFI-A-binding protein 2 (NAB2) as the most significantly enriched protein. NGFI-A is an
alias for EGR1, since NAB2 and its functional homologue, NAB1, were originally identified as
partners of EGR1 and EGR2 [133, 134]. We confirmed the association of NAB2 with INTS13 by
co-immunoprecipitation experiments from the nuclear extract of HL-60 cells, and observed that
NAB2 was lowly abundant in untreated cells but accumulated upon differentiation (Figure 3.6B).
Importantly, we observed a similar regulation in primary cells: NAB2 was barely detectable in primary human stem and progenitor cells (CD34+) and increased dramatically during monocytic differentiation stimulated by M-CSF (Supplemental Figure 3.13). To further validate the interaction
of NAB2 with INTS13 and Integrator, we generated stable cell clones expressing FLAG-tagged
NAB2 and performed a reverse LC-MS/MS experiment. FLAG affinity purification of NAB2 copurified the EGR proteins and INTS13, along with several other subunits of Integrator (Figure
3.6C). Our data imply that NAB2 bridges the interaction of INTS13 with EGR1/EGR2 and suggest that a ternary complex composed of INTS13/NAB2/EGR may form at monocytic enhancers.
We performed ChIP-seq of endogenous NAB2 in HL-60 cells and found a distinct distribution
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of NAB2 peaks during differentiation. Consistent with INTS13, NAB2 showed a significant recruitment at the 4,274 monocytic enhancers (Figure 3.6D), colocalizing with EGR1 and INTS13
at most of these sites (Figure 3.6D-E and Supplemental Figure 3.13). Interestingly, best correlation between INTS13 and EGR1 happens on NAB2 peaks (Supplemental Figure 3.13C). Notably, NAB2 binding dynamics resembled those of INTS13, preceding acetylation of the enhancer,
such as in CSF1R (Supplemental Figure 3.13). Further, ChIP-seq on PMA-induced HL-60 showed
that INTS13 binding at the 4,274 monocytic enhancers was severely impaired by NAB2 depletion
(two independent shRNAs; p<0.0001; Figure 3.6F-G, Supplemental Figure 3.13). This suggested
NAB2 as the molecular bridge that recruits INTS13 to EGR1/2 responsive elements. Moreover,
679 genes were differentially expressed in PMA-treated HL-60 upon NAB2-KD (517 downregulated, FDR < 5%, Figure 3.6H-I). IPA analysis confirmed enrichment in hematopoiesis pathways
(Figure 3.6H-I, Supplemental Figure 3.13), thus recapitulating the results obtained upon depletion
of INTS13 (Figure 3.2B-D).
If NAB2 is an essential co-factor that elicits enhancer activation via recruitment of INTS13, depletion of NAB2 should also impair development of monocytic/macrophagic cells and phenocopy
the effect of either INTS13 depletion (Figure 3.1F, H) or EGR1 depletion [122]. Coherently, both
NAB2 and EGR1 were indeed required for differentiation of HL-60 cells (mean fluorescence intensity – MFI - of CD11b, Figure 3.6J) and were essential to form M-CSF-derived monocytic
colonies from CD34+ stem and progenitor cells (Figure 3.6K, Supplemental Figure 3.13).
To further validate the INTS13/NAB2 functional association in physiological conditions, we performed additional ChIP-seq experiments using circulating monocytes obtained from the peripheral blood of healthy donors. Terminal differentiation of monocytes into adherent macrophages
reignites the enhancer-promoter network that is responsible for the earlier differentiation stages
(CD34+ to monocytes) and provides a physiological model for enhancer regulation [105, 124].
Consistent with our findings from HL-60, the ChIP-seq data from the differentiating macrophages
supported a significant recruitment of both INTS13 and NAB2 at the previously identified 4,274
monocytic enhancers, including CSF1R (Supplemental Figure 3.14). Furthermore, we independently depleted EGR1 and NAB2 from a pool of mobilized CD34+ cells, performed INTS13
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ChIP-seq at day 5 of monocytic differentiation, and observed, in both cases, a sharp and significant
decrease of INTS13 across all genome (Supplemental Figure 3.14). Together, the data obtained
in primary cells fully support our previous findings in HL-60 cells, and in particular the role of
NAB2 and EGR1 in the recruitment of INTS13 at thousands of lineage specific enhancers.
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F IGURE 3.6 NAB2 is an essential co-factor of monocytic differentiation and mediates
INTS13 binding at EGR1 sites
(A) Endogenous INTS13 was affinity-purified from undifferentiated and differentiating HL-60 cells. The interactome of INTS13 was detected by LC-MS/MS. The plot shows adjusted protein enrichment values (iBAQ,
y-axis) and the ratio of peptides in differentiated (PMA) vs. undifferentiated (CTRL) cells. INTS13 interacts with nearly all Integrator subunits and RNAPII, interaction with the EGR1 co-factor NAB2 is specific
to monocytic differentiation. (B) Immunoprecipitation of INTS13 in undifferentiated (CTRL) and differentiated (PMA) HL-60 cells confirms the interaction between INTS13 and NAB2 after PMA treatment. (C)
LC-MS/MS analysis of stable HL-60 clones expressing exogenous FLAG-NAB2. NAB2 was affinity purified by anti-FLAG conjugated beads. NAB2 interacts with NAB1, EGR-family members (EGR1, EGR2,
EGR3), INTS13, and other Integrator subunits. (D) Heatmaps of NAB2, INTS13 and EGR1 ChIP-seq in undifferentiated (CTRL) and/or differentiated (PMA) HL-60. Upon PMA treatment, NAB2, INTS13 and EGR1
co-localize at INTS13-gained enhancers. (E) Screenshot of the intragenic CSF1R enhancer shows recruitment of NAB2 and INTS13 during differentiation. (F) Screenshot of the CSF1R intragenic enhancer shows
reduction of INTS13 recruitment upon NAB2 depletion. (G) Average profiles and box-plot display a significant decrease of INTS13 at the 4,274 INTS13-gained enhancers upon NAB2-KD (two different shRNAs).
(H) RNA-seq analysis identified 517 genes downregulated upon NAB2-KD (two different shRNAs) during
PMA-induced differentiation. IPA analysis for these genes revealed enrichment for pathways associated to
hematopoiesis and differentiation, recapitulating the results previously obtained with INTS13 depletion (Fig.
2). (I) Prototypical monocytic genes such as CSF1R and CD84 are severely downregulated by NAB2 depletion in RNA-seq experiments. (J) Mean fluorescence intensity of CD11b is impaired in differentiated
HL-60 cells after depletion of NAB2 with two different shRNAs (16h post-PMA induction). (K) Colonyforming unit (CFU) assay of cord blood derived CD34+ cells infected with shRNAs against NAB2 and
EGR1 shows that the number of monocytic/macrophagic colonies is significantly reduced in both NAB2- and
EGR1-depleted cells when compared to control.

3.3.7

The INTS13/EGR/NAB2 axis brings about activation of poised enhancers

We performed Chromosome Conformation Capture (3C) on the enhancer of CSF1R to infer the
consequences of INTS13 depletion on genome architecture. During differentiation of HL-60 cells,
we detected a robust interaction between the intronic enhancer of CSF1R and the proximal promoter, as compared to other regions within the CSF1R gene or with the promoter of neighboring
genes (Figure 3.7A). Specifically, we observed a 5 fold decrease in the frequency of enhancerpromoter interactions following depletion of INTS13, while all non-specific contact pairs used as
controls (NEG1 to NEG5) were not affected (Figure 3.7A). This assay demonstrated the functional
requirement of INTS13 for enhancer-promoter looping of a monocytic enhancer engaged during
differentiation.
Collectively, our data demonstrated that INTS13/Integrator targets poised enhancers that are required for monocytic differentiation. While these enhancers are primarily bound by the EGR1/2
transcription factors, the co-factor NAB2 is the essential molecular bridge that allows binding of
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INTS13 to EGR-dependent enhancers. Altogether, the INTS13/EGR1/NAB2 axis is functionally
required to coordinate and elicit activation of monocytic and macrophagic genes during myeloid
differentiation (Figure 3.7B).
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Targeted enhancer activation by INTS13
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(A) Chromosome conformation capture (3C) reveals that depletion of INTS13 elicits a significant reduction of
the interaction frequency between the intragenic enhancer of CSF1R (FIRE element) and the promoter of the
same gene, suggesting that INTS13 mediates loop formation, enhancer/promoter interaction, and ultimately
the expression of the CSF1R (see also Fig. 2D). As control, we gauged the interaction frequency between
the enhancer (anchor) and 5 additional surrounding sites (NEG1 to NEG5), including the TSS of 3 additional
genes, the 3’ end of one gene and a non-enhancer intronic region of CSF1R. (B) We propose a model for the
role of Integrator in targeted enhancer activation during cell differentiation. In undifferentiated cells, lineagespecific genes are not expressed, and their corresponding enhancers are inactive or poised. (I). Upon lineage
commitment, EGR1 recognizes and binds to its motifs across monocytic enhancers, together with NAB2 (II).
INTS13 is recruited by the NAB2/EGR1 complex, and co-localizes at the same enhancers (III). Following
INTS13 priming of the enhancers, the Integrator complex is assembled, facilitating enhancer activation and
chromatin looping to ultimately activate transcription of the target genes (IV).

3.4

Discussion

In this work, we characterize a novel function of the Integrator protein complex, and demonstrate
that an accessory (non-catalytic) subunit of a general activator machinery can operate as a mediator of lineage-determining TFs. We characterize a novel mechanism of enhancer regulation, in
which a co-activator subunit (INTS13), a DNA-binding transcription factor (EGR1/2), and a nonDNA-binding co-factor (NAB2) take part. We demonstrate co-occupancy of this ternary complex
at chromatin and capture their physical interaction by co-immunoprecipitation and LC-MS/MS.
Our data suggest that the INTS13/EGR/NAB2 axis is a priming complex for enhancers. In fact, we
initially found that INTS13/EGR/NAB2 bind to active and poised enhancers. Poised enhancers,
which lack H3K27 acetylation but retain mono-methylation of H3K4, have been previously described in differentiated and multipotent cells [106, 117, 107, 135]. We showed that INTS13 and
NAB2 target poised enhancers during monocytic differentiation, preceding the wave of H3K27 hyperacetylation. Persistently poised enhancers, that we detect after 16h of PMA stimulation, may
become activated at a later time point, as our data suggest. It is also possible that additional cofactors are needed to elicit activation of a subset of INTS13/EGR1/NAB2 targets. Importantly,
enhancers regulated by INTS13, EGR1 and NAB2 are required for proper expression of genes
that confer monocytic identity. Our analysis of EGR1 represents the first profiling of this zinc finger TF in differentiating progenitors and reveals the unexpected breadth of its role as a lineagedetermining factor via enhancer regulation. TFs such as PU.1 and ERG (Ets) are generally con117

sidered master regulators of myeloid commitment [102]. In fact, when we searched for DNA motifs associated with INTS13-enhancers we retrieved both PU.1 and ERG, though less significantly
enriched than EGR1 and not centrally positioned with respect to the INTS13 peak summit, underscoring that the Integrator complex preferentially operates via EGR1 during monocytic differentiation. EGR1 and EGR2 were previously proposed to regulate monocytic differentiation by repressing granulocytic genes [121, 122, 123]. Instead, our data suggest that EGR1 and EGR2 (which we
find functionally redundant by ChIP and proteomic analyses) directly regulate enhancer-mediated
activation of monocytic- and macrophagic-specific genes, such as CSF1R. Furthermore, we revealed an essential and unexpected role of the co-factor NAB2. EGR1 and EGR2 were previously
shown to interact with NAB2 by two-hybrid and in vitro pull-down experiments, such interaction is deemed important for neuronal differentiation and development [136, 125, 134]. Previous
biochemical evidences suggested that NAB2 merely served as co-repressor for a subset of EGR1
target promoters [137, 134]. Our data reveal, instead, that NAB2 functions as a molecular switch,
determining INTS13 recruitment at EGR1 sites in both primary and HL-60 cells. Furthermore, depletion of NAB2 phenocopies loss of INTS13 and EGR1: cell lines and primary CD34+ cells depleted of NAB2 fail to activate a monocytic transcriptome and are blocked at a progenitor stage.
Collectively, we present the first comprehensive molecular characterization of NAB2 and provide the first evidence of NAB2 binding profile at chromatin. We propose that the role of NAB2
in myeloid differentiation is to regulate timely activation of monocytic enhancers by recruiting
INTS13. Beyond monocytic differentiation, EGR1/NAB2-dependent enhancers may play a role
in other developmental pathways. For instance, we suggest that T-cell activation may also require
INTS13 as a modulator of EGR1 sites. Also, EGR1 and NAB2 were previously implicated in neural development, raising the possibility that INTS13 is a major effector of cell commitment and
differentiation in such context.
Another critical finding of our work is that the Integrator complex is not functionally homogeneous. In particular, we focus on the INTS13 subunit, which was recently described as an integral component of the human and drosophila Integrator complexes [113, 138]. Our data show that
INTS13 is, de facto, a physical and functional submodule of Integrator. INTS13 is part of the full
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Integrator complex in myeloid cells (Figure 3.1A, 3.3G and 3.6A), but can also exist as a small
subcomplex (perhaps associated with additional INTS subunits, Figure 3.3G). INTS13 is not required for the core catalytic activity of Integrator (RNA endonucleolysis), nor is it essential for
cell growth of progenitor and stem cells under resting conditions (Figure 3.1), but is indispensable
for cell commitment and differentiation. Unlike INTS11, INTS9, and INTS1 [1, 113], INTS13 is
dispensable for processing of U snRNAs and, likely, for termination of noncoding eRNAs that employs the same catalytic activity centered around the β-CASP domain of INTS11 [7]. A previous
report suggested that INTS13 (also known as ASUN) had an influence on U snRNA processing
[113]. However, the effect of INTS13 depletion on a GFP-UsnRNA reporter system was significantly lower than the effect of INTS9 depletion [113]. Furthermore, reporter constructs may not
entirely reflect Integrator’s activity at endogenous U snRNA loci. However, we cannot exclude
that INTS13 may retain regulatory activity towards U snRNA processing in lower eukaryotes. Further studies are needed to address the evolution of the Integrator complex and to determine the
complete map of core and accessory subunits of this essential transcriptional regulator.
In conclusion, our data suggest that large and ubiquitously expressed co-activator complexes are
not just passive facilitators of transcription, but may actively partake in the organization of celland tissue-specific enhancer-promoter activity.
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3.8

Methods

3.8.1

Cell Lines

293T were obtained from American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% super calf serum (GEMcell) and 2 mM L-glutamine (Corning). HL-60 cells were obtained from ATCC and maintained in
Roswell Park Memorial Institute (RPMI)-1640 medium (Corning) supplemented with 10% (v/v)
of super calf serum (GEMcell) or Tet system approved fetal bovine serum (Clontech) and 2 mM of
L-glutamine (Corning). Jurkat cells were a kind gift of Dr. M. Abdel-Mohsen (Wistar Institute).
Bone marrow (BM)-derived CD34+ were obtained from Calabretta’s lab at Thomas Jefferson University. CD34+ CD33- cells were sorted at the Flow Cytometry facility at Wistar Institute. Fetal
liver (FL)-derived CD34+ cells were obtained from Stem Cell and Xenograft Core at University
of Pennsylvania and were maintained in StemSpan SFEM medium supplemented with CC100
cytokine cocktail (Stem Cell Technologies). De-identified human cord blood (CB) was obtained
from volunteers with informed consent at Helen F. Graham Cancer Center and Research Institute at Christiana Hospital. Mononucleated cells (MNC) were separated with Ficoll-Hystopaque
Plus (GE Healthcare). CD34+ cells were then isolated using human CD34 MicroBeads Kit (Mil120

tenyi Biotec) following manufacturer’s instructions. CD34+ were maintained in StemSpan SFEM
medium supplemented with 1X CC100 cytokine cocktail. BM- and FL-derived CD34+ were used
for CFU assay, BM-, FL- and CB-derived CD34+ were in vitro differentiated and used for RNAseq and ChIP-seq experiments, respectively. Circulating monocytes were obtained from the Human Immunology Core at University of Pennsylvania.

3.8.2

Lentiviral infection

HL-60 cells were lentivirally transduced through on round of spinoculation (1800 RPM, 45 minutes at 30°C, brake off) and selected with 2 µg/ml puromycin (InvivoGen). CD34+ cells were
spinoculated with ultracentrifuge-concentrated lentivirus at 1800 RPM, for 45 minutes at 30°C,
incubated overnight at 37°C in the virus-containing medium, followed by another round of infection the following day. Cells were collected, washed and selected with 1 µg/ml puromycin in
StemSpan SFEM medium supplemented with CC100 cytokine cocktail (Stem Cells Technologies).

3.8.3

In vitro differentiation

HL-60 cells were differentiated with 100 nM Phorbol 12-myristate 13-acetate (PMA) in growing medium and the status of differentiation was assessed by flow cytometry. Briefly, cells were
incubated in 1X PBS supplemented with 1% heat-inactivated FBS and 2 mM EDTA with FcR
blocking reagent (1:20 dilution, Miltenyi Biotech) for 30 minutes at 4°C, washed with 1X PBS
and incubated with the suitable fluorochrome-conjugated antibody for 30 minutes at 4°C. Cells
were then washed with 1X PBS, fixed in 1% formaldehyde (Sigma-Aldrich) in 1X PBS. Cells
were then washed twice with cold PBS and data acquired with a BD LSR II flow cytometer (BD
Bioscience). Analyses were performed and elaborated using FlowJo Software v10.0.7 (FlowJo,
LLC). CD34+ cells were differentiated in monocytes in SFEM supplemented with 100 ng/ml SCF,
10 ng/ml IL-3, 50 ng/ml M-SCF and 25 ng/ml GM-CSF (Peprotech). Expression of CD14 was
assessed by flow cytometry at different days of treatment as a measure of differentiation (CD14+
cells: day 0: 0-4%, day 3: 3-7%, day 7: 20-40%). Circulating monocytes were differentiated into
adherent macrophages in IMDM supplemented with 10% heat-inactivated FBS and 25 ng/ml of
human recombinant GM-CSF (Peprotech).
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3.8.4

Knockdown of INTS11, INTS13, EGR1 and NAB2

pLKO.1, tet-pLKO-puro and pLENTI-CMV-GFP-Puro vectors were obtained from Addgene
(#10879, #21915 and #17448). pLKO.1-shINTS11 #1 (TRCN0000161507), pLKO.1-shINTS11
#2 (TRCN0000161070), pLKO.1-shNAB2 #1 (TRCN0000019544) and pLKO.1-shNAB2 #3
(TRCN0000019546) were obtained from the Molecular Screening Facility at the Wistar Institute.
shRNA against luciferase was used as control. shINTS13#1, shINTS13#2, shEGR1, shNAB2#2
were designed with the Broad Institute algorithm (https://portals.broadinstitute.org/gpp/public/)
and subsequently cloned in either pLKO.1 or tet-pLKO vectors. Sequences of the designed shRNA
are listed in Supplement Table S3. Expression of tet-pLKO-shEGR1 was induced with 2 µg/ml
doxycycline (Sigma-Aldrich) for 72 hours in growing medium.

3.8.5

NAB2 overexpression

To generate the pLENTI-FLAG-NAB2 vector, NAB2 full-length cDNA was amplified by PCR using the Phusion high-fidelity kit (New England Biolabs), cloned into the pFLAG-puro vector and
sub-cloned into the pLENTI-CMV-GFP-Puro using Gibson Assembly Master Mix (New England
Biolabs). Primer sequences are listed in Supplemental Table 3.

3.8.6

Western Blot

Cells were harvested and washed three times in 1X PBS and lysed in RIPA buffer (50 mM TrisHCl pH 7.5, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 500 µM DTT)
supplemented with 1 µg/ml aprotinin, 1 µg/ml leupeptin (Sigma) and 1 µg/ml pepstatin (BMB).
50 µg of whole cell lysate were loaded in Bolt 4-12% Bis-Tris Plus gel (Invitrogen) or Novex
WedgeWell 10% Tris-Glycine Gel (Invitrogen) and separated through gel electrophoresis (SDSPAGE) in Bolt MES running buffer (Invitrogen) or Tris-Glycine-SDS buffer (Bio-Rad), respectively. Separated proteins were transferred to ImmunBlot PVDF membranes (BioRad) for antibody probing. Membranes were incubated with 10% BSA in TBST for 30 minutes at room temperature, then incubated for 2h at RT or overnight at 4°C with the suitable antibodies diluted in 5%
BSA in 1X TBST, washed with TBST, and incubated with a dilution of 1:10000 of HRP-linked
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anti-mouse or anti-rabbit secondary antibody (Cell Signaling) for one hour at RT. Antibodies were
then visualized using Clarity Western ECL substrate (Biorad) and imaged with Fujifilm LAS-3000
Imager (Fujifilm).

3.8.7

qRT-PCR

Cells were lysed in Tri-reagent and RNA was extracted using the Direct-zol RNA MiniPrep kit
(Zymo research). 1 µg of template RNA was retrotranscribed into cDNA using random primers
and the Revertaid first strand cDNA synthesis kit (Thermo Scientific) according to manufacturer
directions. 50 ng of the cDNA were used for each real-time quantitative PCR reaction with 0.4 µM
of each primer, 10 µl of iQ SYBR Green Supermix (BioRAD) in a final volume of 20 µl, using
a CFX96 real-time system (BioRAD). Thermal cycling parameters were: 3 minutes at 95°C, followed by 40 cycles of 10 seconds at 95°C, 20 seconds at 63°C followed by 30 seconds at 72°C.
Each sample was run in triplicate. 18S rRNA weas used as normalizer. Primer sequences are reported in Supplemental Table S3.

3.8.8

Colony-forming unit (CFU) assays

Infected FL- or BM- derived CD34+ cells were cultured at 37°C at the density of 1.2 × 103/ml in
SF H4236 methylcellulose (Stem Cell Biotechnologies) containing medium supplemented with
15% heat-inactivated fetal bovine serum (Sigma-Aldrich) or 15% of super calf serum (GEMcell),
100 ng/ml SCF, 20 ng/ml IL-3, 50 ng/ml FLT3L, 20 ng/ml IL-6, 50 ng/ml M-CSF, 30 ng/ml GMCSF. Colonies were counted after 10-14 days. Colonies were stained overnight in a solution of 5
mg/ml of Nitrotetrazolium Blue chloride (Sigma-Aldrich) in water.

3.8.9

Proliferation assay

HL-60 or CD34+ cells were seeded at 20,000 cells/ml in 96-well plates at day 1. Cell proliferation
was determined every 24h (HL-60) or 4 days later (CD34+ cells) using the cell growth determination kit MTT based (Sigma-Aldrich), following manufacturer’s instruction.
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3.8.10

Immunoprecipitation

HL-60 cells were washed twice with ice cold PBS before resuspension in BC100 (20mM Tris pH
8.0, 0.1M KCl, 0.1% NP-40, 10% glycerol, 0.2mM EDTA, 0.5mM DTT, 1 µg/ml each of protease inhibitors aprotinin, leupeptin, and pepstatin), and incubated at 4°C for five minutes. The
pellet was resuspended in buffer C (20mM Tris pH 8.0, 1.5mM MgCl2, 0.42M NaCl, 25% glycerol, 0.2mM EDTA, 0.5mM DTT, protease inhibitors) and incubated at 4°C for 30 minutes. For
chromatin-enriched nuclear extracts, Benzonase nuclease (Sigma-Aldrich) was added after 15
minutes and incubated for an additional 30 minutes at 4°C. The resulting extract was spun down at
12,000rpm for 30 minutes. The pellet was discarded and supernatant kept as nuclear extract. The
nuclear extract was dialyzed overnight in BC80 (20mM Tris pH 8.0, 80mM KCl, 0.2mM EDTA,
10% glycerol, 1mM β-mercaptoethanol, 0.2mM phenylmethylsulfonyl fluoride (PMSF)), cleared
and stored at -80°C. 500 µg (for western blot) or 2-4 mg (for mass spectrometry) of nuclear extract
was diluted in co-IP buffer (20mM Tris pH 7.9, 100mM NaCl, 0.1% NP-40, protease inhibitors).
INTS13 antibody-crosslinked Dynabeads Protein A (Invitrogen), or ANTI-FLAG M2 affinity gel
(Sigma-Aldrich) were incubated with nuclear extract at 4°C for four or two hours, respectively.
Supernatant kept as flow-through. Beads were washed three times with co-IP buffer, followed
by one wash with 0.05% NP-40 in PBS. Glycine elution was performed with agitation in 0.1M
glycine pH 3.0 for one minute, and 1M Tris base pH 11.0 was added to neutralize the pH of the
eluate. Flag-peptide competition elution was performed by incubation with excess FLAG peptide
(Sigma-Aldrich) at 4°C for 30 minutes. Eluate was stored at -80°C or prepared for SDS-PAGE.

3.8.11

Size-exclusion chromatography

0.4 ml of HL-60 nuclear extract (5mg total protein) was loaded onto a Superose 6 10/30 GL column (GE Life Science) equilibrated with BC500 buffer. Flow rate was fixed at 0.4 ml/min, and 0.4
ml fractions were collected.
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3.8.12

Antibody crosslinking

Dynabeads Protein A (Invitrogen), 500µl, were washed three times with PBS prior to crosslinking with 20µg INTS13 antibody (Bethyl). Beads and antibody were diluted in PBST and incubated with agitation for 2 hours at room temperature. The antibody-bound beads were washed
three times with 200mM triethanolamine pH 8.2, then resuspended in freshly made 10mM DMP
(dimethyl pimedlimidate dihydrochloride) in 200mM triethanolamine pH 8.2 and gently rotated
for 30 minutes at room temperature. The crosslinking reaction was stopped with gentle rotation in
50mM Tris pH 7.5 for 15 minutes. Crosslinked beads were washed three times with PBST, twice
with 0.1M glycine pH 3.0, twice with PBST, and stored in PBST + 0.02% sodium azide at 4°C.

3.8.13

Mass spectrometry

After co-immunoprecipitation, eluates were prepared for SDS-PAGE as described previously. The
eluates were run into a 10% Tris-glycine gel at 110V for ten minutes. The gel was stained with
Colloidal Blue staining kit (Invitrogen), and further processed at the proteomics facility at the
Wistar Institute. Briefly, the gel lanes were excised, digested with trypsin, and analyzed by LCMS/MS on the Q Exactive HF mass spectrometer. The data were searched against the UniProt
human database (September 2016) and provided sequences using MaxQuant 1.5.2.8 [139]. False
discovery rates for protein and peptide identifications were set at 1%.

3.8.14

Chromosome Conformation Capture (3C)

Chromosome Conformation Capture was performed as reported in [140] with minor changes.
1×107 HL-60 cells were fixed in 1% formaldehyde for 10 min at room temperature for crosslinking. The reaction was quenched with 0.25 M glycine and cells were collected by centrifugation at 225 g for 8 minutes at 4°C. Cell pellet was lysed in 5 ml cold lysis buffer (10 mM Tris-HCl,
pH 7.5; 10 mM NaCl; 5 mM MgCl2; 0.1 mM EGTA) with freshly added protease inhibitors on
ice for 10 minutes. Isolated nuclei were collected by centrifugation at 400 g for 5 min at 4°C then
re-suspended in 0.5 ml of 1X Cutsmart buffer (New England Biolabs) with 0.3% SDS and incubated for 1 h at 37°C while shaking at 900 rpm. Next, samples were incubated for 1 hr at 37°C
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after addition of 2% Triton X-100. 400 U of PstI restriction enzyme (New England Biolabs) were
added to the nuclei and incubated at 37°C over night while shacking at 900 rpm. 5 µl of samples
were collected before and after the enzyme reaction to evaluate digestion efficiency. The reaction
was stopped by addition of 1.6% SDS and incubation at 65°C for 30 minutes while shaking at 900
rpm. The sample was then diluted 10-fold with 1.15× ligation Buffer (660 mM Tris-HCl, pH 7.5,
50 mM DTT, 50 mM MgCl2, 10mM ATP) and 1% Triton X-100 and incubated for 1 h at 37°C
while shaking at 900 rpm. 100 U of T4 DNA ligase (NEB) were added to the sample and the reaction was carried at 16°C over night. For each sample, 300 µg of Proteinase K were added for
protein digestion and de-crosslinking at 65°C overnight. On the next day, RNA was removed by
adding 300 µg of RNAse and incubating the sample for 1 h at 37°C. DNA was purified twice by
phenol-chloroform extraction, and precipitated with ethanol over night at -80°C. Purified DNA
was quantified by qubit, diluted to 3ng/µl and analyzed by real time quantitative PCR. The ∆Ct
method was applied for analyzing data, using the actin Ct values as control. Primer sequences are
reported in Supplemental Table 3.

3.8.15

ChIP-qPCR and ChIP-seq

Samples from different conditions were processed together to prevent batch effects. ChIP-seq was
performed as previously described [7], with some modifications. For each replicate, 10 million
HL-60 cells were cross-linked with 1% formaldehyde for 5 min at room temperature, harvested
and washed twice with 1× PBS. The pellet was resuspended in ChIP lysis buffer (150 mM NaCl,
1% Triton-X 100, 0,7% SDS, 500 µM DTT, 10 mM Tris-HCl, 5 mM EDTA) and chromatin was
sheared to an average length of 200–400 bp, using a Covaris S220 Ultrasonicator. The chromatin
lysate was diluted with SDS-free ChIP lysis buffer. For ChIP-seq, 10 µg of antibody (5 µg for histone modifications) was added to the 10 million lysated cells along with Protein A magnetic beads
(Invitrogen) and incubated at 4 °C overnight. For RNAPII ChIP-seq, a custom rabbit polyclonal
antibody raised against the N-terminal domain was used. On day 2, beads were washed twice with
each of the following buffers: Mixed Micelle Buffer (150 mM NaCl, 1% Triton-X 100, 0.2% SDS,
20 mM Tris-HCl, 5 mM EDTA, 65% sucrose), Buffer 500 (500 mM NaCl, 1% Triton-X 100, 0.1%
Na deoxycholate, 25 mM HEPES, 10 mM Tris-HCl, 1 mM EDTA), LiCl/detergent wash (250 mM
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LiCl, 0.5% Na deoxycholate, 0.5% NP-40, 10 mM Tris-HCl, 1 mM EDTA) and a final wash was
performed with 1× TE. Finally, beads were resuspended in 1× TE containing 1% SDS and incubated at 65 °C for 10 min to elute immunocomplexes. Elution was repeated twice, and the samples
were further incubated overnight at 65 °C to reverse cross-linking, along with the untreated input
(5% of the starting material). On day 3, after treatment with 0.5 mg/ml proteinase K for 3 h, DNA
was purified with Zymo ChIP DNA Clear Concentrator kit (Zymo research) and quantified with
QUBIT. Barcoded libraries were made with NEB ULTRA II DNA Library Prep Kit for Illumina,
and sequenced on Illumina NextSeq 500, producing 75bp SE reads. For ChIP-qPCR samples, on
day 3 DNA was purified with Wizard SV Gel and PCR Clean-Up system (Promega), resuspended
in 200 ul and 5 ul were for each PCR reaction. Primer sequences are listed in Supplementary Table
2.
For ChIP-seq, sequences were aligned to the reference hg19, using Burrows Wheeler Alignment
tool (BWA), with the MEM algorithm [90]. Aligned reads were filtered based on mapping quality (MAPQ > 10) to restrict our analysis to higher quality and likely uniquely mapped reads, and
PCR duplicates were removed. We called peaks for each individual using MACS2, at 5% FDR,
with default parameters [91]. Heatmaps and average profiles were generated with ChAsE v. 1.0.11
[141]. EdgeR [129] was used to detect cis-regulatory elements (CREs) which significantly gained
INTS13 and/or INTS11 after PMA treatment (FDR < 10%). Specifically, INTS11 PMA peaks
replicated across all samples were used as reference for the INTS11 differential binding analysis.
Similarly, INTS13 replicated across all samples were used as reference for the INTS13 differential
binding analysis.

3.8.16

Subcellular fractionation

Subcellular fractionation was performed as described [7], with minor changes. Briefly, cells were
resuspended in cold cytoplasmic lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.15% NP40) using wide orifice tips, incubated on ice for 5 minutes, layered onto cold sucrose buffer (10
Mm Tris-HCl pH 7.5, 150 Mm NaCl, 24% sucrose w/v) and centrifuge at 13,000 rpm for 10 minutes at 4°C. Nuclei were gently resuspended in glycerol buffer (20 mM Tris pH 7.9, 75 mM NaCl,
0.5 mM EDTA, 50% glycerol, 0.85 mM DTT) using wide orifice tips, and same amount of nuclei
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lysis buffer (20 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 0.3 M NaCl, 1 M urea, 1%
NP-40, 1 mM DTT) was added. After a brief incubation for 1 minute on ice, chromatin was isolated by centrifugation at 14,000 rpm for 2 minutes at 4°C. Chromatin-bound RNA was isolated
with Trizol protocol and miRNeasy kit (Qiagen).

3.8.17

RNA-seq

Samples from different conditions were processed together to prevent batch effects. Total RNA
and chromatin-bound RNA were extracted using Zymo Direct-Zol RNA miniprep Kit (Zymo
research) and miRNeasy kit with Trizol protocol and in-column DNAse treatment (Qiagen), respectively. Quality of total RNA was assessed by the RNA Integrity Number (RIN) using Agilent Bioanalyzer. All retained RNA samples had a RIN >8. Total or chromatin-bound RNA (1µg)
were depleted of ribosomal RNA using the NEBNext rRNA depletion kit (New England Biolabs).
rRNA-depleted RNA was purified with the miRNEasy kit (Qiagen) and used to produce barcoded
RNA sequencing libraries using the NEBNext Ultra Directional RNA Library Prep kit (New England Biolabs), and sequenced on Illumina NextSeq 500, producing 75bp SE reads.
Reads were aligned to hg19 using STAR v2.5 [86], in 2-pass mode with the following parameters:
–quantMode TranscriptomeSAM –outFilterMultimapNmax 10 –outFilterMismatchNmax 10 –
outFilterMismatchNoverLmax 0.3 –alignIntronMin 21 –alignIntronMax 0 –alignMatesGapMax
0 –alignSJoverhangMin 5 –runThreadN 12 –twopassMode Basic –twopass1readsN 60000000
–sjdbOverhang 100. We filtered bam files based on alignment quality (q = 10) using Samtools
v0.1.19 [87]. We used the latest annotations obtained from Ensembl to build reference indexes for
the STAR alignment. FeatureCounts [88] was used to count reads mapping to each gene. RSEM
[96] was instead used to obtain FPKM (Fragments Per Kilobase of exon per Million fragments
mapped). We analyzed differential gene expression levels using read counts, normalized by feature length with DESeq2 [142], with the following model: design =~condition, where condition
indicates either CTRL or PMA.
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3.8.18

Data Availability

All statistical analyses were performed using R v3.3.1. Total RNA-seq, chromatin RNA-seq and
ChIP-seq data are available on GEO: GSE106359. Figures were made with the package ggplot2.
BEDtools v2.25.0 [93] was used for genomic analyses.
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3.8.19

Key Resources Table
KEY RESOURCES TABLE
REAGENT or RESOURCE
Antibodies
Rabbit polyclonal anti-Asunder
Rabbit polyclonal anti-EGR1
Mouse monoclonal anti-EGR1
Rabbit polyclonal anti-EGR2
Rabbit polyclonal anti-INTS1
Rabbit polyclonal anti-INTS11
Mouse monoclonal anti-INTS6
Mouse monoclonal anti-NAB2
Rabbit polyclonal anti-NAB2
Rabbit monoclonal anti-GAPDH
Mouse monoclonal anti-γ-tubulin
Mouse monoclonal anti- α-tubulin
Rabbit polyclonal anti-H3K27ac
Rabbit polyclonal anti-H3K4me1
Rabbit polyclonal anti-PolII
Normal rabbit IgG
PE-Cy7 anti-mouse/human CD11b
APC anti-human CD11b
PE anti-human CD14
FITC anti-human CD34
APC anti-human CD33
Anti-rabbit IgG (HRP)
Anti-mouse IgG (HRP)
Biological Samples
De-identified human cord blood

SOURCE

IDENTIFIER

Bethyl
Bethyl
Santa Cruz
Biotechnology
Abiocode
Bethyl
Bethyl
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
ThermoFisher
Cell Signaling
Technology
Santa Cruz
Biotechnology
Sigma-Aldrich
Abcam
Abcam
This paper
Santa Cruz
Biotechnology
BioLegend
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
Cell Signaling
Technology
Cell Signaling
Technology

Cat#A303-575A
Cat#A303-390A
Cat#sc-515830
Cat#R0814-3
Cat#A300-361A
Cat#A301-274A
Cat#sc-376524
Cat#sc-23867
Cat#PA5-27925
Cat#2118
Cat#sc-17788
Cat#T9026
Cat# ab4279
Cat# ab8895
N/A
Cat# sc-2027
Cat#101215
Cat#550019
Cat#561707
Cat#560942
Cat#561817
Cat#7074
Cat#7076

Helen F. Graham
Cancer Center and
Research Institute,
Christiana Hospital

Chemicals, Peptides, and Recombinant Proteins
StemSpan SFEM medium
StemSpan CC100, cytokine cocktail
Phorbol 12-myristate 13-acetate (PMA)
FcR blocking reagent, human
Recombinant human SCF
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STEMCELL
Technologies
STEMCELL
Technologies
Sigma-Aldrich
Myltenyi Biotec
Peprotech

Cat# 09650
Cat# 02690
Cat#P8139
Cat#130-059-901
Cat#300-07

Recombinant human IL-3
Recombinant human M-CSF
Recombinant human GM-CSF
Recombinant human IL-6
Recombinant human FLT3L
MethoCult SF H4236, methylcellulose medium
Dynabeads protein A
protein A – HRP conjugated
Anti-FLAG M2 affinity gel
FLAG peptide
Critical Commercial Assays
CD34 MicroBeads kit, human
Gibson Assembly Master Mix
Phusion High-fidelity DNA polymerase kit
Direct-zol RNA Miniprep kit
Revertaid first strand cDNA synthesis kit
Cell growth determination kit MTT based
ChIP DNA Clean & Concentrator kit
NEBNext Ultra II DNA Library Prep Kit for Illumina
NEBNext Multiplex Oligos for Illumina (Index
Primers set 1)
NEBNext rRNA depletion kit
NEBNext Ultra Directional RNA Library Prep kit
miRNeasy mini kit
Deposited Data
ChIP-seq data
RNA-seq data
Chromatin RNA-seq
Experimental Models: Cell Lines
Human: 293T cells
Human: HL-60 cells
Human: Bone marrow derived CD34+ cells
Human: Fetal liver derived CD34+ cells

Monocytes
Oligonucleotides
Primers (see Supplemental Table 3)
shRNA sequences (See Supplemental Table 3)

Key Resources Table, continued
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Peprotech
Peprotech
Peprotech
Peprotech
Peprotech
STEMCELL
Technologies
Invitrogen
Cell Signaling
Technologies
Sigma-Aldrich
Sigma-Aldrich

Cat#200-03
Cat#300-25
Cat#300-03
Cat#200-06
Cat#300-19
Cat#04236

Miltenyi Biotec
New England
Biolabs
New England
Biolabs
Zymo research
Thermo Scientific
Sigma-Aldrich
Zymo research
New England
Biolabs
New England
Biolabs
New England
Biolabs
New England
Biolabs
Qiagen

Cat#130-046-702
Cat#E2611S

This paper
This paper
This paper

GSE106359
GSE106359
GSE106359

ATCC
ATCC
Calabretta Lab
Stem Cell and
Xenograft Core,
University of
Pennsylvania
Human Immunology
Core, University of
Pennsylvania

Cat# CRL-3216
Cat# CCL-240
N/A
https://www.med.u
penn.edu/cores/ste
m_cell_and_xenog
raft.html
https://pathbio.med
.upenn.edu/hic/site
/

This paper
This paper

N/A
N/A

Cat#10002D
Cat#12291
Cat#A2220
Cat#F3290

Cat#M0530S
Cat#R2051
Cat#K1622
Cat# CGD1
Cat#D5201
Cat#E7645S
Cat#E7335S
Cat#E6310L
Cat#E7420S
Cat#217004

Recombinant DNA
pLKO.1
Tet-pLKO-puro
pLENTI-CMV-GFP-Puro
pLKO.1-shINTS11 #1
pLKO.1-shINTS11 #2
pLKO.1-shNAB2 #1
pLKO.1-shNAB2 #3
pLKO.1-shINTS13 #1
pLKO.1-shINTS13 #2
Tet-pLKO-shEGR1
pLKO-shNAB2 #2
pLENTI-FLAG-NAB2
Software and Algorithms
FlowJo Software v10.0.7
MaxQuant v1.5.2.8
STAR v2.5
Samtools v0.1.19
FeatureCounts
RSEM
DESeq2
BWA tool
MACS2
ChAsE v1.0.11
EdgeR
Ggplot package
BEDtools v2.25.0
SeqMINER v1.3.4
Other
Superose 6 10/30 GL column

Addgene
Addgene
Addgene
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
This paper
This paper
This paper
This paper
This paper

Cat#10879
Cat#21915
Cat#17448
TRCN0000161507
TRCN0000161070
TRCN0000019544
TRCN0000019546
N/A
N/A
N/A
N/A
N/A

FlowJo, LCC
Cox and Mann, 2008
Dobin et al., 2013
Li et al., 2009
Liao et al., 2014
Li and Dewey, 2011
Love et al., 2014
Li, 2013
Zhang et al., 2008
Younesy et al., 2016
Robinson et al., 2010
Wickham, 2009
Quinlan and Hall, 2010
Zhan and Liu, 2015
GE Life Science
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Cat# 17517201

3.9

Supplementary Data

F IGURE 3.8

S UPPLEMENT (related to F IGURE 3.1)

(A). Immunoblot of INTS13 and INTS11 shows protein depletion in HL-60 cells, using two different
shRNAs. GAPDH is used as loading control. (B). Immunoblot of INTS13 and INTS11 shows protein depletion in primary cells. GAPDH and γ-tubulin are used as loading controls. (C). Images of colonies-forming
units formed by primary cells in cytokines-supplemented methylcellulose medium, showing a strong decrease
in the number of colonies upon depletion of INTS13.
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SUPPLEMENTAL FIGURE S2
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S UPPLEMENT (related to F IGURE 3.2)

Supplemental Figure S2. Related to Figure 2.
(A) Gene ontology analysis of 653 upregulated genes after PMA treatment (FDR <5%) in HL-60 depicts an enrichment for
hematopoietic related processes. (B-C) RNA-seq data for HL-60 (PMA) and primary cells (Monocytic differentiation, day 2)
are significantly correlated (Spearman correlation 0.85; p < 2.2 x 10-16), supporting HL-60 as a valid model for monocytic
differentiation, as exemplified by IL16, MMP9, and CSF1R. (D). qRT-PCR analysis of hematopoietic genes whose expression decreases after depletion of INTS13 using two different shRNAs. Data are means ± SD. (E). Heatmaps showing differentially expressed genes upon INTS13 depletion for two independent replicates of RNA-seq.
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(A) Gene ontology analysis of 653 upregulated genes after PMA treatment (FDR <5%) in HL-60 depicts an
enrichment for hematopoietic related processes. (B-C) RNA-seq data for HL-60 (PMA) and primary cells
(Monocytic differentiation, day 2) are significantly correlated (Spearman correlation 0.85; p < 2.2 ×10−16 ),
supporting HL-60 as a valid model for monocytic differentiation, as exemplified by IL16, MMP9, and CSF7R.
(D). GRT-PCR analysis of hematopoietic genes whose expression decreases after depletion of INTS13 using
two different shRNAs. Data are means +/- SD. (E). Heatmaps showing differentially expressed genes upon
INTS13 depletion for two independent replicates of RNA-seq.
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S UPPLEMENT (related to F IGURE 3.5)

(A-B) Jurkat cells were induced with PMA to mock T-cell activation, and INTS13 ChIP-seq was performed
at CTRL and PMA conditions. Upon PMA treatment, 1,026 regions display a significant increase of INTS13,
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stimulation. GAPDH was used as loading control.
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F IGURE 3.13

S UPPLEMENT (related to F IGURE 3.6)
138

(A) Immunoblot of INTS13 and NAB2 along M-CSF induced monocytic differentiation of CD34+ showing
induction of NAB2 by M-CSF. (B) Immunoblot of INTS13 and NAB2 in PMA-induced HL-60 differentiation
showing a strong induction of NAB2 at 16h. GAPDH was used as loading control. (C) Correlation plots
display ChIP-seq normalized read depth for INTS13, EGR1 and NAB2 on all INTS13+EGR1+NAB2 peaks
at PMA. NAB2 peaks are highlighted in red. The plots support co-presence of INTS13, EGR1 and NAB2
at the INTS13-gained regions. (D) ChIP-qPCR of INTS13, NAB2 and H3K27ac over a time course of
PMA induction (2h,4h,6h) for the CSF1R enhancer supports a model in which INTS13 and NAB2 binding
precedes the activation of the enhancer. (E) Immunoblot of NAB2 shows protein depletion in HL-60, using
three different shaRNAs. GAPDH is used as loading control. (F) Immunoblot of NAB2 shows protein
depletion in primary cells. GAPDH is used as loading control. (G) Correlation plot of INTS13-binding peaks
in shNAB2#2 versus shLUC after PMA differentiation. The regions that show binding of NAB2 are depicted
in red. (H) Heatmap showing differentially expressed genes upon INTS13 depletion are also affected by
NAB2 knockdown. (I) Images of colony-forming units formed by primary cells in cytokine-supplemented
methylcellulose showing strong decrease in the number of colonies upon depletion of NAB2 or EGR1.

F IGURE 3.14

S UPPLEMENT (related to F IGURE 3.6)

(A-B) Average profiles of INTS13 and NAB2 binding in circulating monocytes and monocyte-derived
macrophages at the 4,274 INTS13-gained enhancers display significant recruitment of both INTS13 and
NAB2, recapitulating the HL-60 findings, exemplified by the CSF1R intronic enhancer. (C) EGR1 and
NAB2 were independently depleted from CD34(+) cells. INTS13 ChIP-seq was performed at day0 and day5
of monocytic differentiation (shLUC, shEGR1, shNAB2). The ChIP-seq data reveal a significant reduction
of INTS13 binding across all of the 16,662 INTS13 peaks upon both NAB2- and EGR1-KD, suggesting that
the NAB2-mediated INTS13 binding on EGR1 genomic sites is recapitulated in primary cells, and is not an
artifact of HL-60.
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The following additional supplementary data can be found online at:
https://doi.org/10.1016/j.molcel.2018.05.031
S UPPLEMENTAL TABLE S1: Summary statistics from edgeR analysis on differentially bound INTS13
and INTS11 peaks identified by ChIP-seq (related to F IG .3.3)
S UPPLEMENTAL TABLE S2: MaxQuant output from LC-MS/MS analysis of INTS13 IP in untreated
and PMA-treated HL-60 (related to F IG .3.6)
S UPPLEMENTAL TABLE S3: Oligonucleotide sequences (related to Methods)
S UPPLEMENTAL TABLE S4: Information about sequencing experiments (related to F IG .3.2 - 3.6)
S UPPLEMENTAL DATA S1: IPA analysis for genes associated with INTS13-gained enhancers in HL60
(related to F IG .3.4)

S UPPLEMENTAL DATA S2: Motif analyses in HL-60 and Jurkat cells (related to F IG .3.5)
S UPPLEMENTAL DATA S3: IPA analysis for genes associated with INTS13-gained enhancers in Jurkat
(related to F IG .3.5)
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Chapter 4
Conclusions

4.1

Summary

The goal of my thesis work was to study the Integrator complex by dissecting the contributions
of its individual subunits to its overall regulatory functions. I began with the hypothesis that the
Integrator complex utilizes separate submodules to perform its regulatory functions on RNAPII.
In chapter 2, I described my work investigating the subunit INTS6. I found that INTS6, along with
INTS8, is necessary to recruit the phosphatase PP2A to the full Integrator complex (Int-PP2A).
Together, the Int-PP2A complex is recruited to sites of active RNAPII transcription, where it acts
to enforce RNAPII pausing; PP2A dephosphorylates targets of the kinase CDK9, creating a balance between the kinase activity (pro-elongation) and phosphatase activity (pro-pausing). We
showed that targeting this balance point using inhibitors of CDK9 alongside activators of PP2A
has a greater therapeutic benefit than CDK9i alone in mouse models of both circulating and solid
tumors. These results reveal a novel submodule of Integrator with the phosphatase PP2A and shed
light on how Integrator regulates RNAPII pause-release.
In chapter 3, I described the project investigating the subunit INTS13. I found that INTS13 is required for differentiation of hematopoietic progenitors to monocytes. Through NAB2, the transcription factor EGR1 recruits INTS13 to poised enhancers, priming them for activation during
differentiation. These results reveal an additional submodule of the Integrator complex required
for enhancer-promoter looping.
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4.2

Advances

Our understanding of the spatial configuration or structure of subunits within the assembled complex remained the work of careful biochemistry experiments without a solved structure. Concomitant with our work, a structure was determined by cryogenic electron microscopy (cryoEM) for
nine subunits of the Integrator complex with the core PP2A enzyme [143]. This structure confirmed numerous predictions of our studies, including the interaction of Integrator with PP2A.
As our results suggested, INTS6 is the subunit with the most direct contacts with PP2A, while
INTS8 is involved in maintaining contact between INTS6-PP2A and the core of the Integrator
complex. This study also corroborated our results showing that PP2A is able to dephosphorylate
the C-terminal domain (CTD) of RNAPII, and that this function requires recruitment to the gene
body by the Integrator complex [143]. Another recent study showed that the Drosophila IntS8 is
able to interact with PP2A [36], mirroring our results which revealed that Int-PP2A regulation of
pause-release is conserved in D.melanogaster.
Until recently, the mechanism by which Integrator regulates RNAPII pause-release has been an
open question. Recent studies have provided evidence that the endonuclease INTS11 can prematurely terminate mRNA transcripts near the pausing site in both D. melanogaster and mammalian
cell lines [63, 29, 62]. Taken together, our findings and the findings of other groups convincingly
demonstrate that Integrator contains (at minimum) two submodules with the ability to regulate
RNAPII pause-release via different catalytic mechanisms. While the cryoEM structure reveals that
the endonuclease and PP2A submodules are separated by 1̃50 angstroms, it remains to be seen
whether these two domains function separately or in tandem. It is possible that there is crosstalk
between the two submodules; since high phosphatase activity of Int-PP2A would prevent RNAPII
from escaping the pause, this activity may, through allosteric or other mechanisms, be linked to the
endonuclease which would then terminate the transcript, resulting in a reset of initiated RNAPII. It
is also possible that these submodules only act together by nature of them being in the same complex; there may be other cofactors necessary for each enzymatic reaction to occur, unrelated to the
activity of the other. Regardless, this understanding of Integrator containing multiple submodules
prompts us to question how signaling dynamics in the cell are communicated to active RNAPII.
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The kinases involved in RNAPII regulation, specifically CTD phosphorylation, have been well
characterized in many eukaryotes [49, 50], but the opposing phosphatases have been largely studied in yeast. It is only in the past few years that studies of mammalian phosphatase dynamics in
RNAPII regulation have moved forward, opening up many questions about target specificity and
redundancy [25]. Recent work has revealed that the phosphatase PP1 acts during the termination step of the transcription cycle, consistent with findings in yeast [52, 144, 53]. PP4 has been
proposed to act on actively elongating RNAPII, dephosphorylating the CTD and other elongation
factors, before “handing off” phosphatase duties to PP1 for termination [26, 27]. Our work showing that PP2A acts at the pause-release site aligns with these previous studies and suggests that
each phosphatase family (PP2A, PP4, PP1) may act at distinct steps of the transcription cycle. It is
likely that there is crosstalk between the different phosphatases. It has been shown that PP2A can
be activated through dephosphorylation by PP1 during cell cycle progression [57, 145], suggesting a similar mechanism may be at play during transcription. It is also likely that there is built-in
redundancy like that seen for transcriptional kinases. Redundancy may be necessary for a core cellular function like transcription; it would be detrimental to the cell if disruption of just one kinase
or phosphatase could obliterate the ability of transcription to occur.

4.3

Applications for Medicine

Our finding that PP2A and CDK9 mediate the switch of RNAPII pause-release through the Integrator complex has significant implications for health and therapeutics. Impairments in transcriptional control are prominent characteristics of numerous cancers [146, 19, 147, 148], and PP2A
activity in many cancers is reduced through mutations or other silencing mechanisms [70, 71].
Mutations in the PPP2R1A subunit of PP2A have been described in ovarian and uterine cancers
and may affect the ability of PP2A to bind to the Integrator complex [72, 71]. Mutations or loss of
Integrator complex subunits have also been found in cancers [149], including INTS6 in prostate
cancer [67]. Our new understanding of Int-PP2A’s activity promoting RNAPII pausing in transcription may shed light on an additional mechanism for cancer cells to overcome restrictive transcription. In fact, inhibitors of CDK9 have already shown promise in preclinical studies [45], and
143

dual-targeting alongside recently developed PP2A activators [73] may prove to be effective in a
much broader range of malignancies.
Additionally, there have been developmental disorders recently linked to mutations in Integrator
and PP2A subunits. Interestingly, germline mutations of PPP2R1A and other regulatory PP2A
subunits can lead to neurodevelopmental disorders, and these variants are often the same as the somatic variants frequently found in cancer [150, 151]. INTS1, INTS8, and INTS13 mutations have
also been implicated in developmental disorders [152, 153, 154, 155]. Studies in D. melanogaster
have revealed that Integrator is required for neuronal development, specifically to prevent dedifferentiation of committed cell types [156], though a specific subunit was not identified. Taken
together, these results suggest that Integrator is likely involved in regulating transcriptional programs during cell fate commitment, and that disruption of this complex can lead to disorders of
development from germline mutations, or cancer from somatic mutations.

4.4

Future Directions

Many outstanding questions remain regarding the role of the Integrator complex in cell fate determination. While our results showed that INTS13 is required for enhancer regulation in hematopoietic progenitors differentiating into monocytes, does this requirement extend to other branches of
hematopoiesis, or to differentiation of other tissue types? Notably, neuronal differentiation pathways are known to utilize EGR1 and NAB2 [119, 125]. Since Integrator is important for neural differentiation in D. melanogaster [156], and human mutations have been implicated in neurodevelopmental disorders, it is possible that the mechanism of developmental disruption is related to the INTS13-NAB2-EGR1 axis. To test for cell lineages that require INTS13, we could
use publicly available databases to identify tissues and cell types which express high levels of
NAB2 and/or EGR1. We could test these cell types by inducing differentiation after knockdown
of INTS13 and assaying the success of differentiation. I speculate that the specific function of
INTS13 in enhancer regulation will likely be identified in cell lineages that require EGR1 for differentiation, such as neurons. If in fact other cell lineages that do not require EGR1 appear dependent on INTS13, it’s possible that INTS13 is able to bind to a number of pro-differentiation
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transcription factors and/or cofactors, which would be possible to identify through endogenous immunoprecipitation as we identified NAB2. Further study of the structure and domains of INTS13
will be necessary to understand the breadth of its function in enhancer regulation.
A recent study sheds some light on the structure of INTS13 and more closely defines its submodule. A crystal structure of the subunits INTS13 and INTS14 was determined, revealing that they
form a closely interlinked dimer and associate closely with the subunit INTS10 [157], confirming our speculations of a lower molecular weight submodule containing INTS13. Interestingly,
INTS13, INTS14, and INTS10 were not resolved in the cryoEM structure [143], leaving open
speculation as to where this submodule is located. Systematic knockdowns of suspected interacting subunits followed by purification of INTS13 should allow us to answer this question. More
work needs to be done to fully characterize the enhancer-binding role of this Integrator submodule,
as it may add another divergent submodule to Integrator’s repertoire.
Although the cryoEM model of Integrator and PP2A constitutes the most comprehensive structural
information about Integrator to date, it leaves many open questions concerning the association of
Integrator subunits. Another subunit that was not resolved in the cryoEM structure is INTS3. This
subunit is known to interact closely with INTS6 alongside single-stranded DNA binding proteins
in the DNA damage response [64, 158]. Interestingly, the interacting domain of INTS6 and INTS3
was recently defined from crystal structures of INTS3 and INTS6 segments [159], and this domain
of INTS6 is also missing in the cryoEM structure. From these data we can infer where INTS3 assembles on the backbone of the complex, which also raises more questions about its involvement
with the PP2A submodule. Interestingly, INTS3 has also been implicated to function in pauserelease [65], so further research is necessary to understand how INTS3 fits into the complex and
how its association affects Int-PP2A activity and pause-release.
Many questions remain regarding the role of Int-PP2A with CDK9 in the transcription cycle. In
addition to its canonical role in pause-release, CDK9 is also involved in termination of transcription [55]. Our work focused on Int-PP2A-CDK9 in pause release, precluding our ability to study
its role downstream in termination. More careful dissection of the Int-PP2A function with time145

resolved techniques, such as nascent RNA-seq with washout of a small molecule inhibitor, could
inform us more directly how Int-PP2A is regulating distinct steps of the transcription cycle.
The Integrator complex was originally identified after enrichment and purification of the RNAPII
CTD in human cells. Even so, one outstanding question remains to be answered: which subunit(s)
of Integrator bind the CTD of RNAPII? More structural and biochemistry work will be necessary
to understand this interface, to shed light on how the CTD is poised for phosphorylation and dephosphorylation throughout the transcription cycle.
Altogether my thesis work supports the hypothesis that the Integrator complex functions as distinct
submodules to regulate many facets of RNAPII transcription. Research from others in the field further bolsters this hypothesis and leads us to a greater understanding of how the Integrator Complex
is able to perform its different regulatory tasks. Transcriptional regulation drives remarkable cellular diversity, adaptability, and proliferation in all organisms; a better understanding of this critical
process has the potential to transform our understanding of biology and disease.
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Tea Kecman, Krzysztof Kuś, Dong-Hyuk Heo, Katie Duckett, Adrien Birot, Sabrina Liberatori, Shabaz Mohammed, Lucia Geis-Asteggiante, Carol V Robinson, and Lidia Vasiljeva.
Elongation/termination factor exchange mediated by PP1 phosphatase orchestrates transcription termination. Cell reports, 25(1):259–269.e5, oct 2018.
Richard J Smith, Marilia H Cordeiro, Norman E Davey, Giulia Vallardi, Andrea Ciliberto,
Fridolin Gross, and Adrian T Saurin. PP1 and PP2A Use Opposite Phospho-dependencies
to Control Distinct Processes at the Kinetochore. Cell reports, 28(8):2206–2219.e8, aug
2019.
Melissa R Junttila and Jukka Westermarck. Mechanisms of MYC stabilization in human
156

[147]
[148]
[149]

[150]

[151]

[152]

[153]

[154]

[155]

malignancies. Cell Cycle, 7(5):592–596, mar 2008.
Deqing Hu and Ali Shilatifard. Epigenetics of hematopoiesis and hematological malignancies. Genes & Development, 30(18):2021–2041, sep 2016.
Akihiko Yokoyama. Transcriptional activation by MLL fusion proteins in leukemogenesis.
Experimental Hematology, 46:21–30, feb 2017.
A. Federico, M. Rienzo, C. Abbondanza, V. Costa, A. Ciccodicola, and A. Casamassimi.
Pan-Cancer Mutational and Transcriptional Analysis of the Integrator Complex. Int J Mol
Sci, 18(5), 2017.
Lisa Lenaerts, Sara Reynhout, Iris Verbinnen, Frédéric Laumonnier, Annick Toutain,
Frédérique Bonnet-Brilhault, Yana Hoorne, Shelagh Joss, Anna K Chassevent, Constance
Smith-Hicks, Bart Loeys, Pascal Joset, Katharina Steindl, Anita Rauch, Sarju G Mehta,
Wendy K Chung, Koenraad Devriendt, Susan E Holder, Tamison Jewett, Lauren M Baldwin, William G Wilson, Shelley Towner, Siddharth Srivastava, Hannah F Johnson, Cornelia
Daumer-Haas, Martina Baethmann, Anna Ruiz, Elisabeth Gabau, Vani Jain, Vinod Varghese, Ali Al-Beshri, Stephen Fulton, Oded Wechsberg, Naama Orenstein, Katrina Prescott,
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